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1. Chapter 1: Introduction 
Carbohydrates are one of the most abundant and structurally diverse organic 
molecules in nature1. With a wide variety of monosaccharide building blocks 
occurring both naturally and synthetically, a diverse range of possible chain 
lengths and the possibility of multiple configurations, the number of possible 
carbohydrates is infinite2. Unlike proteins and nucleic acid structures, the 
blueprints for carbohydrates are not directly outlined in the sequence of DNA, 
resulting in difficulties identifying carbohydrate sequences. However, unlike 
proteins and nucleic acids, carbohydrates are not susceptible to mutations, 
making their stability an appealing attribute in the medical field. 
The use of carbohydrates in medicine is a very broad field, with their 
characteristics exploited in a number of areas, including therapeutics3 and 
diagnostics4. This thesis set out to develop a glycoconjugate vaccine 
technology which utilises the interaction of carbohydrates with the immune 
system. 
This chapter will give an introduction into b-glucans and how they interact with 
receptors of the immune system. A focus on Dectin-1, a C-type lectin receptor 
with a specificity for b-(1-3)-glucans5, will provide an insight into how this 
interaction can be utilised in targeted vaccination therapies. The latter half of 
this chapter will focus on fungal b-(1-2)-mannan antigens and their use in 
vaccines, along with the need for Q fever specific antibodies. 
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1.1. The structural properties of b-glucans 
Beta-glucans are naturally occurring polysaccharides which are abundant in 
nature, from the cell walls of higher plant species and the storage granules in 
algal species, to surface polysaccharides on microorganisms, such as fungi, 
moulds and yeasts6. They are formed from repeating units of D-glucose in a 
beta-configuration. The relative molecular weight of b-glucans is extremely 
varied, ranging from a disaccharide of 342 Da to several thousands of 
kilodaltons for storage polysaccharides. 
The linear backbone of b-glucans exists in a number of linkage configurations 
depending on the origin of the polysaccharides, including the unusual cyclic b-
(1-2)-glucans excreted by Rhizobium spp.7, b-(1-3)-glucans in the form of 
paramylon and curdlan, b-(1-4)-glucans found within cellulose and b-(1-6)-
glucans such as pustulan6 (Figure 1. 1). As well as linear structures, b-glucans 
also exist in a number of branched forms, primarily of b-(1-6) linkage6. These 
varying structures have contributed to the use of b-glucans in a number of 
industrial applications, including use as a bulking agent in the food industry 
due to their unique gelling properties8.  
 
Figure 1. 1 – The chemical structures of b-glucans. Beta-glucans can exist as linear chains of 
repeating D-glucose units in b-(1-3), b-(1-6) or b-(1-4) linkage configuration. Linear b-glucan backbones 
may also be decorated with branching in b-(1-6) or b-(1-4) configuration. 
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Beta-(1-3)-glucans exist in both soluble and insoluble forms. In solution, the 
number of hydrogen bonds present in the polysaccharide structure allows the 
molecule to take on particular 3D structures, which can be presented as a 
triple helices, single helices or random coil (Figure 1. 2), as determined by x-
ray fiber diffraction9, solid state 13C NMR spectroscopy10, multiangle laser light 
scattering11, fluorescence resonance energy transfer spectroscopy12, and 
molecular dynamics simulation13. Due to the ability of these large molecules 
to form triple helical structures14, it has often been difficult to determine the 
molecular weight and degree of polymerisation (DP)15. 
 
 
Figure 1. 2 – The physical properties of soluble b-(1-3)-glucans. In solution, b-(1-3)-glucans take on 
a helical conformation, allowing them to take on triple helical (A), single helical (B), and random coil (C) 
structures. 
 
Beta-glucans have long been exploited for their health benefits. For thousands 
of years, ancient civilisations have used edible fungi, such as the Shitaki 
mushroom, Lentinula edodes, for their healing powers demonstrated by their 
anticarcinogenic activity and stimulation of Th1 lymophocytes16,17. More 
recently, traditional Chinese medicines have been explored for their extensive 
knowledge of b-(1,3)-glucan polysaccharides18, and their uses as anti-
A B C 
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inflammatory, anticancer and antimicrobial agents19,20. This knowledge has 
been utilised in advancing immunotherapies, by the use of b-glucans as 
adjuvants21, drug delivery systems22, and even in aquaculture as an immune 
stimulant in farmed fish23. Whilst it is evident that these naturally occurring 
moleculars have clear health benefits, the mechanisms by which these effects 
are stimulated remains unclear, with the chain length/branching requirments 
yet to be defined. 
 
1.1.1. Origins and diversity of naturally occurring b-glucans 
b-Glucans from different sources have been demonstrated to not only have 
different structures, but also different biological properties24, as outlined in 
Table 1. 1. A number of b-glucan polysaccharides comprise of a linear 
structure with b-(1-3)-linkages, including paramylon – the storage 
polysaccharide of Euglena gracilis which has been shown to have a pro-
inflammatory effect25, curdlan – a particulate b-(1-3)-glucan produced by 
Agrobacterium spp. shown to have anti-tumour and wound repair traits26, 
whole glucan partical (WGP) – comprised of hollow yeast cell wall with 
functions in wound repair and as a pro-inflammatory agent27, zymosan – a pro-
inflammatory agent found on the surface of yeast28, pachyman – a fungal 
polysaccharide with antitumour activities29, and callose – a plant 
polysaccharide located within the cell wall30. 
Linear b-(1-3)-glucans also exist with occasional b-(1-6)-branching. Laminarin, 
produced as a storage polysaccharide within Laminaria digitata, contains b-
(1-6)-glucan sidechains approximately every 3 residues along a linear b-(1-3)-
glucan backbone31, although the overall structure of laminarin varies 
depending on location of the source, season of harvest, extraction method, 
and a number of other environmental factors32. Scleroglucan also contains b-
(1-6)-branch points approximately every 3-4 residues along the linear 
backbone33. This soluble polysaccharide has shown antitumour and antiviral 
properties34. Schizophyllan has also demonstrated antitumour properties35, 
with b-(1-6)-branch points located every 3 residues along the backbone35. b-
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Glucans with a mixture of b-(1-4) and b-(1-6)-branch points are also present 
in the form of lentinan, a polysaccharide with antitumour and pro-inflammatory 
properties25. 
Linear b-glucans are also present in a number of other linkages, such as b-(1-
6)-glucan polysaccharides - as is the case of pustulan36, b-(1-4)-glucan 
polysaccharides such as cellulose - one of the most abundant b-glucans in 
nature6, and cyclic b-(1-2)-glucans. Whilst many of these polysaccharides 
occur abundantly in nature, their immunological function remains unknown. 
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Table 1. 1 – The physical, chemical and biological properties of b-glucans. 
Origin Source Name Linkage MW (kDa) DPn Soluble Biological Activity 
Algae Laminaria 
digitata 
Laminarin b-(1-3)-glucan main chain, 
b-(1-6)-glucan side chains 
(3:1)31 
~5.331 25-3531 Yes Dectin-1 inhibitor, inhibits 
myeloid leukaemia 
proliferation31 
Euglena gracilis Paramylon b-(1-3)-glucan15 >50015 300015 No Pro-inflammatory25 
Bacteria Alcaligenes 
faecalis 
Curdlan b-(1-3)-glucan15 ~80015 540-
550015 
No Antitumor, wound repair, anti-
HIV26 
Agrobacterium 
spp.37, 
Rhizobium spp.38 
Cyclic b-(1-2)-
glucan 
b-(1-2)-glucan (cyclic) Low 
molecular 
weight 
ND Yes ND 
Fungi 
and 
lichens 
Lasallia pustulata Pustulan   b-(1-6)-glucan36 ~2036 32036 No ND  
Sclerotium rolfsii Scleroglucan b-(1-3)-glucan main chain, 
b-(1-6)-glucan side chains 
(3-4:1)33 
~165033 2400-
250033 
Yes Antitumor, antiviral34 
Fungi 
(edible) 
Schizophyllum 
commune 
Schizophyllan b-(1-3)-glucan main chain, 
b-(1-6)-glucan side chains 
(3:1)35 
~45035 ND* Yes Antitumor35 
Lentinula edodes 
(Shitaki) 
Lentinan b-(1-3)-glucan main chain, 
b-(1-6) or b-(1-4)-glucan 
side chains (3:1)11 
~57011 ND* Yes Antitumor, pro-inflammatory39 
Poria cocos Pachyman b-(1-3)-glucan40 ~4040 70040 No Antitumor29 
Plant Various Cellulose b-(1-4)-glucan6 Var41 Var41 No ND  
Various Callose b-(1-3)-glucan6 Var30 Var30 No ND   
Yeast Saccharomyces 
cerevisiae 
Whole glucan 
particle 
(WGP) 
dispersible 
b-(1-3)-glucan6 Hollow 
yeast cell 
wall 
ND  No Activates Dectin-1, pro-
inflammatory, wound repair27 
S. cerevisiae Zymosan b-(1-3)-glucan6 ND ND  No Pro-inflammatory28 
  ND – not determined; * - may form triple helices; Var - variable across species 
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1.2. Carbohydrates and the immune system 
Carbohydrates play a central role in immunity4, with the fields of glycomics and 
proteomics exploring the interaction carbohydrates have with the immune 
system39. The importance of carbohydrates in immunity is demonstrated by 
the ability of sugars to modulate the immune reaction during microbe-host 
interactions40. The cell surface of microorganisms reveals an abundance of 
carbohydrates in the form of lipopolysaccharides (LPSs), exopolysaccharides 
(EPSs), capsular polysaccharides (CPSs), glycoproteins and cell wall 
carbohydrates. These carbohydrates have a range of functions, including 
preventing desiccation, enabling biofilm formation and evading the hosts 
immune system to allow invasion and infection of the host44. As well as 
mimicking host carbohydrates to aid invasion, carbohydrates found on 
pathogens can also inhibit key pathways of the hosts immune system. 
Invading pathogens take advantage of the hosts immune system, with some 
using receptors to gain entry and infect the host. For instance, the ManLAM 
ligand on the surface of Mycobacterium tuberculosis is able to interact with 
mannose receptor (MR), present on the surface of macrophages, immature 
DCs, and liver sinusoidal endothelial cells, to stimulate internalisation of the 
pathogen where it resides within lysosomes, but is able to inhibit phagosome-
lysosome fusion to evade the immune system45.  
However, the human immune system is well adapted to recognising 
carbohydrate epitopes on pathogens to initiate an immune response. The 
ability of our immune system to recognise carbohydrates on pathogens helps 
to develop our immune system from a young age. Many microbial species 
need to bind to the surface lectins on host immune cells to colonise46. 
Carbohydrates found within human milk mimic those found on the surface of 
pathogens, providing a decoy for invading pathogens and protecting the host 
from infection, as outlined in Figure 1. 3. Analysis of human milk 
oligosaccharides (HMOs) has revealed the presence of lacto-N-biose, a 
known pathogen associated molecular pattern (PAMP) located on the surface 
of Bifidus spp. In the presence of HMOs, Biffidus spp binds to lacto-N-biose, 
which acts as a decoy to the invading microbe47.  
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Figure 1. 3 – Schematic representation of human milk oligosaccharides (HMOs) acting as decoys 
to invading pathogens. HMOs mimic carbohydrate structures which are present on the epithelial 
surface. Receptors on invading pathogens bind to the decoy carbohydrates, allowing the host to evade 
infection. Image adapted from Bode 201247. 
 
1.2.1. The innate (primary) immune system 
Epithelial surfaces of the innate immune system form the first line of defence 
against invading pathogens48 (Figure 1. 4). Physical and chemical barriers, 
such as the skin and mucus membranes, prevent microbes and foreign matter 
from entering the host. If these barriers are breached, the invading body 
encounters a series of primary immune cells which work together to coordinate 
the destruction of the invading material.  
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Figure 1. 4 – The innate immune system defences. Physical and chemical barriers form the first line 
of defence against invading pathogens. If these barriers are breached, pathogens encounter a series of 
immune cells, such as: inflammatory cells (basophil and mast cells), natural killer cells, complement, and 
phagocytic cells (neutrophil, macrophage, dendritic cell, and eosinophil). 
 
Basophil and mast cells play a central role in inflammation and allergic 
reactions by releasing potent mediators, such as histamine. Natural killer (NK) 
cells play a major role in host-rejection of tumours and pathogen infected cells. 
They are cytotoxic cells capable of inducing apoptosis through the release of 
perforin and proteases. Complement consists of a series of >20 proteins found 
in the blood plasma which are capable of opsonisation and killing of bacteria49. 
The complement system also attracts macrophages and neutrophils, and also 
activates mast cells.  
Phagocytic cells are able to engulf and process foreign materials and 
microorganisms. The phagocytic cell family consists of four major cells types; 
neutrophils – specialising in the destruction of bacteria, macrophages – 
capable of engulfing and digesting apoptotic cells, eosinophils – specialising 
in the destruction of multicellular parasites, allergic reactions and cancer, and 
dendritic cells – antigen presenting cells which process foreign materials and 
microbes and present fragments on major histocompatibility complex II 
(MHCII) to T cells. Dendritic cells form the link between the innate immune 
system and the adaptive immune system. 
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1.2.2. The adaptive (secondary) immune system 
Microbes which breach these barriers encounter the more complex adaptive 
immune system. Subsets of antigen presenting cells (APCs), such as 
macrophages and dendritic cells (DCs) lay beneath epithelial cells where 
dendrites can extend and reach between cells to sample foreign materials 
(Figure 1. 5). Surface lectins on APCs allow for recognition of ligands 
displayed by pathogens and therapeutics which stimulate signalling cascades 
leading to phagocytosis of foreign matter. 
 
 
Figure 1. 5 – Schematic representation of Dendritic cells sampling for foreign material. Dendrites 
extend between epithelial cells to sample for foreign material and invading pathogens. 
 
After processing this material, fragments are presented to B cells and T cells 
for cytotoxic (CD8+ T cells) and antibody (CD4+ T cells) responses through 
major histocompatibility complex I (MHCI) and MHCII, respectively50, a 
process known as antigen presentation51 (Figure 1. 6). Cells expressing 
receptors which are able to recognise the antigen fragments being presented 
are selected through clonal selection52. This process initiates clonal 
expansion53, whereby the cells replicate to produce multiple identical copies. 
At this stage, helper T cells begin to release cytokines which causes B cells to 
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mature into antibody producing plasma cells. Also, cytotoxic T cells begin to 
release perforins, which destroy invading pathogens through cell lysis. 
Memory cells of B cells, helper T cells and cytotoxic T cells are also 
produced54, which allows a rapid immune response to be initiated upon future 
infection of pathogens expressing the same epitope. 
 
 
Figure 1. 6 – A schematic representation showing the adaptive immune system.  
 
1.3. The C-type lectin receptor family 
The interaction between host and pathogen forms the molecular basis for 
determining the appropriate immune response. Receptors present on the 
surface of APCs recognise a range of antigenic moieties, including lipids, 
proteins and carbohydrates, which are recognise by a immune receptors, such 
as the NOD-like55 and Toll-like56 families of receptors. Invasive and 
opportunistic pathogens display carbohydrate epitopes on their surface which 
interact with a family of receptors known as the C-type lectin receptors [(CLRs) 
Figure 1. 7]57. The CLRs comprise a large family of receptors, the majority of 
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which bind carbohydrates in a calcium (Ca2+)-dependent manner. 
Carbohydrate binding by these receptors is mediated by at least 1 conserved 
carbohydrate recognition domain (CRD), which coordinates ligand binding 
through key amino acid residues. 
 
 
Figure 1. 7 - Schematic representation of C-type lectin receptors expressed on antigen presenting 
cells. Type I C-type lectin family consists of MR and Dec-205, both of which bind carbohydrates through 
multiple CRDs in a Ca2+-dependent manner. The type II C-type lectin family consists of DC-SIGN, 
Langerin, DCIR, CLEC-1, Dectin-1, Dectin-2 and DLEC, all of which contain a single CRD at their C-
terminus. Image adapted from Figdor et al57. 
 
1.3.1. Type I C-type lectins 
The Type I C-type lectins are defined as having their N-termini oriented outside 
of the cell. Receptors within this family, such as mannose receptor (MR) and 
Dec-205, contain 8-10 carbohydrate recognition domains, a fibronectin type II 
repeat and a cysteine-rich repeat (S-S) at the N-terminal57. As outlined in 
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Table 1. 2, MR is able to recognise mannose, fucose and sialyl-Lewis X 
ligands58 through CRD4 and CRD5 in a Ca2+-dependent manner59, whereas 
Dec-205 is able to recognise ligands containing a-galactosylceramide. Both 
lectins have been utilised in targeted vaccination therapies due to their wide 
spread expression across immune cells and their roles in antigen uptake60–63. 
Whilst their abundant expression makes them an appealing target, this also 
poses potential risks as the desired immune response is more difficult to 
control. 
 
1.3.2. Type II C-type lectins 
The Type II C-type lectins are defined as having their N-termini oriented into 
the cytoplasm. Receptors within this family contain a single CRD at the 
extracellular C-terminal and a diverse range of conserved signalling motifs 
located within the cytoplasm. 
The dendritic-cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) receptor 
has been of great interest recently as it has been identified as the entry point 
for HIV-1 infection64,65. It is expressed solely on DCs and comprises a CRD, 
seven complete and one incomplete tandem repeat motifs, cytoplasmic 
tyrosine-based motif, triad of acidic amino acids and di-leucine motif66. 
Homologues of DC-SIGN have been identified, DC-SIGNR67 or L-SIGN68, and 
show the same ligand specificity68,69, but they are not expressed by DCs or 
Langerhan cells (LCs). 
Langerin, originally thought to be expressed exclusively on LCs in the 
epidermis and localised with Birbeck granules, is expressed on a range of DC 
subsets70–72. The ligand comprises a CRD with an affinity for mannose, 
GlcNAc and fucose, a stalk region, and a cytoplasmic PPP putative signalling 
domain73.  
DC immunoreceptor (DCIR), also known as lectin-like immunoreceptor – 
LLIR74) is expressed on a wide range of immune cells. The ligand comprises 
of a CRD with an affinity for sialyl-Lewis A (sLeA), a stalk region, and a 
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conserved cytoplasmic immunoreceptor tyrosine-based inhibitory motif 
(ITIM)75. Little is known about this receptor, but it is thought to play a role in 
antigen handling76. 
C-type lectin receptor 1 (CLEC-1) is a membrane spanning receptor 
comprising of a extracellular CRD and cytoplasmic tyrosine-based motif77. 
Ligands for the CRD, as well as the downstream signalling pathway, have yet 
to be determined. It has been proposed that signalling may be mediated 
through the tyrosine-based motif, comprising of amino acids tyrosine-serine-
serine-theonine (YSST), in a similar way to tyrosine-independent signalling 
stimulated by Dectin-177, although there is currently no evidence to support 
this. 
Dectin-1 is an extensively researched C-type lectin-like receptor. The CRD 
domain has been shown to have an exclusive affinity for b-(1-3)-glucans of at 
least 12 degrees of polymerisation (DP12)5. Coupled to the CRD is a linker 
region which spans the membrane to an immunoreceptor tyrosine-based 
activation motif (ITAM)78. This receptor is expressed primarily on DCs and 
macrophages79, and is discussed more extensively in Chapter 1.4. 
Dectin-2 shares 27 % and 33 % sequence homology with Dectin-1 in human 
and mouse, respectively. The CRD of Dectin-1 is able to bind a-mannan and 
high-mannose structures, but does not contain a cytoplasmic signalling motif 
so is unable to induce an independent signalling cascade80. This receptor is 
essential for protective immunity81,82. 
Previously thought to be a novel C-type lectin, DC lectin (DLEC) has since 
been shown to be identical to blood DC antigen 2 (BDCA-2)83,84. Ligands for 
the CRD of this receptor have not yet been determined, and similarly to Dectin-
2, DLEC does not have a conserved signalling domain.
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Table 1. 2 – Table of C-type lectin receptors 
Family Lectin Ligand Pathogen Expression Function 
Type 1 MR Mannose, fucose, sLeX M. tuberculosis85, C. albicans, 
Leishmania spp86 
DCs, LCs, Mo, Mφ, 
DMECs 
Antigen uptake53 
DEC-205 a-galactosylceramide87 Yersinia pestis88 DCs, LCs, high on 
actDCs, thymic ECs 
Antigen uptake89 
Type 2 Dectin-1 β-glucans5 M. tuberculosis90, C. albicans91, 
A. fumigatus92 
DCs, LCs T-cell interaction93 
Dectin-2 α-mannans, high mannose94 M. tuberculosis95 DCs, LCs Antigen uptake96 
Langerin Mannose, GlcNAc, fucose HIV-197, M. leprae98 DCs, LCs Formation of Birbeck granules99 
DCIR74,75 sLeA HIV-176 DCs, Mo, Mφ, PMN, B 
cells 
? 
CLEC-1 ? ? DCs100 ? 
DC-SIGN HIV (gp120)68, SIV, mannan, 
ICAM-2, ICAM-3 
HIV-1, BCG, C. albicans, M. 
tuberculosis, ebola virus 
DCs T-cell interaction101, HIV-1 pathology68, 
migration102, antigen uptake 
Abbreviations: MR, mannose receptor; DEC-205, dendritic and epithelial cell 205; DCIR, dendritic cell immunoreceptor; CLEC-1, c-type lectin receptor 1; BDCA-2, blood DC 
antigen 2; DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing non-integrin; sLeX, sialyl Lewis X; Mo, monocyte; Mφ, macrophage; DMECs, dermal microvascular 
endothelial cells; DCs, dendritic cells; LCs, Langerhans cells; actDCs, active DCs; GlcNAc, N-acetylglucosamine; sLeA, sialyl Lewis A; PMN, polymorphic nuclear cells; HCV, 
hepatitis C virus. 
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1.4. Dectin-1: A b-(1-3)-glucan receptor 
Dectin-1, a member of the CLR family, has been of major interest in recent 
years as a target for therapeutics against fungal pathogens. The 28 kDa 
membrane-associated protein consists of a conserved CRD coupled via a 
linker region to a transmembrane domain containing an immunoreceptor 
tyrosine-based activation motif (ITAM), characterised by the conserved 
tyrosine-x-x-leucine (YxxL) amino acid sequence (Figure 1. 8). Although it 
lacks key amino acid residues required to coordinate calcium ligation, typical 
of other members of the CLR family, it can bind particles rich in b-(1,3)-
glucans. The results of a microarray, in which over 100 different carbohydrate 
moieties were tested, revealed the CRD specificity of soluble monomeric 
Dectin-1Fc fusion as being highly preferential for β-(1,3)-glucans with a 
minimum degree of polymerisation (DP) of 12 glucose units103, although the 
ability of a molecule to bind to a receptor does not necessarily translate into a 
signalling response. 
 
Figure 1. 8 – Schematic representation of Dectin-1. The receptor consists of a conserved 
carbohydrate recognition domain which is coupled to a transmembrane domain via a linker region. The 
transmembrane domain contained a conserved signalling domain, immunoreceptor tyrosine-based 
activation motif (ITAM), characterised by the conserved YxxL amino acid sequence. 
 
Homologues of Dectin-1 have been found across many mammalian species, 
with conserved amino acid sequences located throughout the proteins (Figure 
1. 9). Murine Dectin-1 shares 61 % sequence identity with human Dectin-1, 
with 62 % identity when comparing the CRDs alone. Homologues have also 
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been identified in rabbits and sheep, with 68 % and 72 % sequence homology 
to human Dectin-1, respectively. Interestingly, comparison of their CRDs with 
human Dectin-1 reveals 72 % and 74 % sequence homology for rabbits and 
sheep, respectively. Single nucleotide polymorphisms (SNPs) within CRD can 
lead to changes in ligand recognition, while a mutagenesis study revealed a 
single SNP within human langerin, where Lys-313 is converted to isoleucine, 
results in loss of binding to oligosaccharides with terminal 6SO4-Gal, but 
enhances recognition towards GlcNAc104. Therefore, it is possible that 
differences in the amino acid sequence for Dectin-1 CRD across species may 
result in altered ligand recognition. 
 
Mus_musculus               MKYHSHIENLDEDGYTQLDFSTQDIHKRPRGSEKGSQAPSSPWRPIAVGLGILCFVVVVV 60 
Oryctolagus_cuniculus      MEFHSGLENVDEDGYTQLVFNSRVTTRTCVLSEKGTRTVSPPWRLMAVTLGVLCLVILVV 60 
Homo_sapiens               MEYHPDLENLDEDGYTQLHFDSQSNTRIAVVSEKGSCAASPPWRLIAVILGILCLVILVI 60 
Ovis_aries                 MEYQSSVENLDEDGYTQLDFSSRSITRRSVVSEKGLCAASSRWRLIAVTLGILCSVLLVI 60 
                           *:::  :**:******** *.::   :    ****  : *  ** :** **:** *::*: 
 
Mus_musculus               AAVLGALAFWRHNSGRNPEEKDNFLSRNKENH-KPTESSLDEKVAPSKASQTTGGFSQPC 119 
Oryctolagus_cuniculus      AVVLSALAFQRSNSGSQPLKNDNFPSRSRENHNQPTKSSLEENVAPTTALKTTGFFSSSC 120 
Homo_sapiens               AVVLGTMAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTTGVLSSPC 120 
Ovis_aries                 TVVLSTLGIWRSSSV-ELLKSDSFPSRNKDNQSQPTQSSLEDSVIPTKALTTTGVFSSAC 119 
                           :.**.::.: * .*  :  :.. * **.::*: :**:***::.* *:.*  *** :*. * 
 
Mus_musculus               LPNWIMHGKSCYLFSFSGNSWYGSKRHCSQLGAHLLKIDNSKEFEFIESQTSSHRINAFW 179 
Oryctolagus_cuniculus      PPNWIMHETSCYLFRTSLDTWNGSKRQCSQLASHLLKIDSSEELEFIEREMSFQPVHSFW 180 
Homo_sapiens               PPNWIIYEKSCYLFSMSLNSWDGSKRQCWQLGSNLLKIDSSNELGFIVKQVSSQPDNSFW 180 
Ovis_aries                 PPNWITREDSCYLFNTLLDSWDGSKRRCFQLGSNLLKIDSSKELEFISRRVSSQPDHSFW 179 
                            ****    *****    ::* ****:* **.::*****.*:*: **  . * :  ::** 
 
Mus_musculus               IGLSRNQSEGPWFWEDGSAFFPNSFQVRNTAPQESLLHNCVWIHGSEVYNQICNTSSYSI 239 
Oryctolagus_cuniculus      IGLSRSQSGSPWLWEDGSTFSSNLFQIRSTATRESSSHNCVWIHMSVVYDQLCNVPSYSI 240 
Homo_sapiens               IGLSRPQTEVPWLWEDGSTFSSNLFQIRTTATQENPSPNCVWIHVSVIYDQLCSVPSYSI 240 
Ovis_aries                 IGLSRRRTEEPWLWEDGSTLLSNLFQIRSTVTEKDSSHNCAWIHVSDIYNQLCSVHSYSI 239 
                           ***** ::  **:*****::  * **:*.*. .:.   **.*** * :*:*:*.. **** 
 
Mus_musculus               CEKEL-- 244 
Oryctolagus_cuniculus      CEKQLSL 247 
Homo_sapiens               CEKKFSM 247 
Ovis_aries                 CEKKLSI 246 
                           ***::   
 
Figure 1. 9 – Amino acid sequence alignment of Dectin-1 homologues. Bold black – conserved 
hemITAM signalling domain, blue – possible Asn-Xaa-Ser/Thr glycosylation site, blue underlined – 
predicted asparagine glycosylation, red and orange – conserved Trp and His residues required for 
binding b-glucans. 
 
Multiple splicing variants have also been identified within species (Figure 1. 
10). Murine Dectin-1 has been well characterised, and has been shown to 
consist of 2 variants, A1 and A2, with the latter being truncated due to the lack 
of a stalk region105. Alternative splicing of human Dectin-1 results in 2 major 
isoforms (A and B) and 6 minor isoforms (C-H)106. Isoforms A and B are the 
Cytoplasmic domain Transmembrane domain 
Stalk region 
Carbohydrate recognition domain 
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major receptors for b-(1-3)-glucans, however, the functions of isoforms C-H 
are yet to be elucidated. Interestingly, isoform E contains a full CRD and ITAM 
signalling domain but has been shown to reside within the cytoplasm and is 
not secreted, the reason for this remains unclear107. 
 
Figure 1. 10 – Schematic representation of Dectin-1 receptor orthologues. Dectin-1 consists of a 
C-terminal carbohydrate recognition domain which contains conserved amino acids required for binding 
carbohydrates, although it lacks key amino acid residues required for Ca2+ ligation. A stalk region links 
the CRD to the transmembrane domain, which links to a cytoplasmic hemITAM-domain containing the 
conserved ‘YxxL’-motif for phosphorylation. 
 
Sequence similarity between human and mouse Dectin-1 CRD orthologues is 
high between the two species, with 61 % sequence identity between the 
hDectin-1_A (Figure 1. 11 yellow) and mDectin-1_1 (Figure 1. 11 light blue)  
CRD receptors. The crystal structure of murine Dectin-1 CRD has been 
solved, and two amino acids, Trp221 (Figure 1. 11 red residue) and His223 
(Figure 1. 11 orange residue), have been identified as being instrumental in 
coordinating b-glucan binding108. Despite this finding, these amino acids are 
located on the side of the CRD, away from the main groove where the 
trisaccharide is shown to be bound. Although crystals of Dectin-1 with a 
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decasaccharide ligand bound have been attempted108, failure to identify the 
carbohydrate ligand within these crystals means that key information is 
missing with regards to b-glucan binding. Referring to the Dectin-1 microarray 
where DP12 was shown to be the minimum chain length required for binding, 
it may be that the carbohydrate chain loops around the protein to also 
coordinate with Trp221 and His223. Interestingly a glycosylation site within 
mDectin-1 (Figure 1. 11 dark blue residue) is located close to these key 
amino acids109, and it is reasonable to speculate that this may affect the 
coordination of the carbohydrates bound, as well as the configuration of 
carbohydrates which bind to this receptor. As the Dectin-1 crystals used within 
the crystal structure study lack glycosylation, producing crystals of Dectin-1 
from cells able to carry out glycosylation would be advantageous for studying 
the effect of murine glycosylation on b-glucan binding. However, as exact 
copies of the protein are required for crystals to form, introducing glycosylation 
to the protein would increase the difficulty of producing viable protein crystals. 
 
Figure 1. 11 – The crystal structure of murine Dectin-1 (blue) with human Dectin-1 overlayed 
(yellow) and laminaritriose bound. Dark blue represents the site of glycosylation, and red and orange 
represent conserved Trp and His residues, respectively, required for b-(1-3)-glucan binding. 
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1.4.1. The Dectin-1 signalling pathway 
Receptor activation on immune cells, such as DCs, induces signalling 
cascades which modulate cellular responses. Dectin-1-mediated signalling 
responses occur as a result of ligand binding to the CRD (Figure 1. 12). Ligand 
engagement leads to the clustering of receptors and the phosphorylation of 
the hemITAM motif by Src kinases, creating a docking site for Syk, a tyrosine 
protein kinase78. Syk docks to two phosphorylation sites and stimulates 
caspase-associated recruitment domain (CARD9), which exists as a complex 
with B cell lymphoma-10 (Bcl-10) and mucosa-associated lymphoid tissue 
lymphoma gene-1 (MALT-1)110, which in turn leads to the activation of IKK 
kinase complex, activating NFkB and leading to the induction of pro-
inflammatory cytokines and the differentiation of CD4+ T cells into Th1 and 
Th17 T cells111–113. 
 
 
 
Figure 1. 12 – The Dectin-1 signalling pathway. Following binding of b-glucans to the CRD, the YxxL 
motif in the cytoplasm is phosphorylated by Src, providing a docking site for Syk. Upon Syk docking to 
two phosphorylated YxxL motifs, ROS production is induced and the CARD9 signalling cascade initiated. 
CARD9 exists in complex with BCL-10 and MALT-1 which activate the IKK kinase complex leading to 
induction of pro-inflammatory cytokines and the differentiation of CD4+ T cells into Th1 and Th17 cells. 
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1.4.2. Activation of Dectin-1-mediated signalling 
As mentioned previously, binding to Dectin-1 requires b-(1-3)-glucans of at 
least DP125, however, it is not yet clear if this translates into a Dectin-1-
mediated signalling response. Laminarin is often used as a Dectin-1 
antagonist due to its high binding capacity114, but it is not able to trigger a 
Dectin-1-mediated signalling response in its free form115. Goodridge et al116 
have proposed that short b-(1-3)-glucans are indeed able to bind to Dectin-1, 
but the close proximity of hemITAM to dephosphorylation motifs of CD45 and 
CD148 on the cell membrane quickly remove the phosphorylation on 
hemITAM, preventing a signalling cascade from taking place (Figure 1. 13). 
 
 
Figure 1. 13 – Schematic representation of short b-(1-3)-glucans preventing a Dectin-1-mediated 
signalling response. Binding of short b-glucans to CRD does not result in a Dectin-1-mediated 
signalling response due to inhibition of the signalling motif by CD45 and CD148. Adapted from Goodridge 
et al116. 
 
For a signalling cascade to be initiated, Goodridge et al propose the formation 
of a ‘phagocytic synapse’ (Figure 1. 14)116. Unlike short b-(1-3)-glucans, large 
particulate b-(1-3)-glucans are able to produce a larger Dectin-1 cluster117, 
forcing CD45 and CD148 aside and thus creating a ‘phagocytic synapse’ 
which allows hemITAM to remain phosphorylated and Dectin-1-mediated 
signalling to occur. 
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Figure 1. 14 – Schematic representation showing formation of a ‘phagocytic synapse’ resulting 
in Dectin-1-mediated signalling. Binding of Dectin-1 to particulate b-(1-3)-glucans results in the 
formation of a ‘phagocytic synapse’. The clustering of multiple Dectin-1 receptors forces CD45 and 
CD148 aside, allowing the phosphorylation of YxxL by Src, and a signalling cascade to be initiated. 
Adapted from Goodridge et al116. 
 
1.5. Carbohydrate vaccination therapies 
In an era of widespread antibiotic resistance, microbial infection rates are on 
the rise. As well as many bacterial species becoming resistant to second-line 
antimicrobials, many fungal species are no longer responding to antifungal 
treatments118. It is estimated that 7 % of all infections caused by Candida 
glabrate are resistant to fluconazole (Figure 1. 15 A), a second-line antifungal 
medication which inhibits 14a-demethylase, a fungal cytochrome P450 
enzyme, preventing the conversion of lamosterol to ergosterol, an essential 
component of the fungal cytoplasmic membrane. It is also estimated that 8% 
of infections are resistant to echinocandin (Figure 1. 15 B), an antifungal agent 
which inhibits b-(1-3)-glucan synthase, preventing synthesis of b-(1-3)-glucan 
– a major component of the fungal cell wall119. Antifungal resistance is not 
limited to Candida species, with 3-6 % of Aspergillus species, the causative 
agent of aspergillosis, also showing signs of azole resistance (antifungal 
medicines containing azole rings)120. Although the full extent of antimicrobial 
resistance is still not known, it is clear that preventative measures need to be 
taken, with targeted therapeutics becoming an attractive option121.  
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Figure 1. 15 – Chemical structure of fluconazole (A), and echinocandin (B). 
 
As mentioned in Chapter 1.2, carbohydrates play a pivotal role in generating 
immune responses towards invading pathogens. Polysaccharides located on 
the surface of pathogens are ideal candidate antigens due to their stability and 
exposure on the cell surface. On their own, carbohydrates are poorly 
immunogenic, however, conjugation to a protein carrier vastly enhances their 
immunogenicity, as discovered by Avery and Goebel in late 1929122. Since 
then, many glycoconjugate vaccines have been generated and have 
successfully made it through clinal trials to market123. One particular success 
story is the elimination of Meningococcus C from the UK following a substantial 
vaccination programme in 1999 using the MenC vaccine, a conjugate vaccine 
of Meningococcus C capsular polysaccharide conjugated to Tetanus Toxoid 
carrier protein124.  
The ability of DCs to activate CD8+ T cells makes them an ideal target for 
vaccination therapies. Studies have explored the possibility of preloading ex 
vivo generated DCs with antigens in order to enhance the immune response, 
however this approach did not provide conclusive results, and proved to be 
very labour intensive125. The possibility of inducing a strong immune response 
by targeting receptors expressed on immune cells is proving to be a more 
promising and robust approach. Vaccines targeted towards receptors using 
monoclonal antibodies have proven to provide enhanced immune responses 
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when administered with an adjuvant126, although the mechanism by which 
adjuvants stimulate the immune system is not well understood, leading to 
safety concerns over the use of adjuvants in vaccines127. 
Vaccines targeted towards DCs using carbohydrates provides a stable 
alternative to mAb targeting126, and their ability to stimulate an immune 
response eliminates the need of adjuvants. The Dectin-1 antagonist, 
laminarin, has been investigated for its ability to target vaccines towards 
Dectin-1 by introducing the b-glucan tag onto glycoconjugates in a multivalent 
manner, thus eliminating the need to use adjuvants to stimulate a strong 
immune response128. Free laminarin is able to bind to Dectin-1 CRDs, but is 
unable to initiate a Dectin-1-mediated signalling response, however multimeric 
presentation of laminarin on carrier proteins is likely to induce a larger Dectin-
1 clustering effect, thus enabling a signalling response. In a study performed 
by Lipinski et al128, laminarin was incorporated into a tri-component 
glycoconjugate vaccine along with a b-(1-2)-mannotriose antigen, and tetanus 
toxoid as a carrier protein, as shown in Figure 1. 16. The addition of laminarin 
to the vaccine conjugate resulted in a 5- to 10- fold increased antibody titre, 
with IgG showing an increase in protective b-mannan mAbs from immunisation 
in mice. Such results reveal promising prospects for the use of b-(1,3)-glucan 
address tags in vaccination therapies. 
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Figure 1. 16 – Structure of b-(1-2)-mannotriose-Tetanus Toxoid-laminarin vaccine conjugate. 
Image taken from Lipinski et al128. 
 
The studies in this thesis focused on fungal b-(1-2)-mannan antigens, and 
Coxiella LPS, both of which are introduced in the next two sections. 
 
1.5.1. b-(1-2)-Mannans as antigens 
The surface carbohydrates of pathogens play an important role in immunity, 
as mentioned in Chapter 1.2, with carbohydrate epitopes being key markers 
for pathogen recognition. Candida albicans, the causative agent of 
candidiasis, is a major cause of disease amongst immunocompromised 
patients129. Two infective strains of C. albicans, serotype A and serotype B, 
contain antigenic mannose regions within their CPS, comprising of both a-(1-
2) and b-(1-2) oligomannosyl residues130. These oligomannans comprise an 
acid-stable region which is coupled to asparagine residues (Asn) via an inner 
core and two GlcNAc residues (Figure 1. 17). The composition of mannans 
within this region vary between the serotypes, with mannans specific to 
serotype A shown in bold in Figure 1. 17. Both serotypes also comprise of 
acid-label b-(1-2)-mannans which are thought to be responsible for inducing 
an immune response in infected patients131. 
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Figure 1. 17 – The representative structure of C. albicans mannan. Bold circles represent serotype 
A-specific antigenic mannose regions. Red arrows represent b-(1-2)-linkages. Figure adapted from 
Shibata et al132. 
 
b-(1-2)-Mannan antigens have been incorporated into vaccines for 
immunisation studies, and it has been shown that antibodies raised against b-
(1-2)-mannotriose antigens are able to protect against disseminated 
candidiasis and vaginal infection in mouse models133. Until recently, b-(1-2)-
mannans could only be obtained by extraction from microbial cultures134, or 
chemical synthesis135, requiring category 2 containment facilities or complex 
protecting group chemistry, respectively. The recent identification of two 
enzymes, Teth514_1788 and Teth514_1789136, both able to synthesis b-(1-
2)-mannans, allows the potential production of linkage specific b-(1-2)-
oligomannans. In this thesis, Teth514_1788, was utilised to generate b-(1-2)-
mannan antigens for incorporation into targeted vaccination therapies.  
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1.5.2. Q Fever: A potential Biowarfare Agent 
Coxiella burnetii, the causative agent of Q fever, is widespread amongst 
livestock worldwide137. The zoonotic bacteria are able to survive within the 
bodily fluids of domesticated livestock and are released into the environment 
through their natural waste cycles, such as urination, defecation and waste 
birth products. Wind can carry dust particles containing C. burnetii for long 
distances, allowing the infection to spread. People in direct contact with 
infected animals, particularly during birthing such as farmers and 
veterinarians, are at greater risk of contracting the disease. Characteristics 
such as strong environmental persistence and high infectivity rates have 
resulted in this bacterium being categorised as a potential biowarfare agent by 
the Centre for Disease Control (CDC)138,139. 
Only two commercial vaccines are licenced for protection against Q fever, Q-
Vax for use in humans140, and Coxevac for livestock use141. Both vaccines 
comprise of whole-killed C. burnetii cells which results in a broad range 
antibody response. Lack of antibodies specific to Q fever means diagnosis of 
the disease is slow, with current methods relying on timely polymerase chain 
reaction (PCR) analysis, where detection is confirmed by successful 
amplification of key marker genes.142. In this thesis, an attempt was made to 
produce antibodies specific for C. burnetii to provide human protection against 
Q fever, but also for use in diagnostic kits to allow rapid and precise detection 
of the disease. 
Coxiella burnetii is a Gram-negative bacterium, displaying a complex array of 
carbohydrates on its cell surface (Figure 1. 18). The lipopolysaccharide (LPS) 
of C. burnetii has been shown to contain components unique to this organism. 
Linked to the membrane bound lipid A component is the core region, which is 
divided into the inner and outer regions. The inner core is proposed to contain 
a combination of mannose, heptose and kdo carbohydrates, whilst the outer 
core is proposed to contain mannose and heptose residues. Together, the lipid 
A and core region comprise the phase II (avirulent) form of LPS. The virulent 
form LPS is known as phase I, and comprises of phase II LPS with an 
additional O antigen domain attached to the outer core.  
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Figure 1. 18 – Proposed structure of C. burnetii LPS. The putative LPS structure is comprised of an 
avirulent phase (phase II) and a virulent phase (phase I). Phase II comprises of a membrane-bound lipid 
A domain coupled to an inner core which comprises of Man, Hep and Kdo. Linked to the inner core is 
the outer core, which consists of Man and Hep carbohydrates. Together these domains form Phase II 
LPS. Phase I LPS contains all the components of phase II with the addition of an O antigen domain in 
which Vir, DHHS, Man, GlcNAc, Glc and GalNAc have been identified. 
 
Within the O antigen of C. burnetii LPS, the composition of sugars has been 
identified, although the sequence and linkage of many have yet to be 
elucidated. The structural composition of LPS I has been proposed as follows 
(mol %); Man (32.6), Vir (32.3), Hep (14.4), GlcN (12.2), 
dihydrohydroxystreptose [DHHS (6.7)], Glc (1.8) and Gal (trace)143. The 
unique characteristics of virenose and DHHS (Figure 1. 19) make them 
appealing target antigens for both vaccination and diagnostic therapies. 
Streptose, a component of the antibiotic streptomycin, is found in 
Streptomyces spp. Virenose has been identified in only a few species of 
bacteria, C. burnetii144, Streptomyces spp.145 and Bacillus cereus146 (where it 
is referred to as cillose). It has been proposed that virenose exists at the 
terminal end of C. burnetii O antigen in a (1,4)-linkage, with the linkage 
configuration yet to be determined147.  
 
Inner Core
Man, Hep, Kdo
Outer Core
Man, Hep
O antigen
Vir, Strep, Man, GlcNAc, Glc, GalNAc
Phase I
(virulent)
Phase II
(avirulent)
Lipid A
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Figure 1. 19 – The chemical structure of virenose and dihydrohydroxystreptose (DHHS). 
 
Although a vaccine against Q fever exists for each humans and livestock, they 
are produced from whole killed Coxiella burnetii cells and require a 7 days skin 
test before administration141. Using whole killed cells in vaccination therapies 
also poses a risk of cross-reactivity with other species due to the broad range 
of antibodies being produced. Engineering a vaccine to protect against unique 
components of C. burnetii LPS would not only allow immediate administration, 
but also generate a more potent antibody response specifically towards C. 
burnetii due to the selective specificity. 
Generation of specific antibodies also holds scope for improved diagnostic 
tests against Q fever. Current methods of detection involve either nucleic acid 
amplification, which itself requires specialist laboratory safety procedures for 
handling and storage of a category 3 pathogen, or serological screens of 
antibody titers via immunosorbent assays which have been shown to have 
cross-reactivity148. Specific antibodies raised towards virenose would vastly 
improve the efficiency of diagnosis of the pathogen. Used in lateral flow 
devices, diagnosis would not only be specific for Q fever, but the time for 
accurate diagnosis would be reduced to a matter of minutes, allowing for fast 
and convenient diagnosis. 
 
1.6. General Aim 
It is evident that binding to the Dectin-1 receptor requires b-(1-3)-glucans of at 
least DP125. However, the requirements for b-glucan binding to translate into 
a Dectin-1-mediated signalling response are not clear. It is possible that this 
O
OH
CH3
OH
H3C
OH
OH
O
OH
OH
CH2OH
OH
Virenose
HO
DHHS
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response is dependent on b-glucan chains larger than DP12, physical size, 
branching and orientation of carbohydrates. Elucidating the requirements for 
such a response would have a profound effect on the development of 
vaccination therapies, by stimulating signalling cascades to result in better 
antigen presentation on dendritic cells, and therefore a more robust antibody 
response. The primary aim of this thesis was to investigate the minimum chain 
length required for inducing such an immune response and assess the use of 
these polysaccharides as ‘molecular address tags’ (MATs) for targeting to 
Dectin-1 (Chapter 2).  
The latter part of this thesis focuses on the recent advances in the enzymatic 
synthesis of b-(1-2)-mannan antigens136, and the application of b-(1-3)-
glucans in targeted glycoconjugate vaccine candidates (Chapter 3). The initial 
aim was to generate a b-(1-2)-mannotriose and b-(1-2)-mannotetraose 
antigens to determine the immunogenic effect of these oligosaccharides, 
along with the addition of a b-(1-3)-glucan MAT to enhance antigen 
presentation.  
b-(1-3)-Glucan targeted vaccination therapies would also be applied to a 
vaccine conjugate containing virenose antigens, in collaboration with JIC spin-
out Iceni Diagnostics, in order to improve vaccination therapies towards C. 
burnetii, the causative agent of Q fever. The vaccine would comprise of 
comprise of chemically synthesised virenose antigens, a laminarin MAT, and 
a virus-like particle (VLP) proteinaceous carrier. The efficacy of the vaccine 
would be determined via immunisation trials in rabbits, in collaboration with 
Mologic. ELISA analysis of the resulting sera would determine the specificity 
of the antibody response generated. The ability to generate antibodies specific 
to unique antigens present within capsular polysaccharide of C. burnetii, would 
pave the way for an improved vaccination therapy for Q fever, and also specific 
and rapid diagnostics of the disease. 
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2. Chapter 2: Generation of b-(1-3)-glucan address 
tags and characterisation of their ability to interact 
with Dectin-1 
 
2.1. Introduction 
This chapter describes the process taken to generate b-(1-3)-glucan address 
tags and the analysis of their interaction with the C-type lectin receptor, Dectin-
1. In brief, the aim was to use curdlan, a naturally occurring b-(1-3)-glucan 
produced by Agrobacterium spp., to generate b-(1-3)-glucans of varying 
degrees of polymerisation by subjection to acid degradation. Coupling of b-(1-
3)-glucan DP15 and laminarin to bovine serum albumin (BSA) via copper-free 
“click chemistry”, as outlined in Scheme 2. 1, would allow analysis of their 
interactions with Dectin-1 through the use of a reporter cell line expressing the 
receptor in a plate-based assay.  
 
 
Scheme 2. 1 - Schematic diagram of b-glucan glycoconjugate generation (1), conjugation (2), and 
reporter assay (3). Curdlan was subjected to acetolysis (a) to produce acetylated curdlan fragments 
which were deprotected and fractionated (b) to yield a fraction containing predominantly DP15. 
Laminarin and b-(1-3)-glucan DP15 were functionalised with an anomeric azide (c) and coupled to BSA 
via click chemistry (d). The ability of these glycoconjugates to initiate a Dectin-1-mediated signalling 
response was determined using a Dectin-1 expressing reporter cell line. 
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2.1.1. Generation of b-(1-3)-glucan molecular address tags 
Beta-(1-3)-glucans are a naturally occurring group of oligo- and 
polysaccharides comprising of repeating D-glucose residues, joined by b-(1-
3) glycosidic linkages1. As discussed previously in Chapter 1, these molecules 
have been chosen to act as molecular address tags for targeted vaccination 
therapies towards the Dectin-1 receptor on APCs due to the receptors unique 
ability to bind these molecules exclusively2. Producing b-(1-3)-glucan 
polysaccharides of defined chain lengths is an arduous task, with chemical 
synthesis limited to short hexasaccharides3, and chemical4 and enzymatic5 
degradation resulting in b-(1-3)-glucan fragments with a broad distribution of 
degrees of polymerisation6. Although large b-(1-3)-glucan particles exist in 
nature as storage polysaccharides, with DPs ranging from 35 for laminarin7, 
to 3000 for paramylon8,9, and as large as DP 5500 for the bacterial 
polysaccharide curdlan10, at the time of commencing this work, the enzyme 
responsible for synthesis of these materials had not yet been identified11. 
Although chemical synthesis would allow more control over the chain length, 
the degree of polymerisation and quantities needed for this study would make 
chemical synthesis impractical. Therefore, chemical degradation was explored 
as a means of generating milligram quantities of b-(1-3)-glucan 
oligosaccharides of between DP10-25 in order to target the Dectin-1 receptor, 
which is known to bind b-(1-3)-glucans with a minimum DP of 1212. 
As described in Chapter 1.1.1, laminarin is a low molecular weight b-(1-3)-
glucan with b-(1-3)-glucan side branches approximately every 3 residues 
along the backbone. This soluble b-(1-3)-glucan is able to act as a Dectin-1 
antagonist, blocking the binding site and suppressing the immune response13. 
It is possible that laminarin is able to bind to Dectin-1 receptors, but the short 
chain lengths results in a small clustering effect of Dectin-1 receptors which is 
not sufficient for inducing a signalling response14. This thesis investigated the 
ability of laminarin to bind to Dectin-1, as both a free oligosaccharide and when 
conjugated to a BSA protein carrier, and trigger a Dectin-1-mediated signalling 
response.  
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2.1.2. Conjugation via “click chemistry” 
The conjugation of carbohydrates to carrier proteins is essential for inducing a 
strong immune response (Chapter 1.4.2), as well as to allow efficient 
adhesion to surfaces in high-throughput assays. Recent advances in “click 
chemistry” have dramatically increased the potential for azide functionalised 
molecules in conjugation chemistry and microarrays. First coined by Sharpless 
and co-workers in 2001, the term “click” chemistry is traditionally a copper(I)-
catalyzed azide-alkyne cycloaddition (CuAAC). These reactions have proven 
to be extremely versatile in conjugation chemistry, due to their 
chemoselectivity and ability to be performed in aqueous media and have 
transformed the trends in contemporary chemistry for its uses in biological and 
medicinal chemistry. Advances in click chemistry have quickly led to the 
development of copper-free, bioorthogonal click chemistry15. These strained-
ring cyclooctynes are unstable and react spontaneously with azides and 
eliminate the need for a copper catalyst, the mechanism for which is outline in 
Scheme 2. 2, making the chemistry much safer for use in vivo.  
 
 
Scheme 2. 2 – Chemical mechanism for copper-free bioorthogonal click chemistry. 
 
Research into incorporating bioorthogonal reagents into living systems in a 
targeted manner has led to advances in cancer diagnosis through the use of 
azide functionalised carbohydrates. Cancerous prostate tissues cultured in the 
presence of azide functionalised Ac4 ManNAz, the biosynthetic precursor for 
azide-functionalised sialic acid, was metabolised into azidosialic acid and 
incorporated into cell surface polysaccharides16. The introduction of 
cyclooctyne functionalised fluorophores was able to reveal the location of 
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cancerous prostate tissue. Such specific targeting of cancerous tissues would 
allow for targeted delivery of therapeutics17. 
The selective reactivity and biocompatibility of biorthogonal, copper-free click 
chemistry was chosen to couple b-(1-3)-glucan molecular address tags 
(MATs) to BSA as it offered a safe, quick and clean method of conjugation. 
(1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate, an 
NHS-functionalised strained-ring cyclooctyne linker (BCN-NHS) was 
employed due to its dual reactivity, ideal for conjugation (Scheme 2. 3). 
 
 
Scheme 2. 3 - Chemical structure of (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl 
carbonate (BCN-NHS). 
 
The incorporation of NHS-esters into linker molecules allow for reactivity with 
exposed amines, such as those found on surface lysines (Scheme 2. 1a), and 
strained-ring cyclooctynes allow for copper-free click chemistry with azide 
functionalised glycans (Scheme 2. 1b and c). These attributes make this 
linker a very attractive option for protein conjugation. 
 
2.1.3. Ligand-lectin interactions 
Dectin-1, a member of the C-type lectin family of receptors, has a high binding 
specificity for b-(1-3)-glucans, with a minimum chain length DP12 required to 
bind to this receptor12, however, it is not known whether this chain length is 
sufficient for inducing a Dectin-1-mediated signalling response. As outlined in 
Chapter 1.4, it is proposed that clustering of Dectin-1 receptors to form a 
O O
O
N
O
O
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phagocytic synapse triggers Src/Syk-dependent signalling in myeloid cells14. 
To determine if our b-(1-3)-glucan oligosaccharides and conjugates were able 
to induce such a response, our aim was to employ a murine Dectin-1 
macrophage reporter cell assay (Figure 2. 1)18, with a cell line expressing a 
murine Dectin-1 receptor-CD3V fusion protein (Figure 2. 1 A). Upon 
successful binding of b-(1-3)-glucans, clustering of Dectin-1 receptors initiates 
CD3V to stimulate the IL-2 promoter, leading to the transcription of b-
galactosidase (LacZ) from the lacZ gene (Figure 2. 1 B). Addition of 
chlorophenol red b-D-galactopyranoside (1.5 mM CPRG) containing 100 mM 
2-mercaptoethanol causes cell lysis and allows lacZ activity to be observed 
due to cleavage of the glycosidic linkage within CPRG, resulting in a visual 
colour change from yellow to red. If ligand-lectin binding is unsuccessful, b-
galactosidase is not produced, and no colour change occurs. Mock cell lines, 
BWZ.36 cells lacking receptor expression act as a control to determine if lacZ 
responses are a result of ligand-lectin interactions. Use of this cell line provides 
a clear indication as to whether a signalling cascade has been initiated by 
ligand binding to Dectin-1. 
 
Figure 2. 1 – Schematic diagram of the Dectin-1 reporter cell assay. (A) A Dectin-1-CD3V-fusion 
protein is expressed on the surface of a BWZ.36 cell line. (B) Successful binding of b-(1-3)-glucan 
ligands to Dectin-1 receptors leads to stimulation of the IL-2 promoter to induce lacZ, resulting in the 
production of b-galactosidase allowing for colorimetric detection upon addition of CPRG. Green curly 
line represents carbohydrate ligands. Red stars represent b-galactosidase. 
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2.2. Results and Discussion 
2.2.1. Generation of β-(1-3)-glucan tags 
2.2.1.1. Production of acetylated b-(1-3)-glucan fragments 
Beta-(1-3)-glucan address tags were generated by partial acid degradation of 
curdlan, as outlined in Chapter 5.2.1. A handful of methods exist in the 
literature for generating b-(1-3)-glucan oligosaccharides via both top-down 
and bottom-up approaches, such as the degradation of curdlan to 
laminaribiose and peracetylated laminaribiose by enzymatic hydrolysis5 and 
chemical degradation4, respectively. 
In this study, efforts were focused on the chemical degradation of a large b-
(1-3)-glucan polysaccharide, curdlan, to achieve a series of b-(1-3)-glucan 
oligosaccharides with varying degrees of polymerisation. Initial attempts 
focused on the degradation of curdlan by treatment with neat trifluoracetic acid 
(TFA). Curdlan was mixed with TFA at 5 mg mL-1 and reacted in a Biotage 
Microwave Initiator at 80 °C with the frequency set to very high for 5, 10, 15, 
20, and 30 minutes. To determine the chain length the resulting 
oligosaccharides were dried under compressed air and reacted with APTS via 
reductive amination. Briefly, 10 µL of each 10 mM 8-amino-1,3,6-
pyrenetrisulfonic acid (APTS) and 1 M sodium cyanoborohydride (NaCNBH3) 
was added to each dried oligosaccharide sample and the reaction incubated 
at 37 °C overnight. The labelled samples were then dried under nitrogen gas 
and resuspended in 50 µL of 6 M urea. Samples (5 µL were loaded) were 
loaded on to an acrylamide gel and run at 300 V for 30 minutes and visualised 
using a gel imager equipped with a 420 nm light source. 
Whilst the degradation of curdlan was successful, as shown by the gel image 
in Figure 2. 2, large quantities of particulate material remained, suggesting 
the degradation was only effective at the terminal ends of the polysaccharide. 
After 5 minutes, the reaction had produced significant quantities of DP1-DP10, 
with larger chains also clearly present. 
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Figure 2. 2 – Gel analysis of TFA degraded Curdlan. Curdlan in TFA (5 mg mL-1) was degraded in a 
Biotage Microwave Initiator at 80 °C set to very high frequency for 5, 10, 15, 20 and 30 minutes. 
Degraded curdlan oligosaccharides were reacted with APTS via reductive amination and analysed on 
an acrylamide gel at 300 V for 30 minutes. The gel was visualised under a 420 nm wavelength light. 
 
The large presence of glucose, and the remaining particulate material, 
suggested this approach was not efficient at producing b-(1-3)-glucans of 
DP15. Further attempts were focused on the partial degradation of curdlan via 
acetolysis, as outlined in Scheme 2. 4. 
 
  
Scheme 2. 4 – Generation of acetylated b-(1-3)-glucan fragments by acetolysis of curdlan. 
Reagents and conditions: curdlan, AcOH-Ac2O (1:1), concentrated H2SO4), 30-40 °C for 30 mins, 28 °C 
for 24 hr, 20 °C, NaOAc. n = DP5500, x = DP12-24. 
 
Partial degradation of curdlan (10g scale) by acetolysis [acetic 
anhydride/acetic acid (1:1)], the mechanism for which is outlined in Scheme 
2. 5.  
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Scheme 2. 5 - Reaction mechanism for the acetolysis of curdlan. 
 
The resulting acetylated curdlan fragments were subsequently 
fractionationated by flash chromatography on silica gel (300 g) to produce 
eleven 42 mL fractions of acetylated b-(1-3)-glucan fragments containing both 
individual oligosaccharides and their mixtures (Figure 2. 3).  
 
Figure 2. 3 – TLC of acetylated b-(1-3)-glucan fragments fractionated by flash chromatography. 
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Fractions containing acetylated b-(1-3)-glucan fragments of DP12-24 
(fractions IX and X), as determined by MALDI-TOF/MS (Figure 2. 4), were 
combined and concentrated to yield 520 mg of product. 
 
 
 
 
 
 
 
 
Figure 2. 4 – MALDI-TOF/MS analysis of acetylated curdlan fragments, fractions IX and X. Mass 
analysis was performed on an MTP AnchorChip 384 target plate with DHB matrix (10 mg mL-1 in 30 % 
aq. MeCN) using a Bruker Daltronics Ultraflex ToF/ToF mass spectrometer. For calculated and found 
masses, see Appendices 6. 1. 
 
1H and 13C NMR spectroscopic analysis confirmed the presence of acetates 
by characteristic signals at 20.6 ppm and 2.22-1.94 ppm for 13C and 1H NMR, 
respectively (Figure 2. 5). Signal assignments for both 13C and 1H NMR, as 
shown in Figure 2. 5,  were achieved as reported in the literature19–21. A signal 
at 53.5 ppm and 5.32 ppm for 13C and 1H NMR, respectively, confirms the 
presence of residual dichloromethane22.  
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Figure 2. 5 – HSQCed NMR analysis (400 MHz, CDCl3) of acetylated curdlan fragments. For 
chemical shift assignments, see Appendices 6. 2. Characteristic acetate signals are labelled in red. 
 
 
2.2.1.2. Deprotection of acetylated b-(1-3)-glucan fragments 
Prior to use as address tags, the acetylated curdlan oligosaccharides were 
deprotected to produce free sugars. A number of methods of deprotection are 
available for the removal of acetates, ranging from the mild conditions of 
triethylamine (TEA) in aqueous methanol23, to the faster conditions of sodium 
methoxide (NaOMe) in methanol24. b-(1-3)-Glucans have been shown to be 
susceptible to ‘chemical peeling’ under basic conditions, the mechanism for 
which is shown in Scheme 2. 6, resulting in shortened b-(1-3)-glucan chains. 
To avoid compromising the degree of polymerisation of b-(1-3)-glucan address 
tags, harsh basic conditions should be avoided. 
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Scheme 2. 6 – The process of ‘chemical peeling’ of b-(1-3)-glucans under basic conditions. 
Adapted from Zhang et al25.  
 
To ensure the complete removal of acetates, deacetylation was performed 
using 1M NaOMe in dry MeOH and DCM (0.1:20:5) to aid the solubility of 
acetylated products, as outlined in Scheme 2. 7. 
 
  
 
Scheme 2. 7 – Deprotection of acetylated b-(1-3)-glucan fragments. Reagents and conditions: 
MeOH/DCM/1M NaOMe (20:5:0.1), 2h, RT, under nitrogen. n = DP1-23. 
 
From 260 mg of acetylated b-(1-3)-glucans DP13-24, deprotection with 
NaOMe yielded 115 mg of deacetylated product, which was subsequently 
analysed by 1H and 13C NMR (Figure 2. 6), MALDI-TOF/MS (Figure 2. 7) and 
high-performance anion-exchange chromatography with pulsed amperometric 
detection [HPAEC-PAD (Figure 2. 8)] to determine chain lengths. 
1H and 13C NMR analysis (Figure 2. 6) clearly shows the removal of acetates, 
indicated by lack of a signal at 20.6 ppm and 1.94-2.22 ppm for 13C and 1H 
NMR, respectively, confirming that deprotection was successful. Signal 
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assignment (Appendices 6. 3) corresponds with literature reports for laminari-
oligosaccharides26–28. 
 
Figure 2. 6 - HSQC NMR analysis (400 MHz, D2O) of deacetylated b-(1-3)-glucan curdlan 
fragments. For chemical shift assignments, see Appendices 6. 3. 
 
Masses obtained from MALDI-TOF/MS (Figure 2. 7) indicate the complete 
deprotection of the b-(1-3)-glucans, with identified masses correlating with the 
calculated sodium adducts of DP5-23. It is possible that masses as low as 
DP1 exist, however strong matrix peaks below 500 Da did not allow adequate 
resolution. However, the distribution of masses has shifted towards the lower 
molecular weight range. As mentioned previously, b-(1-3)-glucans may be 
susceptible to ‘chemical peeling’ under basic conditions, and it is possible that 
a degree of peeling has occurred here. The ionizability of carbohydrates is 
much greater at short DPs, with increases in DP leading to a decrease in 
ionizability29. Removal of acetates from the polysaccharides significantly 
decreases the ionizability of the molecules29. Although MALDI-TOF/MS is able 
to provide m/z charge data of these compounds, it is not a method of 
quantification due to the reasons outlined previously and should not be 
considered so.  
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Figure 2. 7 – MALDI-TOF/MS analysis of deprotected b-(1-3)-glucan curdlan fragments. Mass 
analysis was performed on an MTP AnchorChip 384 target plate with DHB matrix (10 mg mL-1 in 30 % 
aq. MeCN) using a Bruker Daltronics Ultraflex ToF/ToF mass spectrometer. For calculated and found 
masses, see Appendices 6. 1. 
 
HPAEC-PAD analysis of b-(1-3)-glucans was performed on a Dionex IC 
system equipped with a CarboPac PA100 (4 x 250 mm) anion exchange 
column coupled with an electrochemical detector, allowing the determination 
of retention times for the b-(1-3)-glucans. These analyses allowed for clear 
resolution of oligosaccharides in a single run, confirming the presences of 
DP1-23 (Figure 2. 8). Peak assignments were made following analysis of a 
laminarihexaose standard. The presence of b-(1-3)-glucan oligosaccharides 
below DP5 suggest a small degree of chemical peeling may have occurred 
during the deprotection stage. As the objective to generate b-(1-3)-glucan 
chains of DP10-25 was achieved in sufficient quantities for further 
investigation, the methods employed here were deemed successful and milder 
means of deprotection were not investigated. 
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Figure 2. 8 – HPAEC-PAD analysis of deprotected b-(1-3)-glucan curdlan fragments. HPAEC-PAD 
analysis was performed using a CarboPac PA100 (4 x 250 mm) anion exchange column. Mobile phases 
(eluent A: 100 mM NaOH; eluent B: 100 mM NaOH with 500 mM NaOAc) were applied as a gradient to 
100 % eluent B over 30 mins, isocratic eluent B for 10 mins and ending with isocratic 100 % eluent A for 
0.1 mins. Flow rate remained constant at 0.25 mL min-1. Numbers indicate the DP for each peak. For 
retention times, see Appendices 6. 5. 
 
2.2.2. Fractionation of mixed b-(1-3)-glucan polysaccharides 
It has been demonstrated that a minimum b-(1-3)-glucan length of DP12 is 
required for binding to Dectin-1. In order to achieve these chain lengths, 
fractionation of the deprotected b-(1-3)-glucan curdlan fragments was 
required. Although the solubility of b-(1-3)-glucan oligosaccharides decreases 
with increased chain length, it was found that they became soluble in aqueous 
solution with heating to 40 °C. This allowed fractionation to be achieved by 
GPC using a Biogel P2 chromatography column (26 x 900 mm) heated to 40 
°C (Figure 2. 9). Large oligosaccharides of DP6-23 eluted as a broad peak 
between 190-240 mins, with smaller oligosaccharides eluting as individual 
peaks later on. 
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Figure 2. 9 – Seperation of b-(1-3)-glucans by gel permeation chromatography. Mixed linear b-(1-
3)-glucans were in injected into a Biogel P2 column (2.6 x 90 cm) at 40 °C in 30 mg batches with dH2O 
at a 1 mL min-1 flow rate. Fractions were collected between 160 and 600 mins at 5.5 mL intervals. Blue 
shading highlights fractions taken for further analysis. 
 
MALDI-TOF/MS analysis of fractions collected at 5.5 mL intervals between 
190-240 mins reveal a narrower distribution of DPs within each fraction, with 
the average DP ranging from DP17 (Figure 2. 10 B) to DP7 (Figure 2. 10 J).  
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Figure 2. 10 – MALDI-TOF/MS analysis of deprotected b-(1-3)-glucans, prior to (A) and following 
fractionation by GPC (B-J). MALDI-TOF/MS analysis performed on an MTP AnchorChip 384 target 
plate with DHB matrix. Grey labels represent minor peaks, black labels represent dominant peaks. A – 
Deprotected b-(1-3)-glucan curdlan fragments, B-J – GPC fractions. For calculated and found masses, 
see Appendices 6. 1. 
 
Low molecular weight peaks, corresponding to Na+ and H+ adducts of DP5-9 
can been seen in fractions B-E (Figure 2. 10 B-E). As previously mentioned, 
low molecular weight oligosaccharides are more readily ionisable in 
comparison to medium-high molecular weight oligosaccharides, hence the 
strong signals seen here. Although MALDI-TOF/MS is able to provide the 
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masses of compounds present in these fractions, further analysis was required 
to determine the relative proportion of each oligosaccharides in these mixed 
fractions. 
Chromatograms obtained for each b-(1-3)-glucan fraction show a narrower 
distribution of chain lengths with the average DP decreasing across fractions. 
Figure 2. 11 B shows an average chain length of DP17/18, with the average 
chain length decreasing in size to Figure 2. 11 J with an average DP of 7. This 
data is consistent with the data obtained my MALDI-TOF/MS (Figure 2. 10), 
allowing us to determine the average DP within each fraction with confidence. 
The absence of low molecular weight oligosaccharides (DP1-9) in fractions B-
E (Figure 2. 11 B-E) by HPAEC-PAD analysis suggest the presence of these 
peaks by MALDI-TOF/MS (Figure 2. 10 B-E) is an artefact of the instrument, 
likely caused by the higher ionizability of short oligosaccharides. 
In order to target the Dectin-1 receptor on APCs, a minimum chain length of 
DP12 is required, as determined by microarray data30. b-(1-3)-Glucan chains 
within fraction C comprise an average DP of 15, therefore this fraction was 
selected for further investigation for use as an address tag and will hereby be 
referred to as DP15.  
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Figure 2. 11 – Analysis of GPC fractionated b-(1-3)-glucans by HPAEC-PAD. Analysis was 
performed using a CarboPac PA100 (4 x 250 mm) anion exchange column. Mobile phases (eluent A: 
100 mM NaOH; eluent B: 100 mM NaOH with 500 mM NaOAc) were applied as a gradient to 100 % 
eluent B over 30 mins, isocratic eluent B for 10 mins and ending with isocratic 100 % eluent A for 0.1 
mins. Flow rate remained constant at 0.25 mL min-1. A – Deprotected curdlan fragments, B-J – GPC 
fractions 7-15, K – Laminarihexaose standard. For retention times, see Appendices 6. 5. 
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2.2.3. Characterisation of commercial laminarin 
Laminarin, from Laminaria digitata, was purchased from Sigma (L9634) to 
investigate its use as an address tag to activate Dectin-1-mediated signalling. 
Characterisation was performed by HSQC NMR (Figure 2. 1). 
 
Figure 2. 12 – HSQCed NMR analysis (400 MHz, D2O) of commercial laminarin. For chemical shift 
assignments, see Appendices 6. 6. 
 
2.2.4. Azide functionalisation of b-(1-3)-glucan address tags 
Alkyne-azide cycloaddition “click” reactions provide an efficient, highly 
selective and convenient method for producing stable covalent bonds, making 
this reaction popular for the coupling together of molecules31–33. In this study, 
copper-free click reactions between azides and a strained-ring alkyne34 was 
utilised to conjugate b-(1-3)-glucan tags onto protein carriers.  
Beta-(1-3)-glucan DP15 and laminarin were prepared for conjugation by 
introducing an azide at the anomeric position of the reducing terminus. 
Numerous reactions exist for introducing an anomeric azide onto 
carbohydrates, often requiring protecting group chemistry35, or multiple step 
reactions36–39. In the case of higher oligosaccharides, neither of these 
approaches are suitable as they may result in cleavage of inner glycosidic 
bonds38,40. As a result, a one-pot method of introducing an anomeric azide was 
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selected (Mechanism 2. 1)41, as outlined in Scheme 2. 8. 2-Chloro-1,3-
dimethylimidazolinium chloride (DMC) activates the anomeric hydroxyl group 
to form a reactive intermediate. Nucleophilic attach by azide ions at the 
anomeric centre allows to the reaction to proceed to form azido sugars. 
 
Mechanism 2. 1 – Reaction mechanism for the synthesis of sugar azides via DMC intermediate. 
 
 
Scheme 2. 8 – Generation of b-glucosyl azides. Reagents and conditions: NaN3 (2.5 M), DMC (5 eq), 
DIPEA (15 eq), D2O, 18 hr, RT. n = 7-10. 
 
The large size of these oligosaccharides, an average of DP15 for the linear 
curdlan fragments, makes it challenging to analyse their reducing terminal 
anomeric position. However, lengthy scan NMR analysis confirmed the 
introduction of a b-azide at the anomeric position of DP15 by the presence of 
a 13C NMR signal at 89.9 ppm, which correlated to a 1H NMR signal at 4.7 ppm 
by HSQCed (Figure 2. 13). This data is consistent with literature values 
reported for anomeric laminaritriosyl azide42. However, this reaction had not 
gone to completion with approximately 50 % of unreacted hemiacetal 
remaining, as is evident from 13C NMR signals remaining at 92.1 and 95.8 
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ppm, correlating to 1H NMR signals at 5.2 and 4.6 ppm, corresponding to 
unreacted a and b reducing termini, respectively.  
 
Figure 2. 13 – HSQCed NMR analysis of linear b-(1-3)-glucan DP15 azide. Diagnostic signal at 1H 
NMR 4.7 ppm and 13C NMR 89.9 ppm confirms the presence of an anomeric b-azide. 1H NMR signals 
at 5.2 and 4.6 ppm, correlating to 13C NMR signals at 92.1 and 95.8 ppm show unreacted anomeric a 
and b hydroxyl groups, respectively, indicating the reaction had not gone to completion. A – reducing 
glucose residue, X – remaining glucose residues of b-(1-3)-glucan chains, Y – complete b-(1-3)-glucan 
chains.  
 
The heterogeneity, average DP of 25-35, and the presence of both G- and M-
series made laminarin more challenging to analyse. Although an anomeric b-
azide was confirmed by correlating 13C and 1H NMR signals of 89.8 and 4.7 
ppm, respectively, it was not possible to detect reducing C-1 position in either 
the starting material or the azide product, therefore the reaction efficiency 
could not be determined by NMR (Figure 2. 14). 
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Figure 2. 14 – HSQCed NMR analysis of azide functionalised laminarin. Characteristic signals at 1H 
NMR 4.7 ppm and 13C NMR 89.8 ppm confirm the presence of an anomeric b-azide. 
 
Mass spectrometry analysis was unsuccessful at identifying masses for b-(1-
3)-glucan DP15 azide and laminarin azide due to the reduction of azide 
functional groups to amines under MALDI-TOF MS conditions43.  
FTIR analysis was also used as a means of detecting the presence of azide 
functional groups (Figure 2. 15). Characteristic azide shifts at 2122 and 2120 
cm-1 can be seen in the spectra for DP15 azide (Figure 2. 15 B) and laminarin 
azide (Figure 2. 15 C), respectively, which are absent in the spectra for DP15 
(Figure 2. 15 A) and laminarin (Figure 2. 15 B) starting materials. 
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Figure 2. 15 – FTIR analysis of (A) DP15 linear b-(1-3)-glucans, (B) azide functionalised DP15, (C) 
laminarin, and (D) azide functionalised laminarin.  
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2.2.5.  Alkyne functionalisation of BSA and conjugation of glucans via 
click chemistry 
The amino acid sequence of BSA reveals the presence of 59 lysine residues, 
30-35 of which are exposed for conjugation44. Introduction of a strained-ring 
bioorthogonal alkyne functionalised with an NHS-ester allows for selective 
reactivity to exposed amines to readily incorporate a reactive alkyne for 
conjugation through click chemistry, the mechanism for which is illustrated in 
Scheme 2. 9.  
 
Scheme 2. 9 – Reaction mechanism for conjugation to primary amines via NHS-esters. 
 
BSA was functionalised with (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyl N-
succinimidyl carbonate (BCN-NHS), as outlined in Scheme 2. 10a. 
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Scheme 2. 10 – Functionalisation of BSA with BCN-NHS and conjugation to b-(1-3)-glucan address tags. Reagents and conditions: a) BSA (2 mg ml-1), BCN-NHS (10 µL 
at 0.15 M in DMSO), PBS, 1 h, RT; b) DP15 azide/BCN-BSA (2:1) in PBS, 18 h, RT; c) laminarin azide / BCN-BSA (5:1) in PBS, 18 h, RT. n = 7-10. 
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The dual functionality of the BCN-NHS linker allows for specific reactivity via 
both the strained-ring cyclooctyne to azides, and the NHS ester to exposed 
amines. The optimal degree of BCN loading on BSA was determined by 
reacting 5x, 10x, 20x and 30x molar excess of BCN-NHS to BSA. As shown 
in Table 2. 1, molar excess of BCN-NHS of 20x and greater resulted in protein 
precipitation due to changes to the isoelectric point of the protein. To maintain 
the solubility of BSA, a 10x molar excess of BCN-NHS to BSA was used. 
Table 2. 1 – Table of BSA functionalisation optimisation. See Appendices 6. 7 for MALDI-TOF/MS 
spectra. 
Conjugate m/z (Da) Degree of 
conjugation 
BSA 66379 0 
Molar 
excess of 
BCN-NHS 
to BSA 
5x 67315 5.3 
10x 68304 10.8 
20x Precipitate ND 
30x Precipitate ND 
 
Excess BCN-NHS reagent was quenched by the addition of Tris and removed 
by dialysis against PBS. BCN-functionalised BSA was analysed by SDS-
PAGE (Figure 2. 16) and MALDI-TOF/MS (Figure 2. 17) to reveal an average 
of 9 linkers per protein (Table 2. 2). 
 
Figure 2. 16 – Characterisation of BSA conjugates by SDS-PAGE (left) and western blot (right). 
Lane L – ladder; lane 1 – BSA; lane 2 – BSA-linker; lane 3 – BSA-linker-DP15; lane 4 – BSA-linker-
laminarin. SDS-PAGE (left) was run on a 12 % SDS gel at 200 V for 60 minutes at 4 °C before staining 
with Coomassie. Western blot (right) was transferred onto nitrocellulose membrane at 100 V for 1 hour 
at 4 °C before blocking with 1 % milk powder in PBST and probing with a mouse anti-b-(1-3)-glucan mAb 
and subsequent probing with a goat anti-mouse HRP secondary antibody.  
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Figure 2. 17 – MALDI-TOF/MS analysis of BSA conjugates. A) Native BSA, m/z 66430 Da calculated, 
m/z 66221.2 Da found; B) BSA-BCN, m/z 68104 Da calculated, m/z 68071.1 Da found; C) BSA-BCN-
DP15, m/z 71567 Da calculated, m/z 69284.7 Da and 71567.9 Da found; D) BSA-BCN-laminarin, m/z 
75104 Da calculated, m/z 75146.9 Da found. 
 
Copper-free click chemistry is an efficient and clean method for coupling 
molecules together. The lack of a copper catalyst not only allows for a faster 
and cleaner work up, but also makes the product safe for use in in vivo studies. 
Beta glucan address tags, DP15 azide and laminarin azide, were reacted with 
BCN-functionalised BSA using a 2x and 5x molar excess of glucan per mole 
of protein, respectively. Laminarin azide was reacted in a 5x molar excess to 
compensate for the mixed G- and M-series present. Analysis of the BSA 
conjugates by SDS-PAGE (Figure 2. 16 left) did not reveal whether 
successful conjugation has occurred, as the 12 % SDS gel used did not 
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provide adequate resolution. A gradient gel may have increased the resolution 
of conjugates, providing a clearer indication. However, analysis of the 
conjugates by Western blot revealed successful conjugation of DP15 azide 
and laminarin azide to BCN functionalised BSA when probed with a mouse 
anti-b-(1-3)-glucan mAb (Figure 2. 16 right). 
Successful conjugation was further confirmed by MALDI-TOF/MS analysis 
(Figure 2. 17), revealing the introduction of an average of 1.4 and 2 glucan 
chains for DP15 azide and laminarin azide, a conjugation efficiency of 70 % 
and 40 % respectively (Table 2. 2), as determined by differences in mass 
between BSA-b-glucan conjugates and BCN functionalised BSA, divided by 
the mass of the corresponding b-glucan azide. 
 
Table 2. 2 – Summary of b-(1-3)-glucan conjugation to BSA 
Glycoconjugate Molar 
excess* 
 
Average 
conjugation 
per protein 
molecule 
Conjugation 
efficiency 
(conjugate/molar 
excess) x100 
BSA-BCN 10 9.4 94 % 
BSA-BCN-DP15 2 1.4 70 % 
BSA-BCN-Laminarin 5 2.0 40 % 
The top half of the table (above the double line) corresponds to the conjugation of BCN to BSA, below 
the double line corresponds to the conjugation of b-(1-3)-glucan DP15 and laminarin to BCN 
functionalised BSA. * = molar excess is the ratio between the moles of conjugate used per mole of 
protein. 
 
Although the efficiency of laminarin conjugation appears low at 40 %, this is in 
part due to the presence of M-series laminarin which lacks a reducing 
terminus. Peak broadening is characteristic for conjugations of this nature due 
to a number of factors, including the heterogenicity of chain lengths, the 
number of branch points (in the instance of laminarin)45 along with the range 
of conjugated lysine residues.  
 79 
Figure 2. 17 C shows splitting of the mass peak, suggesting the click reaction 
for DP15 azide was more efficient on a select portion of BCN-functionalised 
BSA. As the formation of DP15 azide did not go to completion (Figure 2. 13), 
DP15 azide consists of a mixture of reactive azide functionalised and 
unreactive hydroxyl groups at the reducing terminus, therefore only a portion 
(approximately 50 %) of this is able to react with the strained-ring alkynes on 
BCN-functionalised BSA. Conducting the click reaction prior to conjugation 
may have provided better control over the reaction and yielded a more uniform 
product. It was therefore concluded that the conjugation reaction was deemed 
sufficiently successful for this purpose, however, other conjugation techniques 
need to be explored for greater efficiency.  
The BSA conjugates prepared herein were subsequently used to determine 
their ability to induce a Dectin-1-mediated signalling response, as discussed 
in Section 2.2.6. 
 
2.2.6. The ability of b-(1-3)-glucans to induce a Dectin-1-mediated 
signalling response 
The ability of b-(1-3)-glucan address tags to initiate a Dectin-1-mediated 
signalling response was determined by use of a Dectin-1 expressing reporter 
cell assay (Figure 2. 1). BSA conjugates were bound to the surface of 96-well 
ELISA plates and blocked with milk powder. The BWZ.36 reporter cell line18, 
either Dectin-1 expressing, or a mock cell line which lacks expression of this 
receptor, were then applied. Upon successful binding to Dectin-1, b-
galactosidase is produced as a result of CD3V signalling inducing the IL-2 
promoter leading to transcription of the lacZ gene and production of b-
galactosidase. Addition of the substrate CPRG containing 2-mercaptoethanol 
causes cell lysis and allows binding efficiency to be determined via colorimetric 
detection as cleavage of the glycosidic linkage by b-galactosidase results in a 
colour change from yellow to red, as outlined in Scheme 2. 11. 
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Scheme 2. 11 – Schematic representation of reporter assay detection method: b-galactosidase 
activity on CPRG leading to a colour change from yellow to red. 
 
BSA conjugated with either b-(1-3)-glucans with an average DP of 15, or 
laminarin, allowed us to investigate whether the DP12 b-(1-3)-glucan ligand 
reported in the literature as being required for binding to Dectin-1 is able to 
initiate a Dectin-1-mediated signalling response. Curdlan, the parent molecule 
from which the linear b-(1-3)-glucans used in this study were derived, showed 
a strong binding response when treated with Dectin-1 expressing reporter cells 
(Figure 2. 18). In addition, laminarin, which has been reported to act as both 
a Dectin-1 agonist and antagonist46, was also able to induce a significant 
signalling response of  0.25x the strength of that initiated by curdlan. Lack of 
a response from the mock cell line when exposed to all of the ligands tested 
in this assay demonstrates that the responses seen are a result of ligand-
Dectin-1 interactions. 
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Figure 2. 18 - Dectin-1 reporter cell assay of free-sugars and glycoconjugates. Filled bars represent 
Dectin-1 reporter cells, white bars represent mock reporter cells. Black borders represent free-sugar 
ligands, red borders represent BSA-conjugates. Error bars show standard deviation. Statistical analysis 
shows one-way ANOVA with post-hoc Sidak’s multiple comparison test (P <0.0001 = ****). 
 
It is proposed that Dectin-1-mediated signalling responses occur as a result of 
receptor clustering on the cell surface to form a phagocytic synapse14. The 
insoluble, particulate nature of curdlan contributes to Dectin-1 clustering14, 
leading to a strong binding response by the reporter cell assay. The ability of 
laminarin to initiate a signalling response suggests that branching and not just 
molecular size may play an important role in Dectin-1-mediated signalling. 
Studies have demonstrated that a single branch point inserted onto synthetic 
b-(1-3)-glucan nonasaccharide (29 µM) significantly enhanced the binding 
affinity to Dectin-1 in comparison to linear nona- (2.6 mM) and deca-
saccharides (0.8 mM), with laminarin showing a strong binding capacity (22 
nM)47. 
Interestingly, the linear b-(1-3)-glucan oligosaccharides derived from curdlan, 
both the mixed DP1-23 b-(1-3)-glucans prior to GPC fractionation and the 
DP15 dominant fraction, failed to elicit a Dectin-1-mediated signalling 
response. However, it is possible that these materials do not adhere well to 
the ELISA plate. 
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Conjugation of b-(1-3)-glucans to BSA, to ensure their binding to the ELISA 
plate, (shown by red bars in Figure 2. 18) led to a 2.5x increase in signal 
strength in the case of laminarin conjugates. However, it failed to elicit a 
response from the case of linear DP15 conjugates, suggesting that the simple 
linear b-(1-3)-glucan oligosaccharides of this size are not inducers of Dectin-1 
signalling, even though they are able to bind to Dectin-148. 
 
2.3. Conclusions 
This chapter described efforts to generate and assess b-(1-3)-glucan 
molecular address tags by means of chemical degradation of curdlan. b-(1-3)-
glucans of predominantly DP15, and low molecular weight, branched chain 
laminarin were functionalised with an anomeric azide and coupled to BCN-
functionalised BSA via copper-free click chemistry to yield BSA-BCN-DP15 
and BSA-BCN-laminarin glycoconjugates. Glycoconjugates were 
subsequently analysed for their ability to stimulate signalling in a Dectin-1-
expressing reporter cell line. 
Efforts to generate fragments of b-(1-3)-glucans by partial degradation of 
curdlan through acetolysis produced an array of acetylated b-(1-3)-glucan 
fragments.  Deprotection with NaOMe yielded 115 mg of b-(1-3)-glucans of 
DP1-23. Separation of these chains into their individual counterparts is not 
possible with the technology available today; however, narrowing the average 
DP was achieved by fractionation using aqueous GPC at 40 °C (to aid 
solubility). 
Utilising bioorthogonal click chemistry to conjugate b-(1-3)-glucan tags to BSA 
proved to be an efficient means of coupling. Functionalisation of b-(1-3)-
glucans with anomeric azides using methodologies outlined by Tanaka and 
colleagues41, was selective for the anomeric position in b-configuration. FTIR 
analysis of both DP15 azide and laminarin azide confirmed the introduction of 
an azide, with NMR analysis confirming the location at the anomeric position 
in b-configuration. NMR analysis also revealed the reaction had not gone to 
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completion for DP15 azide, and lack of adequate resolution of the reducing 
terminus meant the reaction efficiency for laminarin could not be determined, 
despite lengthy NMR scans. This one-pot approach of introducing an anomeric 
azide has many advantages over traditional azide introduction via glycosyl 
bromides, in that it does not require the use of protecting group chemistry, and 
does not necessitate the need for multi-stage synthesis. As the reaction is 
conducted in water, the workup can be carried out by aqueous gel permeation 
chromatography. However, this method has been optimised in the literature 
for low molecular weight oligosaccharides up to DP441. In order to improve the 
efficiency of the reaction on large oligosaccharides of DP15+, further 
optimisation is required. In the case of this study, sufficient quantities of azide 
functionalised DP15 and laminarin were generated for further investigation, 
therefore optimisation was not continued further. 
Copper-free click chemistry was employed to conjugate b-glucans to BSA. The 
use of a strained-ring cyclooctyne linkers allows a spontaneous click reaction 
to occur with azide-functionalised molecules, eliminating the need of a copper 
catalyst and making the reaction biocompatible as all by-products are 
biologically safe and easily removed by dialysis. NHS-functionalised 
cyclooctynes (BCN-NHS) allowed for convenient functionalisation of BSA via 
reaction with exposed amines on surface lysine residues. BCN-
functionalisation was successful, with an average of 9.4 BCN moieties 
introduced per mole of BSA, as determined by MALDI-TOF/MS. Conjugation 
of laminarin azide to BCN-functionalised BSA resulted in average conjugation 
of 2 laminarin molecules per mole of BSA. Conjugation of DP15 azide to BCN-
functionalised BSA appeared uneven, with peak splitting being observed by 
MALDI-TOF/MS. The reasons for this remains unclear, to ensure an even 
distribution of conjugation, it may be more efficient to click the azido sugars 
and linker together prior to coupling to protein. Alternatively, it is feasible to 
explore the multitude of conjugation methods available to find an alternative 
reaction allowing more control.  
Linear b-glucans of DP12 have previously been shown to bind to Dectin-130; 
however, the present study shows that a signalling response was not elicited 
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by b-(1-3)-glucans with an average of DP15, either unconjugated or coupled 
to BSA. Interestingly, laminarin and its BSA conjugate were able to induce a 
strong signalling response from the reporter cell line, as was curdlan. This is 
likely due to the large particles being able to induce Dectin-1 clustering, 
allowing a phagocytic synapse to be formed14, as described in Chapter 1.4.2. 
Laminarin is a Dectin-1 antagonist49, however, a recent report suggests that it 
is able to act as both a Dectin-1 agonist and antagonist depending on the 
source from which it is was aquired46. The laminarin used in this study was 
purchased from Sigma (L9634) and was identified as a Dectin-1 agonist by 
Smith et al46 The ability of laminarin to act as a Dectin-1 agonist holds potential 
in targeted vaccination therapies and has been utilised in murine vaccines to 
protect against C. albicans and A. fumigatus in mouse models6. Microscopy 
studies have also shown co-localisation of fluorescently labelled laminarin-
OVA conjugates with fluorescently labelled Dectin-1 expressed on CHO 
cells45.  
It is also worth noting that a common polymorphism in the human langerin 
receptor, which changes Lys-313 to isoleucine, abolishes recognition of 
oligosaccharides with terminal 6SO4-Gal residues and enhances binding to 
oligosaccharides with terminal GlcNAc residues, due to loss of Ca2+ ligation51. 
It is, therefore, possible that differences in nucleotide sequences for receptors 
may lead to differences in ligand recognition between species. In this study, 
murine Dectin-1 has been used as a model to test the ability of b-(1-3)-glucans 
to initiate a Dectin-1-mediated signalling response. Murine Dectin-1 shares 61 
% sequence similarity with human Dectin-1, as outlined in Chapter 1.4, which 
is worth consideration if b-(1-3)-glucans are to be utilised in vaccines for 
humans. Expression of soluble murine and human Dectin-1 receptor proteins 
would allow for differences in binding specificities to be determined. This study 
has shown that binding is not always sufficient to initiate a signalling cascade, 
therefore, generation of a reporter cell line expressing human Dectin-1 would 
be advantageous. Alternatively, isolation of human and murine dendritic cells 
would allow for comparison of cytokine stimulations upon binding to b-glucan 
ligands. Future work in these areas would advance research into the use of b-
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(1-3)-glucans as MATs and allow vaccination therapies to be tailored to each 
organism. 
In conclusion, generation of linear b-(1-3)-glucan DP15 did not produce a 
signalling response when either unconjugated or conjugated to BSA, whereas 
conjugation of laminarin to BSA was able to significantly enhance Dectin-1-
mediated signalling responses. The introduction of laminarin on to vaccine 
therapeutics would give rise to better presentation of antigens on the cell 
surface, resulting in an enhanced antibody response. 
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3. Chapter 3: Antigen generation and immunisation 
This chapter discusses the efforts made to generate carbohydrate antigens, 
conjugation techniques used to generate glycoconjugate vaccines, and 
immunological assessment of sera by ELISA plate assays. 
 
3.1. Mannose antigens 
3.1.1. An introduction into b-(1-2)-mannans as antigens 
As discussed in Chapter 1.5.1, b-(1-2)-mannosides are an uncommon PAMP 
present on the surface of pathogen Candida albicans and have been chosen 
as antigens in this chapter. Research suggests antibody recognition is 
dependent on mannans comprising of a high proportion of b-(1-2)-linkages 
which corresponding to the antigenic region1. Results indicate b-(1-2)-mannan 
trisaccharide antigens are optimal for antibody binding, with a significant 
decrease in activity reported for b-(1-2)-mannan tetra-, penta- and 
hexasaccharides2, with internal residues proving to be immunodominant 
epitopes3, implicating their viability for use as antigens in vaccine conjugates. 
Until recently, b-(1-2)-mannoside antigens could only be obtained by isolation 
from microorganisms4 or by lengthy protecting group chemistry, involving 
multiple steps, complex chemistry and toxic reagents5–8. Discovery of two b-
(1-2)-mannoside phosphorylase enzymes, Teth514_1788 and Teth514_1789, 
has vastly improved the efficiency to synthesise these compounds9. In this 
thesis, Teth514_1788 was utilised to generate b-(1-2)-mannosides, with 
emphasis on the generation of tri- and tetra- saccharides (Figure 3. 1).  
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Figure 3. 1 – Structure of b-(1-2)-mannotriose and b-(1-2)-mannotetraose oligosaccharides. 
 
Immunisation trials of glycoconjugate vaccines consisting of b-(1-2)-
mannotriose antigens have reported a robust antibody response in immunised 
rabbits, with trisaccharide IgG ELISA titres in excess of 1:100,00010. Although 
it has been reported that antibody binding to b-(1-2)-mannotetraose is 
significantly weaker when compared with b-(1-2)-mannotriose2, to the best of 
our knowledge, the immunological effects of b-(1-2)-mannotetraose in 
response to immunisation with b-(1-2)-mannotetraose have not yet been 
investigated. As previously mentioned, b-(1-2)-mannotriose has been shown 
to be optimal for antibody binding, with internal mannose residues proving to 
be the immunodominant epitopes. Using b-(1-2)-mannotetraose as an antigen 
in vaccination studies is a strong candidate for improved antibody responses 
due to an internal b-(1-2)-mannotriose epitope. In order to investigate the 
ability of b-(1-2)-mannotetraose as a carbohydrate antigens, this thesis set out 
to generate both b-(1-2)-mannotriose and -tetraose antigens for use in 
immunisation trials. 
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3.1.1.1. Tetanus toxoid as a protein carrier 
Carbohydrates are often not immunogenic on their own, making them poor 
antigens. Their immunogenicity can be enhanced by coupling to an 
immunogenic carrier proteins, such as keyhole limpet haemocyanin (KLH)11, 
non-toxic diphtheria toxin CRM19712 and virus-like particles13. Tetanus 
Toxoid, a potent neurotoxin produced by Clostridium tetani, is also an effective 
carrier protein14, consisting of both a heavy chain (100 kDa) and a light chain 
(50 kDa). Mild enzymatic cleavage with papain yields two major polypeptides, 
the smaller of which forming the carrier protein, TetHc. Conjugation of 
synthetic b-(1-2)-mannotriose to TetHc improved the immunogenicity 
compared with native Candida cell wall antigen, with average titres in excess 
of 180,000 and 40,000, respectively10. The high immunogenicity and low 
toxicity of TetHc make it an appealing option for a vaccine carrier15. Expression 
of TetHc at high levels in E. coli has been reported16, allowing sufficient 
quantities to be generated with ease. The presence of 33 lysine (Figure 3. 2) 
residues allow for conjugation of antigens17. 
 
 
 
Figure 3. 2 – The structure of tetanus toxoid heavy chain fragment with lysine residues 
highlighted in yellow. 
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3.1.1.2. Conjugation chemistry 
Conjugation chemistry is an extensive research area, with numerous methods 
available for a multitude of applications18. As previously discussed (Chapter 
2.1.2), bifunctional linkers allow two different conjugation methods to be used, 
making them ideal for use in conjugate vaccines. In this chapter, methyl 5-
hexynoate, was employed for conjugation (Figure 3. 3), allowing azide 
functionalised antigens to be reacted with the linker via click-chemistry prior to 
protein conjugation through derivatisation of the methyl ester. 
 
 
Figure 3. 3 – Structure of methyl 5-hexynoate linker. 
 
b-(1-2)-Mannotriose and b-(-1-2)-mannotetraose oligosaccharides were 
functionalised with anomeric azides19 and coupled to methyl 5-hexynoate via 
copper-catalysed click chemistry20. This methodical approach allows 
characterisation of the molecules at each step of the synthesis, and complete 
removal of excess reagents prior to exposure to the protein carrier. Conversion 
of the methyl ester to an acyl azide in situ allows conjugation to carrier proteins 
via the exposed amines on lysine residues21,22, as outlined in Scheme 3. 1. 
OCH3
O
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Scheme 3. 1 – Synthesis of b-(1-2)-mannan glycoconjugates via hydrazide chemistry. Reagents and conditions: a) DMC (5 eq), DIPEA (15 eq), NaN3 (2.5 M) in D2O (0.5 
mL) at RT for 3 hrs; b) methyl 5-hexynoate (5 eq), CuSO4 (0.1 eq), NaASc (0.2 eq), THPTA (10 mM), water/t-butanol (1:10) at 50 °C for 16 hr; c) hydrazine monohydrate (1 mL), 
ethanol (2.5 mL) at 55 °C for 6 hr; d) DMF (1 mL), 4 M HCl in dioxane (9.5 µL), tert-butyl nitrite (1.6 µL) at -25 °C under nitrogen for 15 mins; e) Sulfamic acid (100 µL at 7.4 mg 
mL-1), -25 °C – 0 °C, protein solution (2 mg mL-1 in Borax Buffer) at 4 °C for 36 hr. 
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3.1.2. Results and Discussion 
3.1.2.1. Expression of TETH514_1788, a b-(1,2)-mannose 
phosphorylase 
Enzymatic synthesis of β-(1-2)-mannosides was performed with 
Teth514_1788, a b-(1,2)-mannoside phosphorylase enzyme capable of the 
synthesis and hydrolysis of b-(1,2)-mannosides9. E. coli Rosetta (DE3) cells 
transformed with pET24a (+) Teth514_1788 were a kind gift from Josef 
Voglmeir. Expression of the protein was carried out as outlined by Chiku  et 
al9, as described in Chapter 5.3.1. Analysis of Teth514_1788 performed by 
SDS-PAGE (Figure 3. 4 A) revealed the presence of a large band around 35 
kDa in the induced soluble fraction (Figure 3. 4 A - lane 4). Affinity 
chromatography purification revealed the large band to be comprised of a 
band at 35 kDa and a marginally smaller band at 34 kDa (Figure 3. 4 A – 
lanes 5-11), both corresponding with the Teth514_1788 control in lane 12.  
 
 
Figure 3. 4 – Characterisation of expressed Teth514_1788 by SDS-PAGE (A) and western blot (B). 
Gels were run at 200 V for 60 mins on a 12 % SDS-PAGE gel followed by staining with Coomassie to 
detect protein. Western blot was probed with a mouse anti-His primary antibody and a goat anti-mouse 
HRP conjugate secondary antibody. Lane 1 – Ladder; lane 2 – non-induced; lane 3 – induced, insoluble 
fraction; lane 4 – induced, soluble fraction; lanes 5-11 – AKTA fractions 1-7; lane 12 – Teth514_1788 
standard. 
 
Western blot analysis (Figure 3. 4 B) confirmed the expressed proteins 
contain a His-tag when probed with a mouse anti-His primary antibody and 
developed with a goat anti-mouse HRP conjugate secondary antibody. 
Expression of the His-tagged protein can be seen across all lanes of the blot, 
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including in a non-induced culture (Figure 3. 4 B - lane 2) and in the insoluble 
fraction of an induced culture (Figure 3. 4 B - lane 3), suggesting that ‘leaky 
expression’ of the protein is occurring. Intense bands can be seen in the 
induced soluble fraction (Figure 3. 4 B - lane 4) and across AKTA fractions 1-
7 (Figure 3. 4 B - lane 5-11), with the bands corresponding to the 
Teth514_1788 control in lane 12. The data obtained by western blot is 
consistent with that of SDS-PAGE gel analysis (Figure 3. 4 A). A total of 124.5 
mg of Teth514_1788 was produced from 2 L of culture, as determined by 
Bradford assay (Appendices 6. 8). 
The theoretical mass of His-tagged Teth514_1788 was calculated as 35085.2 
Da. MALDI-TOF/MS analysis of purified Teth514_1788 revealed a mass of 
35003.3 Da (Figure 3. 5), confirming the expressed protein is the correct mass 
for His-tagged Teth514_1788. 
 
 
Figure 3. 5 – MALDI-TOF/MS of purified Teth514_1788. Calculated mass = 35085.2 Da, mass found 
= 35003.3 Da. 
 
3.1.2.2. Synthesis of b-(1,2)-manno-oligosaccharides 
Enzymatic synthesis of oligosaccharides allows fast, linkage specific 
generation of complex carbohydrates, a huge advantage over chemical 
synthesis. To date, access to b-(1-2)-manno-oligosaccharides has relied on 
either isolation from microorganisms, or multistep chemical synthesis5,6,23,24. 
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Teth514_1788 was used to enzymatically synthesise b-(1-2)-manno-
oligosaccharides, as shown in Scheme 3. 2. 
 
 
Scheme 3. 2 – Enzymatic synthesis of b-(1-2)-mannans catalysed by a b-(1-2)-mannose 
phosphorylase. Reagents and conditions: mannose, mannose-1-phosphate (4 eq), 0.1 M ammonium 
acetate (pH 5.0), 30 °C, 6 hr. 
 
Optimisation of the reaction revealed 2 mM mannose, 8 mM mannose-1-
phosphate, Teth514_1788 (10 mg mL-1) in 0.1 M ammonium acetate buffer 
(pH 5.0) at 30 °C for 6 hr was adequate to generate oligosaccharides, as 
confirmed by TLC (Figure 3. 6), 
 
 
Figure 3. 6 – Enzymatic synthesis of b-(1-2)-mannosides analysed by TLC. Solvent system: 
ButOH/EtOH/H2O (10:8:7). M = mannose, * = mannose-1-phosphate, 1 = M:* (1:1), 2 = M:* (1:2), 3 = 
M:* (1:3), 4 = M:* (1:4). TLC developed using orcinol spray and charring. 
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Teth514_1788 was removed from the reaction solution by heating, to 
precipitate proteins, and filtration through a 0.22 µm filter to remove protein 
precipitates. The resulting oligosaccharides were analysed by HPAEC-PAD, 
as outlined in Chapter 5.1.3. Injection of mannose on a CarboPac PA100 
column revealed a retention time of 3.7 minutes (Figure 3. 7 A), which allowed 
for peak assignment of oligosaccharides from DP1 to DP8 at 15.9 min within 
the enzymatic reaction mixture (Figure 3. 7 C). Injection of a mannose-1-
phosphate standard confirmed a retention time of 16.2 min (Figure 3. 7 B). 
Although further oligosaccharides were eluted after this time, peak assignment 
could not be clearly attributed. It is possible that Teth514_1788 is able to use 
M1P as an acceptor, and that these signals are a result of mannose 
oligosaccharides terminated with mannose-1-phosphate. It is also possible 
that Teth514_1788 is not as selective for the b-(1-2)-linkage as initially 
thought, and the unidentified peaks are mannose oligosaccharides with 
linkages other than b-(1-2). 
 
 
Figure 3. 7 – HPAEC-PAD analysis of mannose (A), mannose-1-phosphate (B) and enzymatically 
synthesised b-(1-2)-mannosides (C). Analysis was performed as outlined in Chapter 5.3.2. For 
retention times, see Appendices 6. 9.  
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Buffer salts and excess M1P were removed from solution by passing the 
oligosaccharide mixture through an activated charcoal/Celite (50:50) column. 
Carbohydrates are retained within the lattice structure of the charcoal column, 
allowing functionalised carbohydrates, such as M1P, and salts to pass straight 
through. Oligosaccharides are then eluted from the column by washing with 
95 % ethanol. Concentration of the ethanol fraction yielded 45 mg of mixed 
oligosaccharides. Analysis by HPAEC-PAD confirmed the presence of DP1-8 
with a small number of minor peaks eluting after Man8 (Figure 3. 8). 
 
 
Figure 3. 8 – HPAEC-PAD analysis of b-(1-2)-mannosides purified on a charcoal/celite (1:1) 
chromatography column. For table of retention times, see Appendices 6. 9. 
 
Oligosaccharide masses were determined by MALDI-TOF/MS and were 
consistent with the calculated masses for sodium adducts of DP3-12 (Figure 
3. 9). Matrix interference up to 400 Da did not allow for adequate resolution of 
m/z signals within this region, therefore the presence of DP1 and DP2 could 
not be confidently determined by MALDI-TOF/MS. 
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Figure 3. 9 – MALDI-TOF/MS analysis of enzymatically synthesised b-(1-2)-mannosides. For table 
of masses, see Appendices 6. 10. 
 
3.1.2.3. Isolation of b-(1-2)-mannotriose and b-(1-2)-mannotetraose 
oligosaccharides 
The solubility of b-(1-3)-glucans in water allowed b-(1-2)-mannotriose and b-
(1-2)-mannotetraose to be isolated via gel permeation chromatography. A 
Biogel P2 column (2.5 x 90 cm) was used in water with a flow rate of 0.5 mL 
min-1. Fractions were collected at 6 minutes intervals between 320 and 800 
minutes (Figure 3. 10). Fractions were analysed by HPAEC-PAD 
(Appendices 6. 11) and TLC (Appendices 6. 12) to determine the 
oligosaccharides. 
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Figure 3. 10 – Seperation of b-(1-2)-mannosides (15) by gel permeation chromatography. GPC 
was performed using a Biogel P2 column (2.5 x 90 cm) with an aqueous mobile phase at 0.5 mL min-1. 
Fractions were collected every 6 minutes from 320 to 800 mins. 
 
Fractions containing exclusively b-(1-2)-mannotriose (fractions 43-49) were 
pooled together, as were fractions containing exclusively b-(1-2)-
mannotetraose (fractions 36-41). Following lyophilisation, yields of 6.2 mg and 
5.3 mg were recorded for b-(1-2)-mannotriose and b-(1-2)-mannotetraose, 
respectively. TLC analyses confirmed the samples contained exclusively 
either b-(1-2)-mannotriose (Rf 0.36) or b-(1-2)-mannotetraose (Rf 0.31), as 
shown in Appendices 6. 13.  
HPAEC-PAD analysis also confirmed the homogeneity of the samples, with 
peaks at retention times 9.8 and 11.7 min for b-(1-2)-mannotriose and b-(1-2)-
mannotetraose, respectively (Figure 3. 11). 
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Figure 3. 11 – HPAEC-PAD analysis of b-(1-2)-mannose oligosaccharides. For table of retention 
times, see Appendices 6. 11. 
 
Electrospray ionisation-mass spectrometry (ESI-MS) analysis was chosen to 
perform mass analysis of b-(1-2)-mannotriose and b-(1-2)-mannotetraose as 
oppose to MALDI-TOF/MS were matrix interference results in low mass 
resolution up to approximately 700 Da. ESI-MS confirmed the presences of a 
mass at 526.9 Da, consistent with the calculated mass for [b-(1-2)-
mannotriose+Na]+ (Figure 3. 12 A). The mass for b-(1-2)-mannotetraose was 
also confirmed by the presence of a masses at 688.8 and 689.5 Da, consistent 
with the calculated masses for Na adducts and 13C Na adducts of b-(1-2)-
mannotetraose and b-(1-2)-mannotetraose, respectively (Figure 3. 12 B). 
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Figure 3. 12 – ESI-MS analysis of DP3 b-(1-2)-mannotriose (A) and b-(1-2)-mannotetraose (B). 
Calculated mass [M+Na]+ = 527.2 Da and 689.2 Da, respectively. Masses found [M+Na]+ = 526.9 Da 
and 688.8 Da, respectively, and 13C [M+Na]+ = 528.0 Da and 689.5 Da, respectively. 
 
b-(1-2)-Mannotriose and b-(1-2)-mannotetraose were analysed by NMR. In 
particular, HSQCed 2D NMR spectra showed cross-peak patterns confirming 
the structures of mannose oligosaccharides with b-(1-2) linkages, as the 
values recorded were in line with those stated in the literature for both b-(1-2)-
mannotriose (Figure 3. 13) and b-(1-2)-mannotetraose (Figure 3. 14)4. Clear 
resolution of the anomeric region in b-(1-2)-mannotriose HSQC spectrum 
allowed for assignment of the reducing end signals of H-1Aa and H-1Ab, 
identified by signals at 5.15 and 4.86 ppm, respectively, which correlated with 
13C signals at 91.9 and 93.5 ppm for C-1Aa and C-1Ab hydroxyl groups, 
respectively. Very similar values of chemical shifts were observed for reducing 
end signals. NMR spectra of b-(1-2)-mannotetraose a-anomer can be 
identified by a 1H NMR signal at 5.16 ppm, correlating with 13C NMR signal at 
92.1 ppm; b-anomer was identified by a 1H NMR signal at 4.86 ppm, 
correlating with a 13C NMR signal at 93.5 ppm. Clear identification of the 
anomeric signals of the reducing terminus is essential for these 
oligosaccharides required for subsequent conjugation. 
 106 
 
Figure 3. 13 – HSQC NMR analysis of b-(1-2)-mannotriose (400 MHz, D2O). Red labels represent the 
anomeric position. For a table of chemical shifts, see Appendices 6. 14. 
 
 
Figure 3. 14 – HSQC NMR analysis of b-(1-2)-mannotetraose (400 MHz, D2O). Red labels represent 
the anomeric position. For a table of chemical shifts, see Appendices 6. 15. 
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3.1.2.4. Functionalisation of b-(1-2)-mannosides 
3.1.2.4.1. Generation of methyl 5-hexynoate linker 
By reacting the mannose oligosaccharides to a bifunctional linker prior to 
protein conjugation, it was anticipated that the conjugation efficiency to protein 
carriers would be improved. 
Hexynoic acide was derivatised to methyl 5-hexynoate was generated as 
outlined by Cody et al (Scheme 3. 3)25. Briefly, hexynoic acid (1 g) was reacted 
with methyl iodide (MeI, 1.4 eq) in the presence of potassium carbonate 
(K2CO3, 1.2 eq) in dimethylformamide (DMF, 30 mL) at 0 °C. After 3 hours, the 
reaction was complete, yielding 630 mg of an oily product, with a reaction 
efficiency of 63 %. The complete removal of unreacted starting material was 
confirmed by TLC analysis on silica gel.  
 
 
Scheme 3. 3 – Synthesis of methyl 5-hexynoate linker. Reagents and conditions: Hexynoic acid, 
K2CO3 (1.2 eq), dry DMF, 0 °C. MeI (1.4 eq), 0 °C-RT over 3 hr. 
 
1H NMR analysis of hexynoic acid (Figure 3. 15 A) and methyl 5-hexynoate 
(Figure 3. 15 B) confirmed the conversion of carboxylic acid to methyl ester 
by the appearance of a characteristic signal of the methyl group at 3.6 ppm.  
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Figure 3. 15 – Analysis of hexynoic acid (A) and methyl 5-hexynoate (B) by 1H NMR (400 MHz, 
CDCl3). 
 
13C NMR analysis hexynoic acid (Figure 3. 16 A) and methyl 5-hexynoate 
(Figure 3. 16 B) also confirmed the introduction of a methyl ester by the 
presence of a signal at 51.6 ppm in the spectra for methyl 5-hexynoate. 
 
 
Figure 3. 16 – Analysis of hexynoic acid (A) and methyl 5-hexynoate (B) by 13C NMR (100 MHz, 
CDCl3). 
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3.1.2.4.2. Azide functionalisation of b-(1-2)-manno-oligosaccharides 
Introduction of an azide at the anomeric position of both b-(1-2)-mannotriose 
and b-(1-2)-mannotetraose would allow copper-catalysed click chemistry to be 
utilised for conjugation to the terminal alkyne of the methyl 5-hexynoate linker. 
Functionalisation of the anomeric position of the b-(1-2)-mannosides with an 
azide was achieved as outlined in Scheme 3. 4.  
 
 
R = b-(1-2)-mannotriose b-(1-2)-man-b-(1-2)-man- 
b-(1-2)-mannotetraose b-(1-2)-man-b-(1-2)-man-b-(1-2)-man- 
 
 
Scheme 3. 4 – Reaction scheme for azide functionalised mannose oligosaccharides. a) NaN3 (2.5 
M), DMC (5 eq), DIPEA (15 eq), D2O, 18 hr, RT. 
 
ESI-MS analysis confirmed the correct masses of b-(1-2)-mannotriosyl azide 
(Figure 3. 17 A) and b-(1-2)-mannotetraosyl azide, by [M+Na]+ of 551.9 and 
714.0 Da, respectively. Masses corresponding to unreacted b-(1-2)-
mannotriose and b-(1-2)-mannotetraose were also identified by the presence 
of sodium adduct peaks at 526.9 and 689.1 Da, respectively. 
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Figure 3. 17 – ESI-MS analysis of b-(1-2)-mannotriosyl azide (A) and b-(1-2)-mannotetraose-N3 (B). 
Calculated masses: [b-(1-2)-mannotriose-N3+Na]+ = 552.17, [b-(1-2)-mannotetraose-N3+Na]+ = 714.2. 
Masses found: [b-(1-2)-mannotriose-N3+Na]+ = 551.9, [b-(1-2)-mannotetraose-N3+Na]+ = 714.0. Some 
unreacted b-(1-2)-mannotriose and b-(1-2)-mannotetraose remains, as evident by masses at 526.9 [b-
(1-2)-mannotriose+Na]+ and 689.1 [b-(1-2)-mannotetraose+Na]+. 
 
HSQCed NMR analysis allowed confirmation of the functionalisation on b-(1-
2)-mannotriose with 1-azido group (Figure 3. 18). Chemical shifts at 5.0 ppm 
and 86.9 ppm for 1H NMR and 13C NMR spectra, respectively, are consistent 
with the presence of an anomeric b-azide. A smaller signal at 5.6 ppm in 1H 
NMR spectra, correlating with 87.6 ppm in 13C NMR spectra can be attributed 
to H-1Aa and C-1Aa azide. 
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Figure 3. 18 – HSQCed NMR analysis of b-(1-2)-mannotriosyl azide (400 MHz, D2O). 
 
HSQCed NMR analysis of b-(1-2)-mannotetraosyl azide also confirmed 
formation of anomeric b-azide as followed from 1H NMR chemical shift at 5.0 
ppm, which correlated with a 13C NMR chemical shift at 86.8 ppm (Figure 3. 
19). Unreacted material was also identified by the presence of signals at 5.2 
ppm and 4.9 ppm for H-1Aa and H-1Bb, respectively, which correlated with 13C 
NMR chemical shifts at 92.0 ppm and 93.4 ppm, respectively. 
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Figure 3. 19 – HSQCed NMR analysis of b-(1-2)-mannotetraosyl azide (400 MHz, D2O).  
 
Analysis of compounds by FTIR allows for clear distinction of azide by a strong 
signal within the region of 2160-2120 cm-1. Analysis of b-(1-2)-mannotriosyl 
azide and b-(1-2)-tetraosyl azide confirmed the presence of an azide by a 
strong signal at 2118.5 cm-1 and 2122 cm-1, respectively (Appendices 6. 16). 
 
3.1.2.4.3. Coupling of azide functionalised b-(1-2)-mannosides to methyl 
5-hexynoate via click chemistry 
Traditional methods of copper-catalysed click chemistry26 were employed to 
couple b-(1-2)-mannoside azides to methyl 5-hexynoate, with the addition of 
the accelerating ligand THPTA (tris-hydroxypropyltriazolylmethylamine)27, as 
outlined in Scheme 3. 5. 
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R = b-(1-2)-mannotriose b-(1-2)-man-b-(1-2)-man- 
b-(1-2)-mannotetraose b-(1-2)-man-b-(1-2)-man-b-(1-2)-man- 
 
 
Scheme 3. 5 – Copper catalysed click reaction of azide functionalised b-(1-2)-mannosides with 
methyl 5-hexynoate20. 
 
Briefly, 5 mg of each b-(1-2)-mannotriosyl azide and b-(1-2)-mannotetraosyl 
azide were reacted with methyl 5-hexynoate (5 eq), CuSO4 (0.1 eq), NaASc 
(0.2 eq) and THPTA (0.4 eq) in 300 µL of water/tert-butanol (1:1) at 50 °C for 
16 hr. Extraction by EtOAc washes was used to remove excess reagents 
followed by GPC for further purification. Lyophilisation yielded 4.5 mg and 4.2 
mg of b-(1-2)-mannotriose and b-(1-2)-mannotetraose clicked products, 
respectively. 
Clicked products were analysed by ESI-MS to determine the molecular 
masses of clicked products. b-(1-2)-Mannotriose click product was confirmed 
by the presence of a mass at 678.5 Da, consistent with the calculated mass 
for sodium adducts, 678.2 Da (Figure 3. 20 A).  The presence of b-(1-2)-
mannotetraose click product was confirmed by the presence of a mass at 
840.6 Da, consistent with that calculated for sodium adducts, 840.3 Da 
(Figure 3. 20 B).  
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Figure 3. 20 – ESI-MS analysis of b-(1-2)-mannotriose (A) and b-(1-2)-mannotetraose (B) clicked 
products. Calculated masses = [b-(1-2)-mannotriosyl click+Na]+ = 678.2 Da, [b-(1-2)-mannotetraosyl 
click+Na]+ = 840.3 Da. Masses found = [b-(1-2)-mannotriosyl click+Na]+ = 678.5 Da, [b-(1-2)-
mannotetraosyl click+Na]+ = 840.6 Da. 
 
Successful click reactions were further confirmed by 1H NMR analysis (Figure 
3. 21) which revealed complete disappearance of signals of H-1Aa (5.6 ppm) 
and H-1Ab (5.0 ppm) corresponding to mannosyl azide residues, and the 
appearance of characteristic triazole signals at around 8 ppm28. More 
specifically, triazole signals in both b-(1-2-)mannotriose and b-(1-2)-
mannotetraose click product 1H NMR spectra appeared in pairs at 8.00 and 
7.94 ppm, which can be attributed to b- and a-linked triazole rings, 
respectively. The a-/b-ratio was ca. 1:2 for mannotriose and ca. 1:2.5 for 
mannotetraose derivatives as followed from integration of these signals 
(Appendices 6. 17 and Appendices 6. 18). The same a-/b-ratios were found 
for integrals measured for H-1Aa (6.06 ppm) and H-1Ab (6.14 ppm) signals of 
the reducing ends of triazole-linked b-(1-2)-mannotriose and b-(1-2)-
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mannotetraose derivatives. Multiplets at 1.88-1.95, 2.34-2.39 and 2.70-2.76 
ppm corresponded to protons at positions 3, 4 and 5, respectively, of the linker, 
as numbered in Figure 3. 15. A strong singlet at 3.6 ppm corresponds to the 
methyl group, whereas multiplets between 4.9-3.1 ppm compose the 
characteristic signature of H-2 – H-6 signals of carbohydrates.  
 
 
Figure 3. 21 – 1H NMR analysis of b-(1-2)-mannotriose (A) and b-(1-2)-mannotetraose (B) click 
products (400 MHz, D2O).  
 
3.1.2.5. Conjugation b-(1-2)-mannoside click products to protein 
carriers 
Attempts were made to conjugate b-(1-2)-mannoside click products to TetHc 
and BSA carrier proteins, as outlined in Scheme 3. 6. 
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Scheme 3. 6 – General reaction scheme for conjugation of b-(1-2)-mannotriose and b-(1-2)-
mannotetraosyl click products to carrier proteins. Reagents and conditions: a) hydrazine 
monohydrate, EtOH, 6 hr, 55 °C; bi) tert-butyl nitrite, 4M HCl in dioxane, DMF, -20°C 15 mins; bii) 
TetHc/BSA, 0.08 M Borax/0.35 M KHCO3, pH 9.0, 18 h, 4 °C. 
 
3.1.2.5.1. Expression of soluble tetanus toxoid carrier protein 
Expression of TetHc was performed by induction of E.coli pLysS-TetHc cells 
with IPTG, as described in Chapter 5.3.12. Cell lysate was purified on an 
AKTA prime system equipped with a 5 mL HisTrap HP column (Appendices 
6. 19). Analysis of each stage of the expression process was performed by 
SDS-PAGE and Western blot (Figure 3. 22). A TetHc standard (Figure 3. 22 
– Lane 1) allowed determination of the correct molecular mass by comparison. 
E. coli expression cells prior to IPTG lacked the presence of a 57 kDa His-
tagged protein, as shown by lack of a band at the corresponding size in both 
SDS-PAGE (Figure 3. 22 A – Lane 2) and Western blot (Figure 3. 22 B – 
Lane 2). Following IPTG induction, proteins were isolated into insoluble and 
soluble fractions. SDS-PAGE analysed showed the presence of a large band 
at 57 kDa within the insoluble fraction (Figure 3. 22 A – Lane 3), which 
corresponded with the control band in lane 1. Western blot analysis confirmed 
this protein to contain a His-tag (Figure 3. 22 B – Lane 3). However, analysis 
of the soluble fraction confirmed the presence of a soluble His-tagged protein 
of the correct size (Figure 3. 22 – Lane 4). AKTA purification of His-tagged 
proteins was successful in removing the majority of contaminating proteins 
from the sample, however SDS-PAGE revealed some minor protein bands 
remained (Figure 3. 22 A – Lanes 5-11). Western blot confirmed the large 
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protein band present at 57 kDa was indeed His-tagged (Figure 3. 22 B – Lane 
5-11). 
 
 
Figure 3. 22 – SDS-PAGE (A) and Western blot (B) analysis of TetHc expression. A - 12 % SDS 
gels were run at 200 V for 50 mins. B – Western blot analysis was performed using a mouse anti-His 
primary antibody and a goat anti-mouse(HRP) secondary antibody. L – Ladder, 1 – TetHc standard, 2 – 
Non-induced E.coli cells, 3 – Induced insoluble fraction, 4 – Induced soluble fraction, 5-11 – AKTA 
fractions A1-A7. 
 
In an attempt to remove residual contamination proteins, TetHc was subjected 
to further purification by GPC, as described in Chapter 5.3.12. SDS-PAGE 
analysis confirmed that this purification was successful in removing residual 
proteins (Figure 3. 23). Protein yield was determined, by BCA assay, to be 55 
mg from 1 L of culture. 
 
 
Figure 3. 23 – SDS-PAGE analysis of TetHc AKTA GPC fractions. L – ladder, 1 – TetHc standard, 2 
– AKTA fractions (pre GPC), 3-11 – AKTA GPC fractions C3-D7. 
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MALDI-TOF/MS analysis revealed the molecular mass of the purified protein 
to be 56.4 kDa, consistent with the predicted mass of His-tagged TetHc 
(Figure 3. 24).  
 
Figure 3. 24 - MALDI-TOF/MS of purified TetHc. Expected mass = 57 kDa. mass found = 56.4 kDa. 
 
 
3.1.2.5.2. Conjugation of b-(1-2)-mannoside click products to TetHc and 
BSA carrier proteins 
Conjugate b-(1-2)-mannoside click products was targeted towards exposed 
lysine residues on BSA and TetHc carrier proteins by conversion of the 
terminal methyl ester group to an acyl hydrazide. b-(1-2)-Mannotriosyl and b-
(1-2)-mannotetraosyl click products (4 mg each) were reacted with hydrazine 
monohydrate in ethanol for 6 hr at 55 °C. Co-evaporation of excess reagents 
with toluene yielded 5 mg of b-(1-2)-mannotriose and b-(1-2)-mannotetraose 
acyl hydrazide products. Conversion of methyl ester to hydrazide was 
confirmed 1H NMR analysis by the loss of a signal at d 3.6 ppm for both b-(1-
2)-mannotriosyl (Appendices 6. 20 A) and b-(1-2)-mannotetraosyl 
(Appendices 6. 20 B) acyl hydrazide products. 
In order for conjugation of acyl hydrazide products to exposed lysine residues 
on BSA and TetHc carrier proteins, acyl hydrazides were converted to acyl 
azides29. The reaction conditions for this to occur are described in Chapter 
5.3.13. Briefly, tert-butyl nitrite was reacted with 4 M HCl in DMF at -25 °C to 
produce nitrous acid, allowing in situ conversion of acyl hydrazide to acyl azide 
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via oxidation. Sulfamic acid (740 µg in DMF) was added to the acyl azide 
solutions, to prevent the build-up of nitrous oxide30, and the reaction allowed 
to reach 0 °C before being added dropwise to a cooled solution of protein in 
Borax buffer, pH 9.031. 
Successful conjugation of acyl azide functionalised b-(1-2)-mannotriose and 
b-(1-2)-mannotetraosyl click products is dependent on the primary amines of 
lysine residues being in the free base form (Scheme 3. 7)22,32.  
 
 
Scheme 3. 7 – Reaction mechanism for amide bond formation. 
 
To ensure lysine residues were in the free base form, the conjugation reaction 
was performed in Borax buffer, pH 9.0. However, upon addition of the acyl 
azides to cooled protein solutions, protein precipitation occurred. Attempts to 
determine the degree of conjugation by MALDI-TOF/MS were unsuccessful 
(data not shown). SDS-PAGE analysis of TetHc conjugates did not reveal a 
band shift when compared to native TetHc (Figure 3. 25 A). Analysis of BSA 
conjugates, however, did reveal a slight band shift by SDS-PAGE (Figure 3. 
25 B), although the presence of carbohydrates could not be detected when 
analysed by InvivogenTM Pro-Q™ Emerald 300 Glycoprotein Gel and Blot 
Stain Kit (Figure 3. 25 C). 
TetHc / BSAN
H
HR N
O
N N
TetHc / BSAN
H
R
O
+     HN3
 120 
 
Figure 3. 25 – SDS-PAGE analysis of b-(1-2)-mannoside protein conjugates. Gel analysis was 
performed on 4-20 % SDS-PAGE gels at 200 V. A) SDS-PAGE analysis of TetHc conjugates; B) SDS-
PAGE analysis of BSA conjugates; C) InvivogenTM Pro-QTM Emerald 300 Glycoprotein Gel stain of 
TetHc and BSA conjugates. L = Precision Plus Protein Ladder, 1 = Native TetHc, 2 = TetHc-b-(1-2)-
mannotriose conjugate, 3 = TetHc-b-(1-2)-mannotetraose conjugate, 4 = Native BSA, 5 = BSA-b-(1-2)-
mannotriose conjugate, 6 = BSA-b-(1-2)-mannotetraose conjugate. 
 
These conjugation efforts require further experimentation to optimise, 
however, time did not allow for this and conjugation efforts were not continued 
further. Future work should focus on optimising the conjugation technique for 
coupling to protein carriers. Direct conversion of hexynoic acid to the acyl 
azide would be a more direct approach for conjugation and is worth 
consideration. 
 
3.2. Virenose antigens for a Q fever vaccine 
3.2.1. An introduction to Virenose 
To date vaccination therapies against Q fever have comprised of whole killed 
Phase I Coxiella burnetii cells, as described in Chapter 1.5.233–35. C. burnetii 
exists in two LPS phases, the avirulent phase II, comprising of a lipid A moiety 
coupled to an inner core and an outer core, and the virulent phase I34, which 
in addition to Phase LPS also contains an O antigen region (Figure 3. 26).   
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Figure 3. 26 – Tentative structure of C. burnetii Phase I and II LPS. 
 
Research into the carbohydrate composition of the O antigen has revealed the 
presence of two unique sugars, virenose and dihydrohydroxystreptose 
[(DHHS) Figure 3. 27], accounting for 32.3 % and 6.7 % of the polysaccharide 
composition, respectively, although the exact position of the sugars within the 
O antigen is yet to be determined36. 
 
Figure 3. 27 – The chemical structure of virenose and dihydrohydroxystreptose (DHHS). 
 
Given the uniqueness of virenose, and its presence within the O antigen of C. 
burnetii, it is reasonable to believe that vaccines containing virenose antigens 
would generate a potent enough Ab response to protect against Q fever 
infection. Presently, isolation of virenose from C. burnetii has only resulted in 
crude LPS mixtures which requires the use of category 2 growth facilities, and 
complex chemical synthesis is required to yield pure virenose antigens37,38. In 
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this study, disaccharide virenose antigens of a-Vir(1-4)-a-Vir-propyl azide and 
b-Vir(1-4)-b-Vir-propyl azide were chemically synthesised by Dr Irina Ivanova 
of the John Innes Centre.  
 
3.2.1.1. Virus-like particle carrier protein in a Q fever vaccine 
Virus-like particles are becoming an increasing popular candidate as a protein 
carrier in vaccination therapies39,40 since their first use in the 1980s41,42. To 
date, 5 VLP vaccines are commercially available (Table 3. 1), with a number 
of others currently undergoing clinical trials40. 
 
Table 3. 1 - Commercial VLP vaccines 
VLP Vaccine name Ref 
Human Papilloma Virus (HPV) Cervarix ® 43,44 
Gardasil ® 43–46 
Gardasil9 ® 47–49 
Hepatitis B Virus (HBV) 3rd generation Sci-B-VacTM 50,51 
Malaria MosquirixTM 52–54 
 
VLPs consist of the multi-protein shell of virus particles, spanning 20-200 nm 
in size, but lack a viral genome required for replication allowing them the ability 
to induce potent immune responses55. In this study Conjucore, a Hepatitis B 
VLP modified to contain a DKDKDK insert to enhance conjugation efficiency, 
was provided by Dr Lucy Beales of Mologic to act as a protein carrier, (Figure 
3. 28). 
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Figure 3. 28 – The crystal structure of Hepatitis B HBcAg virus-like particle containing a DKDKDK 
insert. 
 
In this study, laminarin was chosen to act as a molecular address tag due to 
its ability to initiate a strong Dectin-1-mediated signalling response, as shown 
in Chapter 2.2.6. Literature reports have shown the addition of laminarin to 
vaccine conjugates can increase the antibody response towards the antigen14 
and laminarin itself is able to raise antibodies which are effective against 
murine vaginal candidiasis56. Laminarin azide was provided to Dr Simone 
Dedola of Iceni Diagnostics to generate a targeted virenose vaccines 
consisting of a-Vir(1-4)-a-Vir-propyl azide (Figure 3. 29 A) or b-Vir(1-4)-b-Vir-
propyl azide (Figure 3. 29 B) and laminarin conjugated to Conjucore VLP via 
BCN-NHS linkers, as described in Chapter 5.3.14. 
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Figure 3. 29 – Structure of laminarin targeted a-Vir(1-4)-a-Vir (A) and b-Vir(1-4)-b-Vir (B) vaccine 
conjugates. 
 
3.2.2. Results and Discussion 
3.2.2.1. Immunisation trials of laminarin-VLP-virenose conjugates 
In an attempt to generate an improved vaccination therapy to protect against 
Q fever, a tri-component vaccine was generated which consisted of a central 
VLP protein carrier (Conjucore), to which disaccharide virenose antigens and 
a laminarin address tag were coupled, as outlined in Figure 3. 29. Azide-
functionalised laminarin was provided to Dr Simone Dedola of Iceni 
Diagnostics for generation of targeted Q fever vaccination. Vaccines 
comprising of α-Vir(1-4)-α-Vir and β-Vir(1-4)-β-Vir propyl azide constructs and 
azide functionalised laminarin conjugated to Conjucore VLP were prepared via 
copper-free click chemistry, as described in Chapter 2.1.2. Laminarin was 
chosen to act as a molecular address tag as Dectin-1 binding studies 
performed in Chapter 2.2.6 showed laminarin was able to induce a strong 
Dectin-1-mediated signalling response when conjugated to a BSA carrier 
protein.  
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3.2.2.2. Immunisation of vaccine conjugates 
Immunisation trials were performed by Mologic as outlined in Chapter 5.3.15. 
Briefly, VLP conjugates were emulsified with Complete Freunds adjuvant for 
immunisation which were administered to 2 rabbits at 10 µg as 4 x 0.25 mL 
injection sites on days 0, 28, 56 and 84 (Figure 3. 30). Bleeds were taken on 
days 0 (pre-immunisation), 35 (bleed 1), 63 (bleed 2) and 91 (bleed 3). 
 
 
Figure 3. 30 – Immunisation time line for virenose vaccination trials. Purple line represents Day 0 
when a pre-bleed was taken, and the first immunisation was received. Green lines represent days when 
boost immunisations were received. Red lines represent days when bleeds were taken. 
 
VLP conjugates were prepared for immunisation by emulsifying with adjuvant 
to a final injection volume of 1 mL. Immunisation was performed with Complete 
Freunds adjuvant and all boost injections were emulsified in Incomplete 
Freunds adjuvant. VLP glycoconjugate were injected intramuscularly into 2 
rabbits at 4 sites, 1 injection into each thigh muscle and subcutaneously into 
2 sites on the back. A total of 0.25 mL of emulsion was injected at each site. 
Rabbits were immunised with 10 µg of VLP glycoconjugate on day 0 with 
boosts being provided on days 28, 56 and 84. A preimmune bleed was taken 
on day 0, before immunisation, and test bleeds were taken on days 35, 63 and 
91. Blood samples were collected from the marginal ear vein into a sterile vial. 
For preimmune and test bleeds, 25 mL of whole blood was collected, and 50 
mL of whole blood collected for all subsequent bleeds (dependent on body 
weight). 
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3.2.2.3. Generation of BSA conjugates 
To analyse the antibody response generated towards out VLP vaccine 
conjugates, a series of BSA-antigen conjugates were generated (Figure 3. 
31).  
 
Figure 3. 31 – Summary of BSA conjugates generated for ELISA analysis. 
 
 127 
Briefly, virenose mono- and disaccharide antigens were synthesised by Dr 
Irina Ivanova of the John Innes Centre. As well as the laminarin azide prepared 
in Chapter 2.2.4 the antigens were reacted with BSA-BCN, prepared in 
Chapter 2.2.5. As a control, propyl azide was also reacted with BSA-BCN. 
The presence of virenose on BSA conjugates was determined by SDS-PAGE 
and Western blot analysis. Following conjugation, all virenose conjugates 
show a shift in band size by SDS-PAGE, confirming that the molecular mass 
has increased following conjugation (Figure 3. 32 A1, 2, 3 and 4), in 
comparison to BCN-BSA controls (Figure 3. 32 *).  
 
  
 
Figure 3. 32 – SDS-PAGE (A) and Western blot (B) analysis of BCN-BSA (*), a-Vir(1-4)-a-Vir-BCN-
BSA (1), a-Vir-BCN-BSA (2), b-Vir(1-4)-b-Vir-BCN-BSA (3) and b-Vir-BCN-BSA (4). SDS-PAGE 
analysis was performed on pre-cast 4-20 % SDS-PAGE gels at 200 V for 60 mins. Western blot analysis 
was performed with blood serum from rabbits immunised with the corresponding virenose configuration 
and developed with a mouse anti-rabbit HRP secondary antibody. 
 
Western blot analysis of the BSA conjugates was performed with serum 
obtained from the immunisation trials. Serum from rabbits immunised with a-
Vir(1-4)-a-Vir-BCN-VLP-BCN-laminarin were used to probe for a-Vir(1-4)-a-
Vir- and a-Vir- BSA conjugates, and similarly, serum from  b-Vir(1-4)-b-Vir-
BCN-VLP-BCN-laminarin immunised rabbits was used to probe for b-Vir(1-4)-
b-Vir- and b-Vir- BSA conjugates. Blots were developed by probing with a 
secondary mouse anti-rabbit HRP antibody. Clear bands can be observed 
across all virenose conjugates (Figure 3. 32 B1, 2, 3 and 4), whereas no 
bands could be detected in BCN-BSA standard (Figure 3. 32 B*). Therefore, 
it was deduced that virenose conjugation was successful. 
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Laminarin conjugation to BSA was also shown to be successful by the 
presence of a characteristic smear for laminarin-BCN-BSA conjugates by 
SDS-PAGE (Figure 3. 33 A), which was confirmed to contain b-(1-3)-glucans 
by Western blot analysis performed with an anti b-(1-3)-glucan primary 
antibody (Figure 3. 33 B). 
 
 
Figure 3. 33 – Analysis of BSA (*) and laminarin-BCN-BSA (1) conjugates by SDS-PAGE (A) and 
Western blot analysis (B). 
 
 
3.2.2.4. Immunological analysis of anti-virenose conjugate antibodies 
Enzyme-linked immunosorbent assays were employed to determine the IgG 
antibody response generated as a result of immunisation with laminarin 
targeted a-Vir(1-4)-a-Vir and b-Vir(1-4)-b-Vir vaccine conjugates (Scheme 3. 
7). Standard ELISA (Scheme 3. 8A) allowed detection of IgG responses 
directed towards specific antigens, whereas competitive ELISA allows the 
specificity of this interaction to be determined (Scheme 3. 8B). BSA 
conjugates described in Figure 3. 31 were adhered to a 96-well ELISA plate 
and subjected to standard ELISA analysis as described in Chapter 5.3.16. 
Serum samples from all bleeds were analysed (Appendices 6. 21), with bleed 
 129 
3 showing the strongest response, as expected due to the development of 
cellular memory by the immune system. As outlined in Chapter 1.5, after 3-4 
weeks antibody generation ceased. Re-immunisation with the same antigen 
results in constant stimulation of the immune system and a stronger antibody 
response. 
 
 
Scheme 3. 8 – Schematic representation of standard ELISA (A) and competitive ELISA (B). 
Standard ELISA (A) is performed by adhering the target antigen (Ag) to an ELISA plate. Serum is then 
applied to the plate to allow antibody-antigen recognition to occur, any unbound antibodies are washed 
away. A secondary antibody is applied, which recognises the primary antibody and allows colourimetric 
detection. Competitive ELISA (B) differs from standard ELISA in that serum is pre-incubated with a target 
analyte prior to incubation with the target antigen. Specific antibody recognition is determined by a 
colourimetric response if towards the target antigen, or lack of a colourimetric response if antibody 
recognition is specific towards the target analyte. 
 
3.2.2.4.1. Analysis of antibody response towards disaccharide antigens 
Serum derived from a-Vir(1-4)-a-Vir-BCN-VLP-BCN-laminarin-immunised 
rabbits was not able to recognise b-Vir(1,4)-b-Vir antigens (Figure 3. 34 A) 
but showed a strong response towards a-Vir(1-4)-a-Vir-, with a significant 
difference (P <0.05) when compared to the pre-immune serum of the same 
rabbits (Figure 3. 34 B). Interestingly, serum from b-Vir(1-4)-b-Vir-BCN-VLP-
BCN-laminarin immunised rabbits was able to recognise b-Vir(1-4)-b-Vir- 
antigen with a P value of 0.002 (Figure 3. 34 A) but was also able to recognise 
a-Vir(1-4)-a-Vir- antigen (Figure 3. 34 B), although this response was not 
significant with a P value of 0.0514. The ability of serum from b-Vir(1-4)-b-Vir-
BCN-VLP-BCN-laminarin immunised rabbits to recognise both disaccharide 
antigens posed the question of whether the antibody response was generated 
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towards the disaccharide antigen, or whether monosaccharide a or b virenose 
antigens are sufficient to see a response. 
 
3.2.2.4.2. Analysis of antibody response towards monosaccharide 
antigens 
Analysis of the serum towards monosaccharide antigens showed only b-Vir(1-
4)-b-Vir-BCN-VLP-BCN-laminarin immunised was able to recognise b (Figure 
3. 34 C) and a (Figure 3. 34 D) monosaccharide antigens, with P values of 
0.0106 and 0.0280, respectively. Although the serum response from a-Vir(1-
4)-a-Vir-BCN-VLP-BCN-laminarin immunised rabbits was slightly elevated 
above the response from pre-immune serum for both a and b monosaccharide 
virenose antigens, these responses were not significant. 
 
3.2.2.4.3. Analysis of antibody response towards Conjucore VLP 
The use of immunogenic carrier proteins is essential for generating a strong 
immune response towards carbohydrates, which are often not immunogenic 
on their own. Conjucore VLP comprised the carrier protein component of the 
vaccines used in these trials. ELISA analysis of serum derived from a-Vir(1-
4)-a-Vir-BCN-VLP-BCN-laminarin and b-Vir(1-4)-b-Vir-BCN-VLP-BCN-
laminarin immunised rabbits both showed a strong antibody response towards 
Conjucore, with no antibody responses detected prior to immunisation by 
either (Figure 3. 34 E).   
 
3.2.2.4.4. Analysis of antibody response towards laminarin 
Laminarin was incorporated into the vaccine conjugate to target the vaccine 
towards Dectin-1 expressed on APCs in an attempt to generate a more robust 
antibody response. Literature reports have shown increased antibody 
responses upon the addition of laminarin, with IgG antibodies also being 
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raised towards laminarin14,57. However, in this study, a laminarin antibody 
response could not be detected from either a-Vir(1-4)-a-Vir-BCN-VLP-BCN-
laminarin or b-Vir(1-4)-b-Vir-BCN-VLP-BCN-laminarin immunisation serums 
(Figure 3. 34 F). 
 
3.2.2.4.5. Analysis of antibody response towards triazoles 
Reports in the literature raise concern over the immunogenicity of triazoles 
which are formed as a result of azide-alkyne click reactions58. To deduce 
whether an IgG antibody response had been generated towards the triazoles 
used in this study, BCN-BSA was reacted with azidopropanol to generate a 
triazole for use as an antigen in ELISA assay. However, triazole specific 
antibodies could not be detected in the serums of a-Vir(1-4)-a-Vir-BCN-VLP-
BCN-laminarin or b-Vir(1-4)-b-Vir-BCN-VLP-BCN-laminarin immunised 
rabbits (Figure 3. 34 G). 
 
3.2.2.4.6. Ability of antibodies to recognise Coxiella burnetii 
Whole killed C. burnetii cells were kindly provided by DSTL in order to analyse 
the antibody response generated from our immunisation trials. Interestingly, 
serum from a-Vir(1-4)-a-Vir-BCN-VLP-BCN-laminarin and b-Vir(1-4)-b-Vir-
BCN-VLP-BCN-laminarin immunised rabbits did not produce a significant 
response towards C. burnetii cells (Figure 3. 34 H). Similarly, a significant 
response was not detected in response to Coxevac®, a commercial vaccine 
administered to livestock to protect against Q fever composed of whole killed 
cells, by either serum (Figure 3. 34 I). 
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Figure 3. 34 – Comparison of prebleed and bleed 3 standard ELISA of a-Vir(1-4)-a-Vir- (black circles) and b-Vir(1-4)-b-Vir- (red squares) BCN-VLP-BCN-Laminarin 
immunised rabbits. P values: * = 0.05, ** = 0.01, *** = 0.005. 
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Competitive ELISA was performed to determine the binding preference of 
antibodies generated in response to a-Vir(1-4)-a-Vir-BCN-VLP-BCN-
laminarin and b-Vir(1-4)-b-Vir-BCN-VLP-BCN-laminarin immunisation. 
Analysis of serum responses towards a-Vir(1-4)-a-Vir-BCN-BSA antigen were 
performed with and without pre-incubation with b-Vir(1-4)-b-Vir-BCN-BSA 
analyte (Figure 3. 35 A). No significant change in response was seen when 
a-Vir(1-4)-a-Vir-BCN-VLP-BCN-laminarin serum was incubated with analyte, 
however, b-Vir(1-4)-b-Vir-BCN-VLP-BCN-laminarin serum showed an almost 
complete loss of response when incubated with b-Vir(1-4)-b-Vir-BCN-BSA 
analyte when compared to the serum alone. Competitive ELISA analysis of 
serum responses towards b-Vir(1-4)-b-Vir-BCN-BSA antigen did not reveal 
any significant change in response when the serum was preincubated with an 
a-Vir(1-4)-a-Vir-BCN-BSA analyte compared to serum alone (Figure 3. 35 B). 
 
 
Figure 3. 35 – Competition ELISA of virenose disaccharide BSA conjugates. A) a-Vir(1-4)-a-Vir-
BCN-BSA antigen and b-Vir(1-4)-b-Vir-BCN-BSA analyte. B) b-Vir(1-4)-b-Vir-BCN-BSA antigen and a-
Vir(1-4)-a-Vir-BCN-BSA analyte. Bar colours represent the following serum samples: black - a-Vir(1-4)-
a-Vir-BCN-VLP-BCN-Laminarin, grey a-Vir(1-4)-a-Vir-BCN-VLP-BCN-Laminarin serum plus analyte, 
red - b-Vir(1-4)-b-Vir-BCN-VLP-BCN-Laminarin, b-Vir(1-4)-b-Vir-BCN-VLP-BCN-Laminarin serum plus 
analyte. P value: ** = 0.01. 
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A standard ELISA was performed with a commercial C. burnetii monoclonal 
antibody, which was raised against the phase I LPS of C. burnetii. Virenose 
has been shown to be present within the O antigen section of phase I LPS36 
(Chapter 1.5.2), therefore a strong response towards virenose BSA 
conjugates was anticipated. Interestingly, none of the BSA conjugates were 
able to elicit a response with this antibody, however, Coxevac and whole killed 
C. burnetii cells were both able to elicit a strong response (Figure 3. 36).  
 
 
 
Figure 3. 36 – Standard ELISA of BSA conjugates, Coxevac vaccine, Coxiella and VLP probed 
with a commercial C. burnetii Phase I LPS pAb. 
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3.2.3. Conclusions 
The initial work described in this chapter demonstrates the ability to yield b-(1-
2)-mannan oligosaccharides in milligram quantities by enzymatic synthesis, 
with polymerisation ranging from DP1-8. b-(1-2)-Mannotriose and b-(1-2)-
mannotetraose were successfully isolated by GPC, with yields of 6.2 mg and 
5.3 mg, respectively. The isolated oligosaccharides were subsequently 
functionalised with anomeric azides using methodologies outlined by Tanaka 
et al19, resulting in mixture of a and b anomeric azide for b-(1-2)-mannotriose, 
but only b-azides for b-(1-2)-mannotetraose, as determined by HSQCed NMR. 
Methyl 5-hexynoate was chosen to act as a bifunctional linker to allow 
conjugation of b-(1-2)-mannosides to TetHc and BSA carrier protein. Copper-
catalysed click chemistry proved to be an efficient mechanism of conjugation 
of sugar azides to the linker. Although derivatisation of the methyl ester to an 
acyl hydrazide was successful, conjugation to BSA and TetHc carrier proteins 
resulted in protein precipitation. Conjugation by this method has proved 
successful in literature reports, and it is likely that optimisation of the reaction 
conditions would lead to successful conjugation in the future, however time 
restraints meant that these efforts could not be pursued. 
The latter part of this chapter focuses on the immunisation efforts of a 
laminarin targeted vaccination therapy comprised of either a-Vir(1-4)-a-Vir-
BCN-VLP-BCN-laminarin or b-Vir(1-4)-b-Vir-BCN-VLP-BCN-laminarin. Serum 
analysis by ELISA plate assays revealed antibodies were successfully raised 
against virenose antigens, although the specificity varied depending on 
linkage. Immunisation with a-Vir(1-4)-a-Vir-BCN-VLP-BCN-laminarin 
generated an antibody response specific towards the a-Vir(1-4)-a-Vir- 
disaccharide antigen. However, immunisation with b-Vir(1-4)-b-Vir-BCN-VLP-
BCN-laminarin generated a strong response towards b-Vir(1-4)-b-Vir- 
disaccharide and b-Vir- monosaccharide antigens, but a significant response 
towards a-Vir(1-4)-a-Vir- disaccharide and a-Vir monosaccharide was also 
observed. 
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Interestingly, neither whole killed C. burnetii cells nor Coxevac® were 
recognised by antibodies present in the serum of either vaccination therapies. 
Literature reports have revealed a virenose content of 32.2 mol % within the 
O antigen of phase I LPS, although the sequence of O antigen carbohydrates 
is unknown. Although the virenose content is relatively high, it may be that it 
is submerged within the O antigen and not accessible to antibodies. 
The implications of using laminarin to target vaccines towards DCs in 
immunisation trials remains unknown. Lack of rabbit availability meant test 
groups consisted of 2 rabbits for treatment without a non-laminarin control 
group. In this study, laminarin was not able to generate an IgG antibody 
response, contradictory to what is reported in the literature. b-(1-3)-glucans 
are present on the surface of many microbial species, therefore exposure to 
such species prior to commencement of the immunisation may result in a basal 
level anti-b-(1-3)-glucan antibody response. To determine whether the 
addition of laminarin to vaccine translates into a more robust antibody 
response, larger test groups are required. 
In conclusion, b-(1-2)-mannose oligosaccharide antigens were successfully 
synthesised enzymatically, with b-(1-2)-mannotriose and b-(1-2)-
mannotetraose isolated via gel permeation chromatography. Although 
conjugation efforts to BSA and TetHc carrier proteins resulted in protein 
precipitation, further optimisation is required to allow for successful 
conjugation. Although immunisation with virenose antigens were able to raise 
a significant virenose specific antibody response these were not able to 
recognise C. burnetii, the use of virenose antigens in immunisation should not 
be ruled out. The rare occurrence of virenose in nature provides a unique 
opportunity to generate a specific vaccination therapy against Q fever, with 
little cross-reactivity with other species. A better understanding of the 
sequence of carbohydrates within the O antigen of LPS would provide more 
insight into what is needed to generate a protective antibody response. 
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4. Chapter 4: Conclusions and Future Outlook 
Targeting vaccines towards receptors of the immune system holds great 
potential in improving vaccination therapies and diagnostics. The use of 
molecular address tags with high affinities for immune receptors holds the 
prospect of better presentation of antigen epitopes by antigen presenting cells 
(APCs), leading to enhanced antibody responses with greater specificity 
towards the antigen (Figure 4. 1). As discussed in Chapter 1.4, Dectin-1, a 
member of the C-type lectin family of receptors, is an appealing candidate for 
targeted therapies due to its high specificity for b-(1-3)-glucan 
oligosaccharides of at least DP121. This thesis set out to exploit the Dectin-1 
receptor, in order to achieve enhanced antibody responses towards antigens, 
by generating b-(1-3)-glucan address tags for incorporation into vaccination 
therapies. 
 
Figure 4. 1 – Schematic representation of targeted vaccines reading to presentation of antigen 
and generation of a specific antibody response. 
 
This final chapter summarises the progress made during this thesis and the 
implications this research has for future vaccine designs. 
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4.1. b-Glucan address tags and their ability to bind to Dectin-1 
Generation of b-(1-3)-glucan address tags was performed using naturally 
occurring sources of b-(1-3)-glucans, curdlan and laminarin. Curdlan, an easily 
accessible particulate form of b-(1-3)-glucan produced by Agrobacterium spp., 
was subjected to chemical degradation by acetolysis [acetic anhydride/acetic 
acid (1:1)], to afford a range of linear acetylated b-(1-3)-glucan fragments of 
varying chain lengths. Initial fractionation was performed using flash 
chromatograph to isolate a series of acetylated oligosaccharides ranging from 
DP1-DP25. Following deacetylation using sodium methoxide (NaOMe), b-(1-
3)-glucans were further fractionated by gel permeation chromatography to 
yield a fraction of b-(1-3)-glucans with an average DP of 15 which was chosen 
to act as an address tag based on literature reports suggesting a minimum of 
DP12 is required for binding to the Dectin-1 carbohydrate recognition domain 
(CRD)1. Laminarin, a naturally occurring b-(1-3)-glucan with occasional b-(1-
6)-side chains, was also chosen for use as an MAT due to its known 
interactions with Dectin-12.  
Many methods of conjugation exist for coupling carbohydrates to proteins. In 
this thesis, biorthogonal copper-free click chemistry was employed to 
conjugate b-(1-3)-glucan tags to BSA due to the biocompatibility of the 
reaction making it a safe option for use in vaccination therapies. A bifunctional 
linker, BCN-NHS, was used to pre-functionalised BSA with strained-ring 
cyclooctynes, which are able to react specifically and spontaneously with 
azide-functionalised molecules. Azides were introduced at the anomeric C-1 
position of both b-(1-3)-glucan DP15 and laminarin using the methodology 
outlined by Tanaka et al3, allowing the molecules to be conjugated by simply 
mixing together. Successful conjugation was confirmed by SDS-PAGE 
analysis, and Western Blot performed with an anti-b-(1-3)-glucan monoclonal 
antibody (mAb).  
The ability of b-(1-3)-glucans to interact with Dectin-1 was analysed using a 
reporter cell line expressing murine Dectin-1. Whilst linear b-(1-3)-glucans of 
DP12 are able to bind to Dectin-1, DP15 was unable to induce a Dectin-1-
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mediated signalling response, either as free oligosaccharides or conjugated to 
BSA. It was established that curdlan, a particulate b-(1-3)-glucan, was able to 
induce a strong Dectin-1-mediated signalling response, suggesting the 
dimerisation of Decitn-1 receptors, as described by Goodridge et al4. The 
ability of curdlan to initiate a Dectin-1-mediated signalling response highlights 
its potential use as an address tag. Conjugation of antigens directly on to the 
surface curdlan particles, as outlined in Figure 4. 2, possess an interesting 
prospect for a vaccine candidate. Further work is needed to verify this 
potential, but a two-component vaccine could simplify the process for 
generating glycoconjugate vaccines which are able to target to immune 
receptors and provide immunological protection. As carbohydrates are poorly 
immunogenic on their own, the choice of antigen would need careful 
consideration to ensure a robust immune response is achieved. 
 
Figure 4. 2 – Schematic representation of a curdlan vaccine. 
 
Laminarin was able to initiate a small signalling response when subjected to 
the reporter cell assay as a free oligosaccharide, suggest b-(1-6)-side 
branches, which are present in laminarin and possibly within curdlan5, play a 
crucial role in Dectin-1 signalling. Interestingly, conjugation of laminarin to BSA 
enhanced the signalling response by 2.5x orders of magnitude. It is likely that 
the multimeric display of laminarin on the surface of BSA was able to induce 
Dectin-1 clustering, leading to initiation of a signalling cascade. It is possible 
that laminarin could also be implemented into a dual component vaccine, with 
antigens conjugated directly on to laminarin. However, the antagonistic 
propertis of laminarin towards Dectin-1 may hinder its use as an address tag. 
 148 
In order to induce a strong signalling response, formation of laminarin 
glycoclusters is worth consideration. Multimeric presentation of laminarin on 
dendrimers to form glycoclusters, as outlined in Figure 4. 3, may allow for 
larger clustering of Dectin-1 receptors. With the development of new, 
multivalent scaffolds, this may prove a good candidate for targeted vaccines6. 
 
Figure 4. 3 – Schematic representation of b-glucan glycoclusters targeted antigens. 
 
4.2. b-(1-2)-Mannan antigens 
b-(1-2)-Mannotriose has previously been used in glycoconjugate vaccines due 
to its well characterised immunogenic effects7, to the best of our knowledge, 
the immunological effects of b-(1-2)-mannotetraose remain unknown. 
Generation of b-(1-2)-mannose antigens has previously relied on complex 
chemical synthesis, making it difficult to generate scalable quantities for use 
in immunological assays. Enzymatic synthesis of b-(1-2)-mannose 
oligosaccharides offers a reliable route of generating scalable quantities of b-
(1-2)-mannose antigens. It was anticipated, based on internal b-(1-2)-
mannose trisaccharide residues being immunogenic epitopes8, that DP4 could 
prove to be a good antigen for use in vaccines. In this research project, 
Teth514_1788 – a b-(1-2)-mannose phosphorylase enzyme9, was utilised to 
generate b-(1-2)-mannose antigens, followed by isolation of b-(1-2)-
mannotriose and b-(1-2)-mannotetraose by aqueous gel permeation 
chromatography.  
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b-(1-2)-Mannotriose and b-(1-2)-mannotetraose were functionalised with an 
anomic azide3, and coupled to a methyl 5-hexynoate linker via copper-
catalysed click chemistry. Attempts were made to conjugate the clicked 
products to BSA and TetHc via derivatisation of the methyl ester. Initially, the 
terminal methyl ester was successfully converted to an acyl hydrazide, 
however attempts to conjugate to carrier proteins TetHc and BSA resulted in 
protein precipitation. It is possible that changes to the isoelectric point of 
protein carriers resulted from over-conjugation of antigens, or the use of too 
large an excess of organic solvent. Further optimisation of the reaction 
conditions could result in successful conjugation of antigens to protein carriers, 
such as direct conversion of the methyl ester to an acyl azide, eliminating the 
need for the methyl ester to be converted to a hydrazine intermediate. Whilst 
these conjugation efforts were not successful, attempts to optimise this 
approach is ongoing and should focus on streamlining the conjugation efforts. 
 
4.3. Virenose antigens in a vaccine towards Q fever 
Despite being on the Centre for Disease Controls (CDC) list of potential 
biowarfare agents10, there is not yet a human vaccine approved for protection 
against the causative agent of Q fever, Coxiella burnetii. Vaccines which have 
been licensed for use in livestock comprise whole-cell killed C. burnetii. This 
thesis set out to generate a Q fever vaccine with specificity towards unique 
carbohydrates antigens found within the LPS of the bacterium, in collaboration 
with JIC spin out Iceni Diagnostics, and Mologic Ltd. 
Two Q fever vaccines were generated, both with Conjucore VLP, a 
proteinaceous carrier provided by Mologic Ltd, and laminarin address tags 
conjugated via a BCN linker. One vaccine candidate contained a-Vir(1-4)-a-
Vir-propyl antigens, and the other b-Vir(1-4)-b-Vir-propyl antigen, both 
conjugated via BCN linkers. Immunisation trials were performed in 
collaboration with Mologic Ltd. Two rabbits per vaccine candidate type were 
immunised, with boosters administered at 28-day intervals and bleeds taken 
one-week post injection, until the final bleed at day 91. 
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Serum analysis by ELISA revealed a strong antibody reactivity towards a-
Vir(1-4)-a-Vir- disaccharide when rabbits were immunised with a-Vir(1-4)-a-
Vir-BCN-VLP-BCN-Laminarin. Immunisation with b-Vir(1-4)-b-Vir-BCN-VLP-
BCN-Laminarin revealed a reactivity  towards all virenose antigens, regardless 
of their linkage confirmation or chain length. The ability of antibodies within the 
serum to recognise monosaccharide a and b virenose antigens suggests it 
may be possible to immunise with monosaccharide virenose antigens. If so, 
this would have significant beneficial impact on the synthesis of virenose 
antigens which currently depend on complex chemical synthesis11,12.  
Although antibodies raised in this trial were unable to recognise C. burnetii 
whole killed cells, the use of virenose as an antigen should not be ruled out. 
Although the carbohydrates within the O antigen have been identified13, the 
sequence in which they occur has yet to be elucidated. It may be that the 
location of virenose within the O antigen is not accessible to antibodies, or the 
antibodies present in the serum are located terminally within O antigen. 
Further work is required to identify the sequence of carbohydrates would help 
to better inform the optimal carbohydrate sequence to be used as antigens for 
Q fever vaccination. 
 
4.4. Summary 
There is still a long way to go before the research conducted in this thesis can 
be developed into a viable targeted vaccination therapy. The results obtained 
underpin on-going research into the development of monoclonal antibodies, 
currently being conducted by JIC and Iceni Diagnostics. Beyond vaccination 
therapies, the ability to generate antibodies with a strong specificity towards 
antigens has broad potential in the development in diagnostics, such as their 
use in lateral flow devices. Carbohydrates play an important role in disease 
development, prevention and cure, and further research is required to fully 
exploit their potential uses within therapeutics and diagnostics. 
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5. Chapter 5: Materials and Methods 
5.1. General Methods 
All reagents were purchased from commercial suppliers (Sigma Aldrich, 
Pierce, Fisher Scientific Ltd), unless otherwise stated, and used without further 
purification. 
 
5.1.1. Thin-Layer Chromatography 
Thin layer chromatography (TLC) was performed on silica gel 60 F254 
aluminium backed sheets (Merck). Carbohydrates were detected by staining 
with orcinol spray [2 % (w/v) in ethanol/sulfuric acid/water (8.3:1.1:0.6)] and 
developed by charring. 
 
5.1.2. Mass Spectrometry 
MALDI-TOF MS analysis was conducted on a Bruker Daltonics autoflex speed 
ToF/ToF mass spectrometer with a N2 laser in linear 50 shot mode. A total of 
500 shots were collected per sample with 60-90 % laser intensity and 32× 
gain, dependent on signal intensity. Mass data were analysed using Bruker 
Daltronics Flexanalysis software. Samples for MALDI-TOF MS analyses were 
prepared by mixing 0.5 µL of sample (1 mg mL-1) with 0.5 µL matrix [DHB 
matrix for carbohydrate analysis (10 mg mL-1 in 30 % aq. MeCN), SA matrix 
for protein analysis (0.4 mg/mL in 70 % aq. MeCN, 0.1% TFA)], loading 1 µL 
of mixture onto an MTP AnchorChip 384 target plate and allowed to air dry 
and crystallise.  
Low resolution electrospray ionisation mass spectrometry (ESI MS) was 
performed using an Advion expressionL Compact Mass Spectrometer  Prior to 
injection, samples were filtered through a 0.22 µm membrane disk filters. Data 
was recorded in both positive and negative ionisation modes and processed 
using Advion Mass Express software. 
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5.1.3. HPAEC-PAD Analysis 
High-performance anion-exchange chromatography coupled with pulsed 
electrochemical detection (HPAEC-PAD) analysis was performed on a Dionex 
IC system equipped with a CarboPac PA100 (4 x 250 mm) anion exchange 
column and guard cartridge, and an electrochemical detector to register peaks 
and determine their retention times. Mobile phase was composed of various 
combinations of 100 mM NaOH (eluent A) and 100 mM NaOH with 500 mM 
NaOAc (eluent B). For β-D-(1-3)-glucan and its fragments, the elution profile 
was as follows: 100 % A to 100 % B in 30 min then isocratic 100 % B for 10 
min and finally 100 % A for 0.1 min. (1-2)-β-D-Mannooligosaccharides were 
analysed using 100 % A to 100 % B in 40 min then isocratic 100 % B for 10 
min and finally 100 % A for 0.1 min. 
b-D-(1-2)-Mannose oligosaccharides were analysed using mobile phases 
eluent A (100 mM NaOH) and eluent B (100 mM NaOH with 400 mM NaOAc) 
applied as a gradient to 100 % eluent B over 40 minutes, isocratic eluent B for 
10 mins and ending with isocratic 100 % eluent A over 0.1 mins. Flow rates 
remained constant as 0.25 mL min-1 for all analysis. 
 
5.1.4. Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were recorded on a Bruker Avange III HD 400 MHz spectrometer 
equipped with a broadband BBFO probe at 400 MHz (1H) and 100 MHz (13C) 
in deuterated solvents at 298 °C. Chemical shifts (δ) are reported in parts per 
million (ppm) using residual solvent signal for referencing. Spectra 
assignments were carried out with the aid of HSQCed two-dimensional 
correlation spectroscopy. 
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5.1.5. FTIR 
 Fourier transform infrared (FTIR) spectra were recorded on Perkin Elmer 
Spectrum BX II system equipped with MIRacle single-reflection horizontal 
Zn/Se ATR accessory. 
 
5.1.6. SDS-PAGE analysis 
Proteins were analysed by SDS-PAGE using RunBlue precast 4-20 % 
gradient or 8% gels (Expedeon). Before analysis, protein samples (10 µL) 
were mixed with laemmli buffer [10 µL (Biorad)] and boiled at 95 °C for 10 
mins. Samples were allowed to cool, centrifuged briefly and then loaded on to 
SDS-PAGE gels as 10 µL samples. All SDS-PAGE analysis was performed 
alongside a Precision Plus ProteinTM Dual Color Ladder [5 µL (Biorad)] and 
run at 200 V for 50 mins in 1x RunBlue running buffer (Expedeon). Gels were 
stained with Coomassie Brilliant Blue Protein Stain (Sigma) for a minimum of 
2 hrs to visualise proteins. Gels were imaged on a Syngene G:Box. 
 
5.1.7. Western blot analysis 
Unless otherwise stated, Western blot analysis was performed as follows. 
SDS-PAGE gels were carried out as outlined in Section 5.1.6 without protein 
staining. Proteins were transferred to nitrocellulose membrane, pre-wetted 
with water, in a cassette packed with blotting paper on both sides. Protein 
transfer was carried out in transfer buffer [25 mM tris, 192 mM glycine, 20 % 
aqueous methanol (1 L), pH 8.6] at 100 V for 1 hr at 4 °C. Following transfer, 
the membrane was washed with PBS (3x) and blocked with 5 % milk powder 
in PBST (30 mL) for 2 hr at room temperature (RT). The membrane was again 
washed with PBS (3x) before applying the primary antibody, prepared in 1.4 
% milk powder in PBST (30 mL), for 2 hr at RT. After washing again with PBS 
(3x), a secondary antibody containing a horse radish peroxidase (HRP) 
conjugate was applied, prepared as per the primary antibody. The membrane 
was incubated for a further 1 hr at RT before washing a final time with PBS 
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(3x), briefly drip drying to remove excess PBS and developing with 
Chemiluminescence HRP substrate (Clontech) according the manufacturers 
instructions1. Membranes were imaged using an ImageQuant LAS 500 
chemiluminescence CCD camera. 
 
5.2. Chapter 2 experimental 
5.2.1. Generation of acetylated laminarioligosaccharides by acetolysis 
of curdlan 
 
A suspension of curdlan [(10 g) Wako Chemicals] was vigorously stirred in 
AcOH-Ac2O (1:1, 65 mL), and concentrated H2SO4 (10 mL) was added in a 
dropwise manner at 30-40 °C for 30 mins. The mixture was stirred for 24 hr at 
28 °C before being brought to 20 °C and treated with NaOAc (30 g). Water 
(100 mL) was added and the mixture was stirred overnight. The precipitate 
was separated from the supernatant and dissolved in CH2Cl2 (400 mL), 
washed with H2O and saturated aq. NaHCO3 solution. Solvents were removed 
by evaporation and the products were purified by flash chromatography on 
silica gel (300 g) using gradient elution with toluene-acetone (90:10 to 40:60) 
to give twelve fractions containing both individual oligosaccharides and their 
mixtures. High molecular weight fraction 11 was selected. MALDI-TOF MS m/z 
3869.86 [DP13+Na]+, 4157.88 [DP14+Na]+, 4445.90 [DP15+Na]+, 4733.93 
[DP16+Na]+, 5021.83 [DP17+Na]+, 5309.91 [DP18+Na]+, 5597.94 
[DP19+Na]+, 5885.69 [DP20+Na]+, 6173.98 [DP21+Na]+, 6461.89 
[DP22+Na]+, 6749.63 [DP23+Na]+, 7040.99 [DP24+Na]+, calculated m/z 
3870.12 [DP13+Na]+, 4158.20 [DP14+Na]+, 4446.29 [DP15+Na]+, 4734.37 
[DP16+Na]+, 5022.46 [DP17+Na]+, 5310.54 [DP18+Na]+, 5598.63 
[DP19+Na]+, 5886.71 [DP20+Na]+, 6174.80 [DP21+Na]+, 6462.88 
[DP22+Na]+, 6750.97 [DP23+Na]+, 7039.05 [DP24+Na]+; 1H NMR (400 MHz, 
CDCl3), δ 5.10-4.80 (m, H-4), 5.10-4.75 (m, H-2), 4.50-4.30 (m, H-1), 4.40-
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3.95 (m, H-6), 3.90-3.70 (m, H-3), 3.75-3.55 (m, H-5), 2.20-1.95 (m, OAc); 13C 
NMR (100 MHz, CDCl3) δ 100.7 (C-1), 78.2 (C-3), 72.5 (C-2), 71.7 (C-5), 68.0 
(C-4), 61.8 (C-6), 20.6 (OAc). 
 
5.2.2. Deacetylation of fraction 11 of curdlan acetolysis.  
 
Fraction 11 of acetylated curdlan (260 mg) was dissolved in a mixture of dry 
methanol (20 mL) and dry CH2Cl2 (5 mL), 1 M NaOMe (100 µL) was added 
and the mixture was stirred at room temperature for 2 hrs. Solvents were 
removed under vacuum to leave a white powder which was dissolved in water 
(20 mL) and neutralised by Amberlite IR120 (H+) resin until the pH became 
neutral as indicated by litmus paper.   The resin was filtered off and the water 
was removed by freeze-drying to give 115 mg of a white powder. Deacetylated 
products were analysed as unpurified mixture,  MALDI-TOF MS, m/z 1013.17 
[DP6+Na]+, 1175.21 [DP7+Na]+, 1337.24 [DP8+Na]+, 1499.27 [DP9+Na]+, 
1661.30 [DP10+Na]+, 1823.33 [DP11+Na]+, 1985.37 [DP12+Na]+, 2147.38 
[DP13+Na]+, 2309.40 [DP14+Na]+, 2472.41 [DP15+Na]+, 2633.45 
[DP16+Na]+, 2795.47 [DP17+Na]+, 2957.48 [DP18+Na]+, 3119.48 
[DP19+Na]+, 3281.46 [DP20+Na]+, 3443.48 [DP21+Na]+, calculated m/z 
1013.32 [DP6+Na]+, 1175.37 [DP7+Na]+, 1337.42 [DP8+Na]+, 1509.48 
[DP9+Na]+, 1661.53 [DP10+Na]+, 1823.58 [DP11+Na]+, 1985.63 [DP12+Na]+, 
2147.69 [DP13+Na]+, 2309.74 [DP14+Na]+, 2471.79 [DP15+Na]+, 2633.85 
[DP16+Na]+, 2795.90 [DP17+Na]+, 2957.95 [DP18+Na]+, 3120.00 
[DP19+Na]+, 3282.06 [DP20+Na]+, 3444.11 [DP21+Na]+; HPAEC-PAD, 
retention time (min): 3.7 (DP1), 10.3 (DP2), 13.6 (DP3), 16.2 (DP4), 18.9 
(DP5), 21.0 (DP6), 22.9 (DP7), 24.6 (DP8), 26.2 (DP9), 27.6 (DP10), 28.8 
(DP11), 30.0 (DP12), 31.1 (DP13), 32.0 (DP14), 32.9 (DP15), 33.8 (DP16), 
34.5 (DP17), 35.2 (DP18), 35.9 (DP19), 36.5 (DP20), 37.1 (DP21), 37.7 
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(DP22), 38.2 (DP23); 1H NMR (400 MHz, D2O), δ 5.15 (s, H-1Aa), 4.70-4.65 
(m, H-1X), 4.60 (s, H-1Ab), 3.90-3.60 (m, H-6Yab), 3.75-3.65 (m, H-3Y), 3.50-
3.45 (m, H-2Y), 3.50-3.40 (m, H-4Y), 3.45-3.40 (m, H-5Y), 13C NMR (100 MHz, 
D2O) δ 102.6 (C-1X), 95.7 (C-1Ab), 92.0 (C-1Aa), 84.1 (C-3Y), 75.7 (C-5Y), 73.1 
(C-2Y), 67.9 (C-4Y), 60.6 (C-6Y). 
 
5.2.3. b-D-(1-3)-Glucan DP 15 by fractionation using GPC 
To produce β-D-(1-3)-glucan fractions with a narrower molecular weight 
distribution, the deprotected product described in 5.2.2 was fractionated by 
GPC on a Biogel P2 column (2.6 cm x 90 cm) heated to 40 °C and eluted with 
water at a 1 ml min-1 flow rate. Batches of 30 mg of 5.2.2 product were used 
for each run and 5.5 ml fractions were collected between 160 and 600 mins. 
Congruent fractions from each run were pooled and analysed by MALDI-TOF 
MS and HPAEC-PAD to allow selection a fraction with average DP 15. 
Lyophilisation yielded 16.7 mg of a white powder product. MALDI-TOF MS, 
m/z 2309.37 [DP14+Na]+, 2471.38 [DP15+Na]+, 2633.47 [DP16+Na]+, 
2795.47 [DP17+Na]+, calculated m/z 2309.74 [DP14+Na]+, 2471.79 
[DP15+Na]+, 2633.85 [DP16+Na]+, 2795.90 [DP17+Na]+; HPAEC-PAD 
retention time (min): 30.9 (DP13), 31.8 (DP14), 32.7 (DP15), 33.6 (DP16), 
34.3 (DP17), 35.1 (DP18), 35.7 (DP19), 36.3 (DP20), 36.9 (DP21). 
 
5.2.4. Anomeric azide of b-D-(1-3)-glucan DP15 
 
Anomeric azide was introduced following Shoda’s methodology2. 2-Chloro-
1,3-Dimethylimidazolinium chloride [DMC (3.5 mg, 20 µmol, 5 eq)] was added 
to a mixture of b-(1-3)-glucan DP15 (10 mg, 4 µmole), DIPEA (10.7 µL, 61 
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µmol, 15 eq) and NaN3 (81.3 mg, 2.5 M) in D2O (0.5 mL), and the reaction 
mixture was stirred for 36 hrs at RT. The reaction mixture was then passed 
through a TSK HW40S GPC column (1.6 cm x 90 cm) in water at 0.5 ml min-1 
for purification. Fractions containing carbohydrates were identified by TLC and 
staining with orcinol and then pooled. Lyophilisation yielded 8.7 mg of a white 
powder. 1H NMR (400 MHz, D2O), δ 5.15 (s, H-1Aa), 4.75-4.65 (m, H-1X), 4.70 
(s, H-1Ab-N3), 4.60 (s, H-1Ab), 4.10-3.75 (m, H-4Ya), 3.90-3.60 (m, H-6Yab), 
3.80-3.65 (m, H-3Y), 3.60-3.35 (m, H-5Y), 3.50-3.25 (m, H-2Y), 3.50-3.30 (m, 
H-4Yb); 13C NMR (100 MHz, D2O) δ 60.6 (C-6Y), 68.8 (C-4Y), 73.2 (C-2Y), 75.6 
(C-5Y), 84.1 (C-3Y), 89.9 (C-1Ab-N3), 92.1 (C-1Aa), 95.6 (C-1Ab), 102.4 (C-1X); 
FTIR nmax/cm-1 2122 (s, N3). 
 
5.2.5. Functionalised laminarin with anomeric azide group 
 
Laminarin was functionalised with an anomeric azide as described in Section 
5.2.4.   Briefly, DMC (12.1 mg, 71.4 µmol, 5 eq) was added to a mixture of 
laminarin [(50 mg, 14.3 µmol) Sigma],  DIPEA (37.3 µL, 214.3 µmol, 15 eq) 
and NaN3 (2.5 M) in D2O (2 mL), and the reaction mixture was stirred for 36 
hrs at RT. The reaction was then passed through a TSK HW40S GPC column 
(1.6 cm x 90 cm) in water at 0.5 ml min-1 for purification. Fractions containing 
carbohydrates were identified by TLC plate and staining with orcinol and then 
pooled. Lypholisation yielded 46.3 mg of white powder product. 1H NMR (400 
MHz, D2O) δ 5.15 (s, H-1Aa), 4.75-4.65 (m, H-1X), 4.70 (s, H-1Ab-N3), 4.60 (s, 
H-1Ab), 4.10-3.75 (m, H-4Ya), 3.90-3.60 (m, H-6Yab), 3.80-3.65 (m, H-3Y), 3.60-
3.35 (m, H-5Y), 3.50-3.25 (m, H-2Y), 3.50-3.30 (m, H-4Yb); 13C NMR (100 MHz, 
D2O) δ  60.6 (C-6Y), 68.8 (C-4Y), 73.2 (C-2Y), 75.6 (C-5Y), 84.1 (C-3Y), 89.9 (C-
1Ab-N3), 92.1 (C-1Aa), 95.6 (C-1Ab), 102.4 (C-1X); FTIR nmax/cm-1 2120 (s, N3). 
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5.2.6. Preparation of BCN-functionalised BSA 
BSA (2 mg mL-1 in PBS 5 mL) was reacted with (1R,8S,9s)-bicyclo[6.1.0]non-
4-yn-9-ylmethyl N-succinimidyl carbonate (Sigma), hereafter referred to as 
BCN-NHS (10 µL of 0.15 M in DMSO), for 1 h before quenching with the 
addition of 1 M Tris-HCl (50 µl). Dialysis with 6-8 K MWCO Spectra/Por® 
dialysis membrane against dH2O was used to remove small molecules and 
excess reagents. Final purification was via GPC using a TSK-HW40S column 
(26 mm × 900 mm) in water with a 0.5 mL min-1 flow rate. Refractive index and 
UV detectors were used to determine fractions containing protein conjugates, 
which were subsequently pooled. Lyophilisation yielded 9.1 mg of white 
powder. MALDI-TOF MS, m/z 68104, calculated m/z 68071. For SDS-PAGE 
analysis, see Chapter 2.2.5. 
 
5.2.7. Coupling of BCN-functionalised protein to b-D-(1,3)-glucan DP15 
azide and laminarin azide 
Copper-free click reaction was employed to couple azide-functionalised b-
glucans to BSA-BCN. BSA-BCN (2 mg mL-1 in 1x PBS) was mixed with b-D-
(1-3)-glucan DP15 azide (0.8 mg, two times molar excess per mole of protein) 
and laminarin azide (2.6 mg, five times molar excess per mole of protein), 
respectively. The reaction mixtures were incubated at RT for 18 hours with 
gentle agitation followed by removal of unreacted b-glucans via dialysis 
against 1x PBS, using a 10 K MWCO SnakeSkin dialysis membrane tubing at 
room temperature. Successful conjugation was confirmed by MALDI-TOF/MS 
(Figure 2. 17), SDS-PAGE (Figure 2. 16 A) and Western blot analysis using 
a mouse anti-b-(1-3)-glucan mAb [Biosupplies Australia PTY LTD (Figure 2. 
16 B)]. Protein concentration was determined to be 1.6 mg mL-1 and 1.7 mg 
mL-1 by Bradford assay for b-(1-3)-glucan DP15 and laminarin conjugates, 
respectively. 
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5.2.8. Reporter assay 
Reporter cells were used to test the ability of β-D-(1-3)-glucan-containing 
glycoconjugates to initiate a signalling response through Dectin-1. Proteins, 
protein-glycan conjugates and glycans (2 µg in 100 µl) in coating buffer 
(Na2CO3-NaHCO3, pH 9.5) was loaded onto a 96-well NuncTM MaxiSorp plate 
and incubated at 4 °C overnight. Supernatants were then discarded, and the 
plate was washed with PBS (200 µl). BWZ.36 cells expressing Dectin-1 
provided by Dr N. Kawasaki of Quadrum Institute Biosciences-NBI, and were 
maintained on R10 [RPMI  1640 (Sigma) with 25 mM HEPES, FBS (10 % v/v), 
2-mercaptoethanol (50 µM), streptomycin (100 U/ml) and L-glutamine (2 mM)]. 
Cells were washed with PBS and pelleted by gentle centrifugation at 270 x g 
for 5 mins before resuspending in R10 media. Cell density was determined by 
haemocytometer and adjusted to 0.5 x 106 cells/µl in R10. To each sample 
coated well 200 µl of cell suspension was added, and the plate incubated at 
37 °C for 18 h. Following brief centrifugation at 270 x g for 5 mins, the 
supernatant was discarded, and cells were lysed by the addition of 100 µl Z 
buffer (100 mM 2-mercaptoethanol, 9 mM MgCl2, 0.125 % NP-40 in PBS) 
containing chlorophenol red β-D-galactopyranoside (CPRG, 1.5 mM) to each 
well. The plate was again incubated at 37 °C for 1 h, until colour change was 
detected by absorbance measurement at 570 nm with 630 nm as a reference 
wavelength. 
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5.3. Chapter 3 experimental 
5.3.1. Expression of Teth514_1788, a β-D-(1-2)-mannoside 
phosphorylase 
Teth_1788, the β-D-(1-2)-mannoside phosphorylase used in this study was a 
kind gift from Josef Voglmeir3. Rosetta 2 (DE3) (Novagen) strains containing 
the expression plasmid were grown in LB broth [1000 mL (1 % tryptone, 1 % 
NaCl, 0.5 % yeast extract) containing carbenicillin (50 µg mL-1)] at 37 °C with 
200 rpm agitation until an absorbance of 0.6 at 600 nm was reached. 
Expression was then induced by the addition of 0.1 mM IPTG (final 
concentration) and growth continued at 18 °C with 200 rpm agitation for 24 hr. 
Cells were harvested by centrifugation at 10,000 x g for 20 min, followed by 
suspension in Buffer A [50 mM HEPES-NaOH buffer (pH 7.0), 0.5 M NaCl]. 
Cells were disrupted by sonication a Sonics Vibra CellTM probe sonicator at 70 
% intensity and the supernatant collected by centrifugation at 20,000 x g for 
20 mins at 4 °C. The His-tagged protein was isolated by affinity 
chromatography on an AKTA prime system equipped with a 1 mL HisTrap HP 
column equilibrated in Buffer A. Fractions collected were analysed by SDS-
PAGE (Figure 3. 22 A) and Western blot (Figure 3. 22 B) to determine the 
estimated molecular mass. Fractions containing the correct mass were pooled 
and the buffer exchanged to Tris buffer (50 mM Tris-HCl, 0.5 M NaCl) using 
an AMICON Ultra-15 10 K MWCO filter and washing three times at 4,000 x g 
for 15 mins. Protein concentration was determined be 26 mg mL-1 in 5 mL by 
BCA assay from 2 L of culture, and the molecular mass determined by MALDI-
TOF MS (Figure 3. 24). 
 
5.3.2. Synthesis of β-D-(1-2)-mannan oligosaccharides 
A reaction mixture (30 mL) containing mannose (10 mg, 2 mM), mannose-1-
phosphate [(M1P) 62.4. mg, 8 mM] and Teth514_1788 (0.5 mg mL-1 final 
concentration in 0.2 M ammonium acetate buffer, pH 5) at 30 °C for 6 hr. The 
reaction was terminated by boiling at 95 °C for 15 mins, the mixture was briefly 
centrifuged to pellet the denatured protein and the supernatant filtered through 
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a 0.22 µm membrane filter. Salts and excess M1P were removed by passing 
through a charcoal/celite (50:50) Biotage® 10g column prepared in water. 
Mannose oligosaccharides were eluted off the column in 95 % aqueous 
ethanol and the solvent was removed by evaporation in vacuo to yield 
mannooligosaccharides (45 mg). TLC [butanol/ethanol/water (10:8:7)] Rf 0.58 
(DP1), 0.45 (DP2), 0.36 (DP3), 0.31 (DP4), 0.26 (DP5); MALDI-TOF MS m/z 
527.3 [DP3+Na]+, 689.4 [DP4+Na]+, 851.4 [DP5+Na]+, 1013.1 [DP6+Na]+, 
1175.6 [DP7+Na]+, 1337.6 [DP8+Na]+, 1509.7 [DP9+Na]+, 1661.7 
[DP11+Na]+, 1823.7 [DP12+Na]+, 1986.7 [DP13+Na]+; calculated m/z 527.2 
[DP3+Na]+, 689.2 [DP4+Na]+, 851.4 [DP5+Na]+, 1013.1 [DP6+Na]+, 1175.6 
[DP7+Na]+, 1337.6 [DP8+Na]+, 1509.7 [DP9+Na]+, 1661.7 [DP11+Na]+, 
1823.7 [DP12+Na]+, 1986.7 [DP13+Na]+; HPAEC-PAD retention time (min): 
3.7 (DP1), 5.9 (DP2), 9.8 (DP3), 11.7 (DP4), 13.1 (DP5), 14.1 (DP6), 15.0 
(DP7), 16.0 (DP8), 16.1 (M1P). 
 
5.3.3. b-D-(1-2)-Mannotriose 
 
Purification of b-D-(1-2)-mannotriose was performed by GPC using a Biogel 
P2 chromatography column (2.5 x 90 cm) in water with a flow rate of 0.5 mL 
min-1. Fractions were collected at 6 min intervals from 320 to 800 mins. On the 
basis of TLC [butanol/ethanol/water (10:8:7) Rf 0.36 Appendices 6. 12] and 
HPAEC-PAD (Appendices 6. 11), fractions 43-47, containing exclusively b-D-
(1-2)-mannotriose, were pooled. Lyophilisation yielded white powder (6.2 mg). 
ESI-MS m/z 526.9 [M+Na]+, calculated m/z 527.2 [M+Na]+; HPAEC-PAD 
retention time = 9.76 min; 1H NMR (600 MHz, D2O) δ 5.10 (1H, d, J1,2 = 1.68 
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Hz, H-1Aa), 4.85 (1H, d, J1,2 = 2.07 Hz, H-1Ab), 4.85-4.70 (3H, m, H-1Cβ, H-
1Bβ, H-1Cα), 4.70 (1H, s, H-1Ba), 4.30 (1H, d, J1,2 = 3.12 Hz, H-2Bβ), 4.15 (1H, 
d, J1,2 = 3.24 Hz, H-2Bα), 4.00 (1H, d, J1,2 = 3.2 Hz, H-2Aβ), 4.10-4.00 (2H, m, 
H-2Cα, H-2Cb), 3.95 (1H, dd, J1,2 = 2.04 Hz, J2,3 = 3.24 Hz, H-2Aα), 3.85-3.75 
(2H, m, H-6Baα, H-6Cab), 3.80 (1H, d, J1,2 = 3.04, H-3Aα), 3.75-3.70 (2H, m, H-
6Aaα, H-6Aaβ), 3.65-3.60 (2H, m, H-5Aα, H-6Bbα), 3.60-3.55 (2H, m, H-6Cbα, H-
6Abβ), 3.60-3.50 (3H, m, H-3Bα, H-3Bβ, H-3Aβ), 3.55-3.45 (2H, m, H-3Cα, H-
3Cβ), 3.55-3.45 (3H, m, H-4Aα, H-4Bα, H-4Bβ), 3.40-3.35 (3H, m, H-4Cα, H-4Cβ, 
H-4Ab), 3.30-3.20 (5H, m, H-5Aβ, H-5Bα, H-5Bβ, H-5Cα, H-5Cβ); 13C NMR (151 
MHz, D2O) d 100.9 (C-1Bb), 100.8 (C-1Ca), 100.7 (C-1Cb), 98.8 (C-1Ba), 93.5 
(C-1Ab), 91.8 (C-1Aa), 79.5 (C-2Ab), 78.4 (C-2Ba, C-2Aa), 77.9 (C-2Bb), 76.2 
(C-5Ab, C-5Ba, C-5Bb, C-5Ca, C-5Cb), 72.7 (C-3Ca, C-3Cb), 72.3 (C-5Aa), 72.0 
(C-3Ba, C-3Bb, C-3Ab), 70.2 (C-2Ca, C-2Cb), 69.1 (C-3Aa), 67.1 (C-4Ab, C-4Aa), 
66.8 (C-4Ba, C-4Bb), 66.6 (C-4Ca, C-4Cb), 60.9 (C-6Ca), 60.5 (C-6Aa), 60.3 (C-
6Ba). 
 
5.3.4. b-D-(1-2)-Mannotetraose 
 
Purification of the title compound was carried out as described in Section 
5.3.2. Fractions 36-40, identified by TLC [butanol/ethanol/water (10:8:7) Rf 
0.31 (Appendices 6. 12)] and HPAEC PAD (Appendices 6. 11) as containing 
exclusively b-D-(1-2)-mannotetraose, were pooled and lyophilised to yield 
white powder (5.3 mg). ESI-MS m/z 689.0 [M+Na]+, calculated m/z 689.2 
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[M+Na]+; HPAEC-PAD retention time = 11.58 min; 1H NMR (600 MHz, D2O) δ 
5.10 (1H, d, J1,2 = 1.5 Hz, H-1Aα), 4.90 (1H, s, H-1Cβ), 4.85 (1H, s, H-1Aβ), 
4.80-4.75 (3H, m, H-1Cα, H-1Da, H-1Db), 4.70 (1H, s, H-1Bβ), 4.65 (1H, s, H-
1Bα), 4.25 (1H, d, J1,2 = 3.24 Hz, H-2Cα), 4.25-4.20 (2H, m, H-2Bβ, H-2Cβ), 4.10 
(1H, d, J1,2 = 3.24 Hz, H-2Bα), 4.00 (1H, d, J1,2 = 2.99 Hz, H-2Aβ), 4.00-3.95 
(2H, m, H-2Dα, H-2Db), 3.95 (1H, dd, J1,2 = 1.97 Hz, J2,3 = 2.99 Hz, H-2Aα), 
3.80-3.70 (3H, m, H-6Da, H-6Baα, H-6Caα), 3.75-3.70 (2H, m, H-3Aα, H-4Aα), 
3.70 (1H, s, H-6Aaα), 3.65-3.60 (2H, m, H-6Bbα, H-6Abα), 3.65-3.60 (1H, m, H-
5Aα), 3.60-3.50 (2H, m, H-6Cbα, H-6Db), 3.55-3.50 (3H, m, H-3Bα, H-3Bβ, H-
3Aβ), 3.50-3.40 (2H, m, H-3Cα, H-3Cβ), 3.45-3.40 (2H, m, H-4Cα, H-4Cβ), 3.45-
3.40 (2H, m, H-3Dα, H-3Dβ), 3.40-3.35 (2H, m, H-4Dα, H-4Dβ), 3.40-3.35 (2H, 
m, H-4Bα, H-4Bβ), 3.25 (1H, s, H-4Aβ), 3.25-3.15 (7H, m, H-5Aβ, H-5Bα, H-5Dβ, 
H-5Cα, H-5Cb, H-5Dα, H-5Db); 13C NMR (151 MHz, D2O) δ 101.2-100.9 (m, C-
1Ca, C-1Bb, C-1Cb, C-1Da, C-1Db), 99.2 (s, C-1Ba), 93.5 (s, C-1Ab), 92.1 (s, C-
1Aa), 80.0 (s, C-2Ab), 79.4 (s, C-2Ba), 79.0 (s, C-2Bb), 78.7 (s, C-2Aa), 78.4 (s, 
C-2Ca), 78.3 (s, C-2Cb), 76.3-76.1 (m, C-5Ca, C-5Da, C-5Ab, C-5Ba), 72.9 (d, 
C-3Da, C-3Da), 72.4 (s, C-5Aa), 72.2-72.2 (d, C-3Ca, C-3Cb), 71.9-71.9 (t, C-
3Aa, C-3Bb, C-3Ba), 70.4 (s, C-2Da, C-2Db), 69.1 (s, C-3Aa), 67.4 (s, C-4Aa, C-
4Ab), 67.2-67.1 (d, C-4Cb, C-4Ca), 70.0-66.9 (d, C-4Ba, C-4Bb), 66.8-66.8 (d, 
C-4Db, C-4Da), 61.2-61.2 (d, C-6Ca), 60.8 (s, C-6Da), 60.7-60.6 (m, C-6Ba), 
60.4 (s, C-6Aa).  
 
5.3.5. Methyl 5-hexynoate 
 
Methyl hexynoate was synthesised as described by Cody et al4. Hexynoic acid 
(1 g, 15.9 mmol, 1 eq) was mixed with K2CO3 (1.3 g, 19.0 mmol, 1.2 eq) in 
DMF (30 mL) and cooled to 0 °C with stirring. Iodomethane (1.575 g, 22.2 
mmol, 1.4 eq) was added to the reaction mixture dropwise and the solution 
was allowed to warm to room temperature over 3 hours. After 3 hours, the 
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reaction was diluted with water (30 mL), extracted twice with EtOAc (20 mL), 
and washed 3 times with water (20 mL) and 3 times with 50 % brine (20 mL) 
before being dried over magnesium sulfate, filtered and concentrated to afford 
an oily product (620 mg, 62 %); TLC [hexane/ethyl acetate (8:2)] Rf 0.64; ESI-
MS m/z 149.2 [M+Na]+, calculated m/z 149.06 [M+Na]+; 1H NMR (400 MHz, 
CDCl3) d 3.68 (3H, s, CH3), 2.46 (2H, t, J = 7.5 Hz, CH2), 2.26 (2H, td, J = 6.9, 
2.7 Hz, CH2), 1.97 (1H, t, J = 2.6 Hz, CH), 1.85 (2H, q, J = 7.2 Hz, CH2); 13C 
NMR (100 MHz, CDCl3) d 179.6 (COOCH3), 83.2 (CCH2), 69.5 (HC), 51.6 
(OCH3), 32.6 (CH2COOCH3), 23.3 (CH2), 17.7 (CCH2).  
 
5.3.6. b-D-(1-2)-Mannotriosyl azide  
 
Anomeric azide was introduced following Shoda’s methodology2. DMC (8.4 
mg, 49.6 µmol, 5 eq) was added to a mixture of b-D-(1-2)-mannotriose (5 mg, 
9.9 µmol), DIPEA (25.9 mL, 148.8 µmol, 15 eq) and NaN3 (81.3 mg, 1.25 
mmol, 2.5 M) in D2O (0.5 mL), and the reaction mixture was stirred for 3 hrs at 
RT. The reaction mixture was then passed through a TSK HW40S GPC 
column (1.6 × 90 cm) in water at 0.5 ml min-1, fractions containing 
carbohydrates were identified by TLC and staining with orcinol and then 
pooled to yield white powder (4.2 mg, 80 %). ESI-MS m/z 552.1 [M+Na]+, 
calculated m/z 552.2 [M+Na]+; 1H NMR (400 MHz, D2O) d 5.60 (1H, d, J1,2 = 
1.86 Hz, H-1Aa-N3), 5.00 (1H, d, J1,2 = 1.71 Hz, H-1Ab-N3), 4.90-4.80 (4H, m, 
H-1Cb, H-1Bb, H-1Ca, H-1Ba), 4.40 (1H, d, J1,2 = 3.18 Hz, H-2Bb), 4.25 (1H, t, 
J1,2 = 3.66 Hz, H-2Ba) 4.15 (1H, d, J1,2 = 2.99 Hz, H-2Ab), 4.15-4.05 (2H, m, 
(H-2Ca, H-2Cb), 4.05 (1H, m, H-2Aa), 3.95-3.85 (4H, m, H-6Baa, H-6Bba, H-
6Cab, H-6Cba), 3.75 (2H, m, H-5Aa, H-5Ca), 3.75-3.65 (3H, m, H-6Aaa, H-6Aab, 
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H-6Abb), 3.70-3.60 (3H, m, H-3Ba, H-3Bb, H-3Ab), 3.65 (1H, m, H-4Aa), 3.60-
3.55 (4H, m, H-4Ba, H-4Bb, H-3Ca, H-3Cb), 3.55-3.45 (3H, m, H-4Ab, H-4Ca, H-
4Cb), 3.45 (1H, m, H-3Aa), 3.40-3.30 (4H, m, H-5Ab, H-5Ba, H-5Bb, H-5Cb); 13C 
NMR (100 MHz, D2O) d 100.9 (C-1Bb, C-1Ca, C-1Cb), 98.8 (C-1Ba), 87.6 (C-
1Aa-N3), 86.9 (C-1Ab-N3), 79.3 (C-2Ab), 78.5 (C-2Ba), 78.3 (C-3Aa), 77.9 (C-
2Bb), 77.3 (C-2Aa), 76.4 (C-5Ab, C-5Ba, C-5Bb, C-5Cb), 74.6 (C-5Aa), 73.0 (C-
3Ca, C-3Cb), 72.1 (C-3Ba, C-3Bb, C-3Ab), 70.5 (C-2Ca, C-2Cb), 69.0 (C-5Ca), 
66.8 (C-4), 60.8 (C-6); FTIR nmax/cm-1 2118.5 (s, N3). 
 
5.3.7. b-D-(1-2)-Mannotetraosyl azide 
 
Anomeric azide was introduced as described in Chapter 2.2.4. Briefly, DMC 
(6.3 mg, 37.5 µmol, 5 eq) was added to a mixture of b-D-(1-2)-mannotetraose 
(5 mg, 7.5 µmol),  DIPEA (19.6 µL, 112.6 µmol, 15 eq) and NaN3 (81.3 mg, 
1.25 mmol, 2.5 M) in D2O (0.5 mL), and the reaction mixture was stirred for 3 
hrs at RT. The reaction mixture was then passed through a TSK HW40S GPC 
column (1.6cm x 90 cm) in water at 0.5 ml min-1 for purification. Fractions 
containing carbohydrates were monitored by spotting on a TLC plate and 
staining with orcinol and then pooled to yield a white powder product (4.5 mg, 
86.7 %). The introduction of an anomeric azide was confirmed by ESI-MS,  
HSCQed NMR and FTIR. ESI-MS m/z 714.1 [M+Na]+, calculated m/z 714.2 
[M+Na]+; 1H NMR (400 MHz, D2O) δ 5.25 (1H, d, J1,2 = 1.81 Hz, H-1Aa), 5.10 
(1H, d, J1,2 = 1.66 Hz, H-1Ab-N3), 5.00 (1H, d, J1,2 = 2.33 Hz, H-1Cb), 4.95 (1H, 
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s, H-1Ab), 4.95-4.80 (4H, m, H-1Bb, H-1Ca, H-1Da, H-1Db), 4.80 (1H, s, H-1Ba), 
4.40-4.30 (3H, m, H-2Bb, H-2Ca, H-2Cb), 4.20-4.10 (2H, m, H-2Ab, H-2Ba), 
4.10-4.05 (2H, m, H-2Da, H-2Db), 4.05 (1H, t, J1,2 = 2.54 Hz, H-2Aa), 3.95-3.85 
(3H, m, H-6Baa, H-6Caa, H-6Da), 3.90-3.85 (3H, m, H-3Aa, H-4Aa, H-6Aaa), 3.75 
(1H, m, H-5Aa), 3.80-3.65 (4H, m, H-6Bba, H-6Aba, H-6Cba, H-6Db), 3.70-3.65 
(3H, m, H-3Ba, H-3Bb, H-3Ab), 3.65-3.55 (4H, m, H-3Ca, H-3Cb, H-3Da, H-3Db), 
3.60-3.40 (7H, m, H-4Ca, H-4Cb, H-4Da, H-4Db, H-4Ba, H-4Bb, H-4Ab), 3.40-
3.30 (7H, m, H-5Ab, H-5Ba, H-5Bb, H-5Ca, H-5Cb, H-5Da, H-5Db); 13C NMR (100 
MHz, D2O) δ 101.1 (C-1Bb, C-1Ca, C-1Cb, C-1Da, C-1Db), 99.1 (C-1Ba), 93.4 
(C-1Ab), 92.0 (C-1Aa), 86.8 (C-1Ab-N3), 79.1 (C-2Aa, C-2Ab, C-2Ba, C-2Bb, C-
2Ca, C-2Cb), 76.2 (C-5Ab, C-5Ba, C-5Bb, C-5Ca, C-5Cb, C-5Da, C-5Db), 72.3 
(C-3Ab, C-3Ba, C-3Bb, C-3Ca, C-3Cb, C-3Da, C-3Db, C-5Aa), 70.4 (C-2Da, C-
2Db), 69.0 (C-3Aa, C-4Aa), 66.9 (C-4Ab, C-4Ba, C-4Bb, C-4Ca, C-4Cb, C-4Da, 
C-4Db), 60.6 (C-6); FTIR nmax/cm-1 2122.8 (s, N3). 
 
5.3.8. 1-(2-O-(2-O-β-D-mannopyranosyl-β-D-mannopyranosyl)-β-D-
mannopyranosyl)-4-(3-methoxycarbonylpropyl) [1,2,3]-triazole 
 
A mixture of b-D-(1-2)-mannotriosyl azide (4 mg, 7.6 µmol), methyl 5-
hexynoate (4.5 mL, 37.8 µmol, 5 eq), CuSO4 (120 µg, 0.76 μmol, 0.1 eq), 
NaASc (299.5 mg, 1.51 μmol, 0.2 eq) and tris(3-
hydroxypropyltriazolylmethyl)amine [THPTA (1.3 mg, 10 mM)] was stirred in a 
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mixture of water/t-butanol (1:10) at 50 °C for 16 hours. Excess of methyl 5-
hexynoate was removed by extraction with EtOAc and the aqueous fractions 
were purified by GPC using a TSK HW40S  column (1.6 x 90 cm) in water at 
0.5 mL min-1 to afford a white powder, yield 4.5 mg (90.8 %), ESI-MS, m/z 
678.5 [M+Na]+, calculated m/z 678.2 [M+Na]+; 1H NMR (400 MHz, D2O) d 8.00 
(1H, s, H-1Ab-triazole), 7.95 (1H, s, H-1Aa-triazole), 6.15 (1H, d, J1,2 = 2.87 Hz, 
H-1Aa), 6.05 (1H, s, H-1Ab), 4.90-3.15 (36H, m, H-2, H-3, H-4, H-5, H-6), 3.60 
(OCH3), 2.74 (CH2C(O)OCH3), 2.37 (CH2CH2CH2), 1.92 (CHCH2CH2). 
 
5.3.9. 1-(2-O-(2-O-(2-O-β-D-mannopyranosyl-β-D-mannopyranosyl)-β-D-
mannopyranosyl)β-D-mannopyranosyl)-4-(3-
methoxycarbonylpropyl) [1,2,3]-triazole 
 
 
b-D-(1-2)-mannotetraosyl azide (4 mg, 5.79 µmol) was reacted with methyl 5-
hexynoate (3.4 µL, 28.93 µmol, 5 eq), CuSO4 (92.4 µg, 0.58 μmoles, 0.1 eq), 
NaASc (229.3 µg, 1.16 µmol, 0.2 eq) and tris(3-
hydroxypropyltriazolylmethyl)amine [THPTA (1.3 mg, 10 mM)] in 300 µL of 
water/t-butanol (1:10) at 50 °C for 16 hours. Excess linker was removed by 
washing with EtOAc and the aqueous fractions purified by GPC, using a TSK 
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HW40S (1.6 x 90 cm) column in water at 0.5 mL min-1, to afford a white powder 
product (4.2 mg, 88.8 %). Product analysis was performed by ESI-MS Section 
5.1.2 and 1H NMR Section 5.1.4. ESI-MS m/z 840.6 [M+Na]+ found, 
calculated m/z 840.3 [M+Na]+; 1H NMR (400 MHz, D2O) d 8.00 (1H, s, H-1Ab-
triazole), 7.95 (1H, s, H-1Aa-triazole), 6.15 (1H, d, J1,2 = 2.87 Hz, H-1Aa), 6.10 
(1H, s, H-1Ab), 4.95-3.15 (48H, m, H-2, H-3, H-4, H-5, H-6), 3.60 (OCH3), 2.74 
(CH2C(O)OCH3), 2.37 (CH2CH2CH2), 1.92 (CHCH2CH2). 
 
5.3.10. 1-(2-O-(2-O-β-D-mannopyranosyl-β-D-mannopyranosyl)-β-D-
mannopyranosyl)-4-(3-hydrazinocarbonylpropyl) [1,2,3]-triazole 
 
 
A mixture of b-D-(1-2)-mannotriosyl clicked product 5.3.8 (4.5 mg, 7.63 µmol) 
was incubated with hydrazine monohydrate (1 mL) and ethanol (2.5 mL) at 55 
°C for 6 hr. Excess reagents and by-products were removed by co-evaporation 
with toluene (3 x 10 mL). Completion of the conversion of methyl ester into 
acyl hydrozide was confirmed by disappearance of methyl ester a signal at d 
3.6 ppm in 1H NMR spectrum (Appendices 6. 20 A). 
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5.3.11. 1-(2-O-(2-O-(2-O-β-D-mannopyranosyl-β-D-
mannopyranosyl)-β-D-mannopyranosyl)β-D-mannopyranosyl)-4-
(3-hydrazinocarbonylpropyl) [1,2,3]-triazole 
 
 
A mixture of b-D-(1-2)-mannotetraosyl clicked product 5.3.9 (4.2 mg, 6.1 µmol) 
was incubated at 55 °C for 6 hr with hydrazine monohydrate (1 mL) and 
ethanol (2.5 mL). Excess reagents and by-products were removed by co-
evaporation with toluene (3 x 10 mL). Complete conversion of acyl hydrazine 
was confirmed by loss of a signal at d 3.6 ppm by 1H NMR spectrum 
(Appendices 6. 20 B). 
 
5.3.12. Expression of TetHc from E.coli pSK1-TetHc 
The heavy chain of tetanus toxoid was expressed for use as a carrier protein. 
Briefly, cultures of E. coli pSK1-TetHc, provided by Dr A. Scott of DSTL-Porton 
Down, were grown in 1 L culture flasks of LB containing 50 µg/ml kanamycin 
overnight at 37 °C with shaking. After 16 h the cultures were induced by the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 1 mM final 
concentration), and incubated for a further 4 hours. Cells were pelleted by 
centrifugation and lysed in cell lysis buffer (20 mL: HEPES 100 mM, NaCl 500 
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mM, EDTA 1 mM, TCEP 5 mM, protease inhibitor 10 µL/ml and lysozyme 0.25 
mg/ml), followed by sonication of 3 x 20 seconds with 20 second intervals. 
Benzonase nuclease (1 µL) was added and incubated at room temperature 
for 30 mins. Cellular debris was pelleted by centrifugation for 15 mins at 10,000 
x g. His-tagged TetHc was isolated from the supernatant on AKTA by passing 
through a HisTrapHP MT (GE Healthcare) 5 mL purification column (wash 
buffer: 50 mM Tris-HCl pH 8, 0.5 M NaCl, 30 mM imidazole; elution buffer: 50 
mM Tris-HCl pH 8, 0.5 M NaCl, 0.5 M imidazole), followed by further 
purification on a HiLoad 16/600 Superdex 200 pg GPC column (GPC Buffer: 
50 mM HEPES pH 7.5, 100 mM NaCl). Isolated TetHc protein was quantified 
by Bradford assay and analysed by MALDI-TOF/MS (Figure 3. 24), SDS-
PAGE (Figure 3. 22 A) and Western blot with a mouse anti-His monoclonal 
primary antibody (Figure 3. 22 B). 
 
5.3.13. Generation of b-D-(1-2)-mannoligosaccharide 
glycoconjugates 
Conjugation of b-D-(1-2)-mannotriosyl and b-D-(1-2)-mannotetraosyl acyl 
hydrazides (Sections 5.3.10 and 5.3.11 respectively) to BSA and TetHc carrier 
proteins was carried out as outlined by Kim et al5. Acyl hydrazides (4 mg) were 
dissolved in dry DMF (1 mL) and cooled to -25 °C. The reaction was initiated 
by the addition of 4 M HCl in dioxane (9.5 µL) and tert-butyl nitrite (1.6 µL) and 
the mixture allowed to stir under nitrogen for 15 mins at -25 °C. Sulfamic acid 
(100 µL at 7.4 mg mL-1 in dry DMF) was added to prevent the build-up of 
nitrous oxide6. The reaction was allowed to reach 0 °C before being added 
dropwise to a cooled protein solution (2 mg mL-1 in Borax buffer) and left at 4 
°C for 36 hr. Analysis of protein conjugates was performed by SDS-PAGE 
using a 4-20 % gradient SDS-PAGE gel (Figure 3. 25 A and B), and 
InvivogenTM Pro-Q™ Emerald 300 Glycoprotein Gel and Blot Stain Kit as per 
the manufacturer’s instructions (Figure 3. 25 C)7. 
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5.3.14. Generation of virenose BSA glycoconjugates 
All virenose antigens used in this study were synthesised by Dr Irina Ivanova 
of the John Innes Centre. Conjucore VLP was used as a protein carrier in this 
study, and was provided by Dr Lucy Beales of Mologic Ltd. Laminarin azide 
described in Chapter 5.2.5 was provided to Dr Simone Dedola of Iceni 
Diagnostics who assembled the vaccine conjugates a-Vir-(1-4)-a-Vir-BCN-
VLP-BCN-laminarin and b-Vir-(1-4)-b-Vir-BCN-VLP-BCN-laminarin which 
were used for immunisation trials. 
BSA antigen conjugates incorporating a-Vir-(1-4)-a-Vir, b-Vir-(1-4)-b-Vir, a-
Vir, b-Vir and laminarin and azido propyl were generated by reacting 
corresponding azido-functionalised derivatives (Figure 3. 31) with BSA-BCN 
according to the protocol described in Chapter 5.2.6). Azides were used at a 
2 × molar excess per alkyne, except laminarin azide which was used in 5 × 
molar excess. Successful conjugation was confirmed by SDS-PAGE using a 
4-20 % gradient SDS-PAGE gel, and Western blot analysis. Sera from the 
corresponding virenose vaccine conjugate were used to probe for a and b 
mono and disaccharide virenose antigens, and a mouse anti-b-(1-3)-glucan 
monoclonal antibody, used in Chapter 5.2.7, was used to probe for laminarin. 
 
5.3.15. Immunisation trials 
Immunisation trials were performed by Mologic using the following procedures. 
VLP conjugates were prepared for immunisation by emulsifying with adjuvant 
to a final injection volume of 1 mL. Immunisation was performed with complete 
Freunds adjuvant and all boost injections were emulsified in incomplete 
Freunds adjuvant. VLP glycoconjugate were injected intramuscularly into 2 
rabbits at 4 sites, 1 injection into each thigh muscle and subcutaneously into 
2 sites on the back. A total of 0.25 mL of emulsion was injected at each site. 
Rabbits were immunised with 10 µg of VLP glycoconjugate on day 0 with 
boosts being provided on days 28, 56 and 84. A preimmune bleed was taken 
on day 0, before immunisation, and test bleeds were taken on days 35, 63 and 
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91. Blood samples were collected from the marginal ear vein into a sterile vial. 
For preimmune and test bleeds, 25 mL of whole blood was collected, and 50 
mL of whole blood collected for all subsequent bleeds (dependent on body 
weight). 
 
5.3.16. ELISA Protocols 
ELISA assays were performed using NuncTM MaxiSorpTM 96-well ELISA plates 
(BioLegend 423501). Unless otherwise stated, all dilutions were made in PBST 
made from PBS (Sigma P4417) and Tween20 (Sigma P1379). Blocking steps 
were performed using milk powder (Marvel). Goat anti-rabbit IgG (whole 
molecule)-HRP was ordered from Sigma A6154. ELISA assays were 
developed using TMB substrate (Thermo Scientific N301) and quenched with 
HCl (Fisher 10294190). Absorbance readings were recorded using a 
FLUOstar Omega (BMG labtech) plate reader with absorbance at wavelength 
450 nm. All samples were analysed in triplicate with each serum also being 
analysed against a PBS control. Each ELISA was performed in triplicate with 
average result and standard error used for data analysis. Data analysis was 
performed using GraphPad Prism 7.2 software with statistical analysis 
performed by two-way ANOVA with post-hoc Fisher’s LSD. 
 
5.3.16.1. Serum analysis by standard ELISA 
BSA-antigen conjugates (200 μL at 200 ng ml-1 in PBS) were coated on a 96-
well Maxisorb ELISA plate at 4 °C overnight. Each well was washed 3 times 
with PBS and then blocked for 1 hour with blocking buffer (1 % milk powder 
protein in PBST) at room temperature. Plates were again washed 3 times with 
PBS and 200 μL of serum dilutions (1:1000 diluted in 0.1 % milk powder 
protein in PBST) were applied to each well at room temperature for 3 hrs. 
Plates were washed 3 times with PBST before the addition of a secondary 
antibody (Sigma A6154 at 1:10000 dilution in 0.1 % milk powder protein in 
PBST) at room temperature for 1 hr. Plates were washed 3 times with PBST. 
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Stabilised chromogen [TMB substrate (Life technologies)] was added at 100 
μL per well for 15 mins before the reaction was stopped by the addition of 1 M 
HCl (100 μL per well). Measurements were recorded as an absorbance 
reading at 450 nm. 
 
5.3.16.2. Serum analysis by competitive ELISA 
Competitive ELISA was performed similarly to standard ELISA (Section 
5.3.16.1) with the following changes. Target analytes were prepared in PBST 
and mixed 50:50 with a 1 in 800 dilution of serum in PBST and incubated at 4 
°C for 16 hours prior to applying to the ELISA plate. 
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6. Appendix 
Chapter 2 appendices 
 
Appendices 6. 1 – Table of masses for acetylated and deprotected b-(1-3)-glucans. Grey shading 
represents dominant peaks. 
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Appendices 6. 2 – HSQCed NMR (400 MHz, CDCl3) assignment of acetylated curdlan fragments. 
Chemical shifts (d) ppm 
13C 
NMR 
CH2Cl2 C-1 C-2 C-3 C-4 C-5 C-6 
OCOCH3 
(OAc) 
53.5 100.7 72.5 78.2 68.0 71.7 61.8 20.6 
1H 
NMR 
CH2Cl2 H-1 H-2 H-3 H-4 H-5 H-6 
OCOCH3 
(OAc) 
5.29-
5.35 
4.32-
4.51 
4.77-
5.11 
3.69-
3.91 
4.82-
5.09 
3.55-
3.76 
3.97-
4.42 
1.94-2.22 
 
 
Appendices 6. 3 - HSQCed NMR (400 MHz, CDCl3) assignment of deacetylated b-(1-3)-glucan 
curdlan fragments 
 Chemical shifts (d) ppm 
13C 
NMR 
C-
1Aa 
C-
1Ab C-1
X C-2Y C-3Y C-4Y C-5Y C-6Y 
92.1 95.6 102.7 73.3 84.2 68.1 75.7 60.8 
1H 
NMR 
H-
1Aa 
H-
1Ab H-1
X H-2Y H-3Y H-4Y H-5Y H-6Yab 
5.19 4.62 4.70 3.30-
3.56 
3.67-
3.79 
3.44-
3.55 
3.40-
3.49 
3.65-
3.92 
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Appendices 6. 4 – MALDI-TOF analysis of deacetylated curdlan fragments.  
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Appendices 6. 5 – Table of HPAEC-PAD retention times (mins) for linear b-(1-3)-glucans prior to (A) and following (B-J) GPC fractionation and laminarihexaose (LHX) 
standard (K). 
DP   Curdlan Fractions LHX A B C D E F G H I J K 
1 3.7 - - - - - - - - - - 
2 10.3 - - - - - - - - - - 
3 13.6 - - - - - - - - - - 
4 16.2 - - - - - - - - - - 
5 18.9 - - - - - - - 18.7 18.7 - 
6 21.0 - - - - - - 20.9 20.9 20.9 20.7 
7 22.9 - - - - - 22.8 22.7 22.8 22.7 - 
8 24.6 - - - - 24.4 24.4 24.4 24.5 24.4 - 
9 26.2 - - - - 26.0 25.9 25.9 26.1 26.0 - 
10 27.6 - - - 27.5 27.3 27.3 27.3 27.4 27.3 - 
11 28.8 - - 28.8 28.8 28.5 28.6 28.6 28.7 - - 
12 30.0 - - 30.0 29.9 29.7 29.7 29.7 29.9 - - 
13 31.1 - 30.9 31.0 30.9 30.8 30.8 30.8 - - - 
14 32.0 31.9 31.8 31.9 31.8 31.7 31.7 - - - - 
15 32.9 32.8 32.7 32.8 32.7 32.6 32.6 - - - - 
16 33.8 33.6 33.6 33.7 33.5 33.5 - - - - - 
17 34.5 34.4 34.3 34.4 34.3 34.2 - - - - - 
18 35.2 35.1 35.1 35.2 35.0 - - - - - - 
19 35.9 35.7 35.7 35.8 - - - - - - - 
20 36.5 36.4 36.3 36.4 - - - - - - - 
21 37.1 36.9 36.9 - - - - - - - - 
22 37.7 37.5 - - - - - - - - - 
23 38.2 38.0 - - - - - - - - - 
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Appendices 6. 6 – HSQCed NMR (400 MHz, CDCl3) assignment of commercial laminarin. 
 Chemical shifts (d) ppm 
13C NMR 
C-1 C-2 C-3 C-4 C-5 C-6 
102.4 73.3 84.1 68.2 75.7 60.5 
1H NMR 
H-1 H-2 H-3 H-4 H-5 H-6 
4.38-4.72 3.18-3.51 3.56-3.73 3.35-3.50 3.29-3.43 3.54-3.89 
 
 
Appendices 6. 7 – MALDI-TOF analysis of BSA-BCN conjugation optimisation. A – BSA, B – BSA 
reacted with 5x molar excess of BCN-NHS, C – BSA reacted with 5x molar excess of BCN-NHS. 
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Chapter 3 appendices 
 
Appendices 6. 8 – BCA protein concentration analysis of Teth514_1788. 
 
 
Appendices 6. 9 – Table of HPAEC-PAD retention times (mins) for b-(1-2)-mannan 
oligosaccharides. 
  HPAEC-PAD b-(1-2)-mannoside retention times (min) 
DP Ladder Mannose M1P Enzymatic reaction 95% EtOH elution Man3 Man4 
1 3.7 3.7 - 3.7 3.7 - - 
2 5.9 - - 5.9 5.9 - - 
3 9.7 - - 9.8 9.7 9.8 - 
4 11.6 - - 11.7 11.5 - 11.6 
5 13.0 - - 13.1 12.9 - - 
6 14.0 - - 14.1 13.9 - - 
7 14.9 - - 15.0 14.9 - - 
8 15.9 - - 16.0 15.8 - - 
M1P 16.2 - 16.1 16.1 16.3 - - 
  
 
 
​
​
​
​
​
​
​
Teth_1788 (1:20)
y = 0.0016x
R² = 0.9848
0
0.5
1
1.5
2
2.5
3
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0 500 1000 1500 2000
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95
nm
BSA (ug/ml)
BSA Teth_1788 Linear (BSA)
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Appendices 6. 10 – Table of masses for b-(1-2)-mannan oligosaccharides. 
 Calculated Found 
DP [M]+ [M+Na]+ [M+Na]+ 
1 180.1 203.1 ND 
2 342.1 365.1 ND 
3 504.2 527.2 527.3 
4 666.2 689.2 689.4 
5 1542.5 851.3 851.4 
6 1830.5 1013.3 1013.1 
7 2118.6 1175.4 1175.6 
8 2406.7 1337.4 1337.6 
9 2694.8 1509.5 1509.5 
10 2982.9 1661.5 1661.7 
11 3271.0 1823.6 1823.7 
12 3559.1 1985.6 1986.7 
 
 
 
Appendices 6. 11 – HPAEC-PAD analysis of b-(1-2)-mannan oligosaccharides separated by gel 
permeation chromatography. 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0
-1,200
-1,000
-875
-750
-625
-500
-375
-250
-125
0
125
250
400
1 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #547 2mM Mannose ED_1
2 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #542 4_8mM Standard_1 ED_1
3 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #554 1:4_0.1MAA_1 ED_1
4 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #567 1:4_0.1MAA_Charcoal_water elution_3 ED_1
5 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #560 1:4_0.1MAA_Charcoal_95%EtOH elution_2 ED_1
6 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #610 GPC_35_1 ED_1
7 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #611 GPC_36_1 ED_1
8 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #612 GPC_37_1 ED_1
9 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #614 GPC_38_1 ED_1
10 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #615 GPC_39_1 ED_1
11 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #616 GPC_40_1 ED_1
12 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #618 GPC_41_1 ED_1
13 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #619 GPC_42_1 ED_1
14 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #620 GPC_43_1 ED_1
15 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #622 GPC_44_1 ED_1
16 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #623 GPC_45_1 ED_1
17 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #624 GPC_46_1 ED_1
18 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #626 GPC_47_1 ED_1
19 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #627 GPC_48_1 ED_1
20 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #628 GPC_49_1 ED_1
21 - 20171208 - Mannose Oligos time course 5ug enzyme 2mM Man #629 GPC_50_1 ED_1
nC
min
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Az
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Appendices 6. 12 – TLC analysis of b-(1-2)-mannan oligosaccharides separated by gel 
permeation chromatography. Solvent system: BuOH/EtOH/H2O (10:8:7). 
 
 
 
Appendices 6. 13 – TLC analysis of b-(1-2)-mannotriose and b-(1-2)-mannotetraose b-(1-2)-
mannosides. Solvent system - BuOH/EtOH/H2O (10:8:7).  
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Appendices 6. 14 – 1H and 13C NMR chemical shifts of b-(1-2)-mannotriose. 
Units 
and 
anomers 
Chemical shifts (!) 
H-1 H-2 H-3 H-4 H-5 H-6a H-6b 
C ⍺ 4.74 4.04 3.50 3.38 3.26 3.82 3.59 
 β 4.83 4.03 3.50 3.38 3.26 a a 
B ⍺ 4.74 4.16 3.53 3.50 3.26 3.82 3.64 
 β 4.80 4.29 3.53 3.50 3.26 a a 
A ⍺ 5.15 3.99 3.78 3.54 3.66 3.72 3.59 
 β 4.86 4.05 3.56 3.41 3.26 3.72 a 
  C-1 C-2 C-3 C-4 C-5 C-6  
C ⍺ 100.9 70.2 72.7 67.0 76.2 60.8  
 β 100.8 70.5 72.7 67.0 76.2 a  
B ⍺ 98.9 78.5 72.0 66.9 76.2 60.8  
 β 101.0 78.0 72.0 66.9 76.2 a  
A ⍺ 91.9 78.4 69.1 67.0 72.3 60.2  
 β 93.5 79.6 72.1 66.6 76.2 60.2  
  a Not determined 
 
Appendices 6. 15 – 1H and 13C NMR chemical shifts of b-(1-2)-mannotetraose. 
Units 
and 
anomers 
Chemical shifts (!) 
H-1 H-2 H-3 H-4 H-5 H-6a H-6b 
D  4.83 4.05 3.51 3.46 3.28 3.83 3.63 
C ⍺ 4.83 4.3 3.52 3.51 3.28 3.83 3.63 
 β 4.91 4.26 3.52 3.51 3.28 a a 
B ⍺ 4.72 4.13 3.59 3.41 3.28 3.83 3.7 
 β 4.77 4.26 3.59 3.41 3.28 a a 
A ⍺ 5.16 4.01 3.8 3.8 3.69 3.71 3.7 
 β 4.86 4.05 3.59 3.37 3.28 a a 
  
C-1 C-2 C-3 C-4 C-5 C-6   
D  101 70.3 72.9 66.9 76.2 60.8   
C ⍺ 101 78.3 72.1 67.2 76.2 60.8   
 β 101 78.5 72.1 67.2 76.2 a   
B ⍺ 99.2 79.5 71.9 67 76.2 60.8   
 β 101.1 78.5 71.9 67 76.2 a   
A ⍺ 92.1 78.8 69.1 69.1 72.3 60.4   
 β 93.5 80 71.9 67.1 76.2 a   
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Appendices 6. 16 – FTIR analysis of b-(1-2)-mannotriose (A), b-(1-2)-mannotriosyl azide (B), b-(1-
2)-mannotetraose (C) and b-(1-2)-mannotetraosyl azide (D).  
 
 
 
Appendices 6. 17 – 1H NMR integration of b-(1-2)-mannotriosyl clicked products. 
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Appendices 6. 18 – 1H NMR integration of b-(1-2)-mannotetraosyl clicked product. 
 
 
 
Appendices 6. 19 – Chromatogram of TetHc purification by affinity chromatography. 
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Appendices 6. 20 – 1H NMR analysis of hydrazide functionalised b-(1-2)-mannotriosyl (A) and b-
(1-2)-mannotetraosyl (B) click products (400 MHz, D2O). 
 
 
 
Appendices 6. 21 – Comparison of prebleed, bleed 1, bleed 2 and bleed 3 standard ELISA of a-
Vir(1-4)-a-Vir-BCN-VLP-BCN-Laminarin (black), and b-Vir(1-4)-b-Vir-BCN-VLP-BCN-Laminarin 
(red). P values: * = 0.05, ** = 0.01, *** = 0.005. 
 
 
